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INFLUENZA VIRUSES
In humans, seasonal influenza is a highly contagious acute respiratory disease that is 
characterized by myalgia, headache, high fever, malaise, rhinitis and a non-productive 
cough. Highest morbidity rates are found in infants and particularly in the elderly over 
65 years of age, and highest mortality rates in the latter, often in combination with 
underlying disease. Influenza A and B viruses cause the majority of influenza virus 
infections. Influenza C virus has a much lower prevalence and usually causes only 
minor symptoms. Recently, a novel influenza virus exclusively isolated from swine and 
cattle was proposed to represent a separate genus, the influenza D viruses (1).
Influenza viruses have a negative-sense, single-stranded, and segmented RNA 
genome and are classified in the family of Orthomyxoviridae. Influenza A viruses 
are further classified in subtypes based on their surface proteins hemagglutinin (HA) 
and neuraminidase (NA) (Fig. 1). To date, 18 HAs and 11 NAs have been identified 
(2-4). Nearly all combinations of H1-16 and N1-N9 are found in wild birds, which are 
considered the primary natural reservoir of influenza A viruses (2, 5). H17 and 18, and 
N10 and 11 are genetically and functionally distinct from all other known HAs and 
NAs and have exclusively been identified in bats (3, 4), suggesting that wild birds are 
not the only natural reservoir of influenza A viruses. Influenza A viruses infect a large 
variety of host species including humans, birds, pigs, horses, dogs, cats, bats, and sea 
mammals. Influenza B virus forms a single genus within the Orthomyxoviridae family 
and is only known to infect humans and seals (6).
INFLUENZA PANDEMICS AND EPIDEMICS
Influenza pandemics arise when antigenically novel influenza A virus strains enter 
the human population and subsequently spread globally. Zoonotic transmissions 
from wild birds into humans, either directly or via domestic animals such as pigs 
as an intermediate host, resulted in four influenza pandemics over the last century: 
A(H1N1) virus in 1918, A(H2N2) virus in 1957, A(H3N2) virus in 1968, and A(H1N1) 
in 2009 (Fig. 2). The latter is referred to as A(H1N1)pdm09 to differentiate the virus 
from the old seasonal A(H1N1) viruses that circulated during most of the 20th century. 
In 1957 and 1968, the newly introduced pandemic influenza viruses replaced the 
previously circulating subtypes. From 1977 onwards two influenza A virus subtypes 
co-circulated and caused annual epidemics.  An A(H1N1) virus that was genetically 
and antigenically similar to A(H1N1) viruses that circulated in the mid 1940s was re-
introduced in the human population in 1977 and circulated until it was replaced by 
A(H1N1)pdm09 virus in 2009. A(H3N2) viruses continued to circulate alongside both 
seasonal pre-2009 A(H1N1) and pandemic A(H1N1)pdm09 viruses. Influenza B viruses 
formed a single phylogenetic lineage, commonly referred to as the B/Lee/40-lineage, 
until the 1970s. This lineage diverged over time into two genetically and antigenically 
distinct lineages known as the B/Victoria/2/87 (B/Vic) and B/Yamagata/16/88 (B/Yam) 
lineages (7). Currently, two influenza A virus subtypes, A(H3N2) and A(H1N1)pdm09, 
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and viruses from both influenza B phylogenetic lineages cause frequent epidemics in 
humans (Fig. 2).
Influenza viruses are a major cause of morbidity and mortality. The 1918 Spanish 
influenza pandemic claimed an estimated 30 – 50 million lives (8). Subsequent influenza 
pandemics caused approximately 3.5 million deaths in total (9, 10). Seasonal human 
influenza viruses annually infect 5 -15% of the human population and are responsible 
for an estimated 250,000 - 500,000 deaths per year worldwide (11), resulting in 
a cumulative mortality that roughly equals that of pandemic influenza over the last 
century. The isolation of a highly pathogenic avian influenza (HPAI) A(H5N1) virus from 
a 3-year old boy in 1997 raised concerns about the possibility that influenza A virus 
subtypes not currently known to cause epidemics in humans may become pandemic 
(12, 13). To date, more than 700 laboratory-confirmed human cases of avian influenza 
A/H5N1 virus infection have been reported to the World Health Organization (WHO), 
60% of which were fatal (14). Although it was recently shown that HPAI A(H5N1) viruses 
may evolve the ability to become aerosol transmissible (15, 16), no sustained human-
to-human transmission of A(H5N1) viruses has been reported to date. However, since 
their identification in 1996, HPAI A(H5N1) viruses have spread to over 60 countries in 
the Eastern Hemisphere, diversified into multiple distinct genetic lineages, continued 
to cause large-scale outbreaks in domesticated poultry, and frequently crossed the 
species barrier into humans (17-20). HPAI A(H5N1) virus therefore remains a pathogen 
of significant concern from an economic, veterinary, and public health point of view. 
Although HPAI A(H5N1) virus is the most widespread zoonotic avian influenza virus, 
avian influenza viruses of HA subtypes H5, H6, H7, H9, and H10 have in various 
combinations with NA subtypes been isolated from and caused disease in humans 
(14, 21). Recent outbreaks in poultry populations include viruses of subtypes A(H5N8), 
A(H7N9), A(H9N2) and A(H10N8). The A(H7N9) virus is of particular concern because 
of persistent outbreaks in poultry populations, the absence of clinical disease in 
poultry, and the high number of human cases (22, 23). The dissemination of avian 
influenza viruses additional to A(H5N1) virus into poultry populations outside of 
Southeast Asia and potential for genetic diversification by mutation and reassortment 
that may lead to human adaptation are reason for continued surveillance for avian 
influenza viruses in poultry stocks worldwide.
HEMAGGLUTININ
Hemagglutinin (HA) is one of two major glycoproteins present on the surface of 
influenza viruses, the other one being neuraminidase (NA) (Fig 1). HA is synthesized 
as an HA0 precursor protein. Post-translational modifications including glycosylation 
and cleavage by host cell proteases generate the disulfide-bond linked HA1 and 
HA2 subunits of the mature trimeric protein present on the viral surface (Fig. 3). 
HA is responsible for the initial stages of the replication cycle of influenza viruses. 
The receptor binding site (RBS) initiates binding of the viral particle to terminal 
sialic acid residues present on the host cell surface, resulting in receptor-mediated 
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Fig. 1. Schematic representation of an influenza A virus. The surface proteins hemagglutinin (HA), 
neuraminidase (NA), and matrix 2 (M2) are inserted in the viral envelope, which is lined by the matrix 1 
protein (M1). The eight RNA gene segments are present in the form of ribonucleoprotein-complexes 
that entail the nucleoprotein (NP) and the polymerase proteins (PB2, PB1, and PA). M1, matrix protein, 
NS; non-structural protein. The two HA subunits, HA1 (blue) and HA2 (brown), are indicated in 
the figure. Figure from Hedestam et al. (50).
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the HA surface glycoprotein displays a high degree 
of sequence variability (BOX 1; FIG. 1). Interpreted 
loosely, seasonal influenza virus stays ‘one step ahead’ 
of host neutralizing responses by the generation and 
selection of new variants. So rather than persisting 
in individually infected hosts, the virus persists in 
the whole human population by infecting individu-
als with no or low protective immunity against new 
variants: this is known as ‘antigenic drift’15,16. In addi-
tion to seasonal influenza viruses in humans, various 
antigenically variable influenza A viruses circulate in 
animal reservoirs, and these occasionally re-assort 
with other influenza genes to cross the species barrier, 
thereby causing new pandemics in humans by ‘anti-
genic shift’16. These reservoirs, largely avian, provide 
some parallels to the global diversity of HIV-1 (FIG. 1) 
and represent a major challenge in the development 
of vaccine candidates against pandemic influenza. 
Therefore, despite the differences in the biology of 
the influenza virus (an acute infection) and HIV-1 (a 
chronic infection), and despite the different selective 
forces that generate diversity in these viruses, parallels 
can be drawn between the two viruses and between the 
challenges of inducing broadly neutralizing antibody 
responses against them. 
Both viruses possess error-prone polymerases, the 
molecular basis for generating variability. HIV-1 has a 
highly error prone reverse transcriptase (RT), can toler-
ate many mutations and can generate fit variants that 
persist despite diverse host selection pressures. Not only 
is RT-mediated sequence diversity generated at a high fre-
quency by point mutation or recombination, but HIV-1 
also establishes a chronic infection, which includes multi-
ple rounds of viral replication and a continuous generation 
of immune escape variants. Chronic infections provide 
the opportunity to follow virus and antibody evolution in 
infected individuals14,17,18. For HIV-1, longitudinal stud-
ies in a single host have revealed that the envs acquire 
additional glycans (glycan shielding)17, and expansion or 
contraction of variable loop lengths over time19,20. These 
changes coincide with the acquisition of neutralization 
resistance, primarily in antibody epitopes that are located 
in the variable regions and occasionally in more conserved 
epitopes that overlap the receptor-binding site20,21. The 
host antibody repertoire that is directed against the virus 
evolves too, but at a slower rate than does the virus22.
Thus, for both an HIV-1 vaccine and a pandemic 
influenza vaccine, a major challenge is the extreme 
diversity of the envs, which are the major neutralizing 
determinants on the surface of the viruses.
Figure 2 |	Schematic	diagram	of	HiV-1	and	influenza	A	virus.	Both HIV‑1 and influenza A virus are 
approximately 80–120 nm in diameter and are enveloped by a host‑derived plasma membrane. a | In HIV‑1, 
trimeric gp120–gp41 complexes are embedded in the membrane. The transmembrane glycoprotein gp41 and the 
external envelope glycoprotein gp120 are depicted in non‑covalent association. The cytoplasmic tail of gp41 
interacts with the HIV‑1 matrix protein p17. The capsid protein, p24, makes up the cone‑shaped core, which 
contains two positive‑strand RNA copies of the HIV‑1 genome that are surrounded by the nucleocapsid protein 
(yellow). Reverse transcriptase protein is also packaged into the particle. b | In influenza A virus, 3 viral proteins 
are exposed on the outside of virus particles: haemagglutinin (HA, which forms trimers), neuraminidase (NA) 
(which forms tetramers) and M2 (which forms tetramers that make up ion‑channels). Upon proteolytic cleavage, 
HA0 (not shown) is processed to HA1 and HA2. The influenza virus matrix protein M1 associates inside the viral 
membrane, and the viral genome consists of eight negative‑strand RNA segments and is packaged into the 
particle as a ribonucleoprotein in complex with nucleocapsid protein (NP) and the viral polymerases PA, PB1 and 
PB2. On average, the number of HIV‑1 envelope glycoprotein spikes is thought to be considerably lower than the 
number of HA molecules per influenza A virion134.
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Fig. 2 Influenza A and B virus circulation in humans during the past century. Vertical arrows above 
the timeline (grey) indicate the influenza pandemics of the past century, horizontal arrows indicate 
the period of circulation after introduction into humans. The A(H1N1) viruses re-introduced in 1977 
were descendants from the virus responsible for the 1918 influenza pandemic that circulated in the 
mid 1940s. Because these viruses were not antigenically novel the resulting outbreak is usually not 
considered a pandemic. Influenza B viruses formed a singl  phylogenetic lineage until the 1970s, 
after which they diverged over time into the two genetically and antigenically distinct lineages that 
continue to co-circulate until the present day.
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endocytosis. The low pH inside the endosome triggers a conformational change of 
HA that exposes the fusion peptide at the N-terminus of the HA2 subunit. Fusion of 
the viral and endosomal membranes results in release of the gene segments into the 
cytoplasm. Subsequent trafficking of the viral RNA (vRNA) to the cell nucleus initiates 
the next stage of viral replication: the production of mRNA that serves as template for 
viral protein production and complementary RNA (cRNA) that serves as template for 
the production of vRNA, that will be incorporated in the newly formed viral particles.
The RBS is located on the membrane distal surface of HA and contains several 
structural elements that are fundamental to the HA of all subtypes (Fig. 3B). It forms 
a shallow concave pocket on the globular head of the HA molecule that is surrounded 
by the 130-loop, 220-loop, and 190 α-helix (24). Although sequence variation 
exists, the basic conformation of these elements is similar among influenza viruses. 
The amino acids on positions 98, 153, 183, and 195 are conserved throughout 
influenza A and B viruses and form the base of the RBS (24-26). Other amino acids 
within the RBS may also be conserved among subtypes with a similar host range and 
define the receptor specificity of HA. Human influenza viruses preferentially bind to 
α2,6-linked sialic acids (SAs), while avian influenza viruses have a preference for α2,3-
linked SAs (27). Swine viruses bind either α2,6 or both α2,3 and α2,6 linked SAs.
HA is the main component of influenza vaccines because HA-specific antibodies 
can provide protective immunity against disease. Neutralizing antibodies prevent 
infection of the host cell by obstructing attachment of the RBS to SAs on the cell 
surface or preventing the membrane fusion reaction. Anti-HA antibodies are also 
involved in activation of other parts of the immune system that help viral clearance 
through opsonization and antibody-dependent cell-mediated cytotoxicity (28). 
The main antibody subtypes involved in virus neutralization and prevention from 
clinical disease are mucosal IgA in the upper respiratory tract and IgG in the lung 
(29). However, cross-reactivity between antibodies against the different influenza 
A virus subtypes and influenza B virus is very limited, necessitating the use of tri- or 
quadrivalent influenza vaccines.
INFLUENZA VIRUS ANTIGENIC CHANGE
The exceptionally high genetic diversity of influenza viruses results from 
the error prone influenza virus polymerase and allows rapid adaptation to changing 
environments, including evasion of neutralizing antibodies in the human population. 
The HA amino acid composition of seasonal human influenza viruses continually 
changes to avoid neutralization by antibodies generated in response to previous 
infections or vaccinations. The colonization of the European swine population by 
a human A(H3N2) virus in the early 1970s elucidates how antibody immunity shapes 
HA evolution. Whereas humans may experience several influenza virus infections 
during their lifetime, the short life span of pigs limits the buildup of immunity in the 
swine population. The human and swine A(H3N2) virus lineages had comparable rates 
of nucleotide and amino acid substitutions, but antigenic change of the swine virus 
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Fig. 3. Structure of an A/Aichi/2/1968 hemagglutinin. (A) The three monomers of HA (indicated in 
white, grey, and black) assemble during post-translational modification to form a mature trimeric HA 
protein. The receptor binding site (RBS, yellow) is located on the membrane distal globular head of 
HA. (B) Each monomer consists of an HA1 (red) and HA2 (blue) subunit. The amino acid composition 
of the RBS (inset) determines the receptor specificity of influenza virus. However, the overall shape 
of the RBS is similar for all influenza A and B viruses, and contains structural elements (the 130- and 
220-loops and 190 α-helix) and amino acids (98Y, 153W, 183H, and 195Y, indicated in red) that are 
conserved among influenza A and B viruses. The human receptor analog LSTc is indicated in blue. 
PDB accession numbers; 5HMG (panel A), 2YPG (panel B).
lineage occurred at a rate approximately six times slower than the rate of antigenic 
drift in humans (30). Antigenic drift is the gradual antigenic change that results 
from the accumulation of point mutations in HA. Amino acid substitutions occur 
throughout the HA protein, but are most prominent in the HA1 domain. Nearly half of 
the HA1 amino acid positions of human A(H3N2) and A(H1N1) HAs, and the majority 
of surface exposed positions, have changed since 1968 and 1977, respectively, 
illustrating the highly variable nature of HA (31, 32). Owing to the rapid appearance 
of antigenic variants that escape population immunity, influenza vaccines must be 
frequently reformulated.
HA amino acid positions associated with antigenic drift of A(H3N2) and A(H1N1) 
viruses were identified in the early 1980s and the following decade by mapping 
genetic differences between strains from consecutive epidemics and mutations in 
escape variants after growing virus in the presence of antibodies (32-34). The 131 
amino acid positions associated with antigenic change of A(H3N2) virus cover much 
of the HA globular head and were categorized in antigenic sites A – E (Fig. S6C of 
chapter 2) (32, 33). The antigenic sites identified for A(H1N1) and A(H5N1) viruses 
resemble the antigenic sites described for A(H3N2) virus (34-36). Four antigenic 
sites were identified for A(H1N1) virus (corresponding H3 sites in brackets): Ca – 
which is subdivided in Ca1 and Ca2 (D and A), Cb (C), Sa, and Sb (B). For A(H5N1) 
virus, three antigenic sites have been identified. Site 1 corresponds to site A of 
A B
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H3, site 2 consists of two sub-sites; one that corresponds to site B of the H3 HA, 
the other to site Sa of H1 (neither of which have an equivalent H3 antigenic site). Based 
on the original publication of A(H3N2) antigenic sites it was suggested that at least 
one amino acid substitution in each of the four antigenic sites (A - D) was required 
for the production of new epidemic strains (33). However, after identification of 
a fifth site (E), that statement was adjusted to the widely used heuristic that each new 
drift variant of epidemiologic importance has generally had four or more amino acid 
substitutions located in two or more of the antigenic sites (32).
Antigenic differences among influenza viruses are measured routinely using 
the hemagglutination inhibition (HI) assay, which uses the property of influenza 
viruses to agglutinate erythrocytes and the ability of HA specific antibodies to 
block hemagglutination (37). In the HI assay, the highest dilution of antiserum that 
completely inhibits influenza viruses from agglutinating erythrocytes is determined. 
Comparing the reciprocal of endpoint dilutions, the HI titers, for a panel of antisera 
prepared against antigenically diverse viruses provides information about antigenic 
differences between the test viruses. An example HI table is shown in Figure 4. 
The use of antisera in serological assays is based on the finding that the level of serum 
antibodies reflects immunity to influenza virus (38-40). Ferret antisera obtained after 
inoculation with influenza viruses under laboratory-controlled conditions are the most 
sensitive reagents for detection of antigenic variation of influenza viruses, but antisera 
from other species are occasionally preferred. For example, chicken antisera, which 
have IgY instead of IgG, are often used in HI assays testing A(H5N1) viruses. 
Antigenic cartography is a method to visualize and analyze HI data (31). 
The concept of antigenic cartography to generate “antigenic maps” is described in 
Figure 4. Because antisera are tested against multiple antigens, and antigens tested 
against multiple antisera, many measurements can be used to determine the position 
of the antigen and antiserum in an antigenic map, thus improving the resolution of 
HI data. Visualization of HI data in an antigenic map allows studying long-term virus 
evolution. Analyzing HI data of A(H3N2) viruses that circulated between 1968 and 
2003 revealed that antigenic evolution was punctuated rather than gradual, and that 
antigenic evolution proceeded in a mostly linear fashion away from earlier circulating 
viruses, presumably related to escape from existing population immunity (31). Amino 
acid differences between the 11 antigenic clusters—the groups of antigenically similar 
viruses—were dispersed across the five A(H3N2) virus antigenic sites. Several studies 
used sequence information to infer amino acid positions associated with antigenic 
change (41-47). These studies also mostly identified amino acid positions scattered 
over the HA globular head located in multiple antigenic sites. However, only few 
studies pinpointed the exact substitutions responsible for antigenic change based on 
phenotypic analysis (31, 48, 49).
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Fig. 4. Example of an antigenic map of influenza A(H3N2) virus. (A) HI assay results in table format. 
The antigens are indicated in the left most column, antisera in the top row. Each titer in the HI 
table can be thought of as specifying a target distance between an antigen and serum point in 
the antigenic map (N.D: not determined). (B) HI assay results represented in an antigenic map. 
The open squares represent the antisera; colored circles represent the antigens (viruses). The distance 
between antiserum point S and antigen point A corresponds to the difference between the log2 of 
the maximum titer observed for antiserum S against any antigen and the log2 of the titer for antiserum 
S against antigen A. Modified multidimensional scaling methods are then used to arrange the antigen 
and antiserum points in an antigenic map to best satisfy the target distances specified by the HI 
data. The result is a map in which the distance between the points represents antigenic distance as 
measured by the HI assay in which the distances between antigens and antisera are inversely related 
to the log2 HI titer. Each square in the grid of the antigenic map equals a two-fold difference in the HI 
assay. The colored rows in the table and the colors of the antigens in the map indicate antigenically 
similar viruses.
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OUTLINE OF THIS THESIS
Understanding the genetic changes that allow influenza viruses to escape population 
immunity is a critical first step towards the prediction of influenza virus antigenic 
evolution. The current possibility to integrate genetics, classic serology, and 
bioinformatics provides an opportunity to study the molecular basis of influenza virus 
antigenic change in detail. 
The knowledge that antigenic evolution of A(H3N2) virus is punctuated was used 
to identify the amino acid substitutions responsible for the antigenic differences 
between HAs of viruses that belong to consecutive antigenic clusters, and allowed 
us to delineate a small set of HA amino acid positions and substitutions that shaped 
antigenic evolution of human influenza viruses (chapter 2).
Genetic evolution of HPAI A(H5N1) viruses has been studied in detail, mostly 
focusing on the possibility that A(H5N1) viruses cross the species barrier and form 
a stable lineage in humans. Much less is known about the antigenic evolution of 
HPAI A(H5N1) viruses, hampering the design of intervention strategies that could 
help prevent outbreaks in poultry. We mapped antigenic variation of HA of A(H5N1) 
clade 2.1 viruses and identified the evolutionary patterns and molecular basis of 
the observed antigenic changes (chapter 3).
The work described in chapters 2 and 3 indicated that major antigenic changes of 
HA during influenza virus evolution were predominantly caused by single amino acid 
substitutions. Two such substitutions were introduced into the HA of temporally and 
genetically diverse A(H3N2) viruses to investigate the influence of the amino acid 
context in which a substitution occurs on antigenic change (chapter 4).
The majority of A(H1N1)pdm09 viruses isolated since the 2009 influenza pandemic 
remain antigenically similar to the pandemic virus. However, A(H1N1)pdm09 viruses 
are anticipated to change antigenically as a result of increasing population immunity. 
Building on the work from chapters 2 and 3, we introduced substitutions into a virus 
representing the antigenic phenotype of A(H1N1)pdm09 viruses to identify amino 
acid substitutions in HA that support escape from convalescent ferret antisera and 
human sera (chapter 5). 
The main findings and implications of this thesis are discussed in chapter 6.
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ABSTRACT
The molecular basis of antigenic drift was determined for the hemagglutinin (HA) 
of human influenza A/H3N2 virus. From 1968 to 2003 antigenic change was caused 
mainly by single amino acid substitutions, which occurred at only seven positions in 
HA immediately adjacent to the receptor binding site. Most of these substitutions 
were involved in antigenic change more than once. Equivalent positions were 
responsible for the recent antigenic changes of influenza B and A/H1N1 viruses. 
Substitution of a single amino acid at one of these positions substantially changed 
the virus-specific antibody response in infected ferrets. These findings have potentially 
far-reaching consequences for understanding the evolutionary mechanisms that 
govern influenza viruses.
Björn F. Koel,1 David F. Burke,2,3 Theo M. Bestebroer,1 Stefan van der Vliet,1 
Gerben C. M. Zondag,4,5 Gaby Vervaet,1 Eugene Skepner,2,3 Nicola S. Lewis,2,3 
Monique I. J. Spronken,1 Colin A. Russell,3,6 Mikhail Y. Eropkin,7 Aeron C. Hurt,8 
Ian G. Barr,8 Jan C. de Jong,1 Guus F. Rimmelzwaan,1 Albert D. M. E. Osterhaus,1 
Ron A. M. Fouchier,1 Derek J. Smith1,2,3,9
1Department of Viroscience, Erasmus MC, 3015GE Rotterdam, Netherlands. 
2Center for Pathogen Evolution, Department of Zoology, University of Cambridge, 
Cambridge CB2 3EJ, UK. 
3WHO Collaborating Centre for Modeling Evolution and Control of Emerging Infectious Diseases, 
University of Cambridge, Cambridge CB2 3EJ, UK. 
4BaseClear B.V., 2333CC Leiden, Netherlands. 
5Luris, Leiden University, 2333AA Leiden, Netherlands. 
6Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK. 
7Research Institute of Influenza, 197376 St. Petersburg, Russia. 
8WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Melbourne, 
Victoria 3051, Australia. 
9Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA.
Science, 2013, 342(6161): 976-9
2SEVEN KEY POSITIONS DICTATE H3N2 VIRUS ANTIGENIC EVOLUTION
21
Influenza A/H3N2 virus is a major cause of morbidity and mortality in humans and 
poses a considerable economic burden (11, 51). Vaccination is the primary method to 
reduce this public health impact. The HA surface glycoprotein is the main component 
of influenza vaccines and antibodies against HA can prevent serious illnesses (40). 
However, influenza viruses can escape from antibody-mediated neutralization by 
accumulating mutations in HA in a process called antigenic drift, and as a consequence 
influenza vaccines require frequent updates. Several recent studies have focused 
on the identification of conserved domains of HA as targets of virus-neutralizing 
antibodies to circumvent this problem (52-55). Other recent work has focused on 
identifying the mechanisms of antigenic drift (56, 57), and on sequence-based 
prediction to identify positively selected codons (43, 44, 46, 58). This research 
has been restricted by our limited fundamental insight into the molecular basis of 
antigenic evolution.
Seminal work in the 1980s identified 131 amino acid positions in five antigenic 
sites (A-E) on the globular head of HA as main targets for specific antibodies and 
suggested that antigenic drift is caused by accumulation of amino acid substitutions 
in these sites (32, 33). This work led to the widely used heuristic that it takes at 
least four amino acid substitutions, spread between two or more different antigenic 
sites, to cause substantial antigenic change. Smith et al. (31) showed that eleven 
antigenic clusters of viruses have emerged since the introduction of the A/H3N2 virus 
in humans in 1968 until 2003, each of which was subsequently replaced by viruses 
with distinct antigenic properties. Between 1 and 13 amino acid substitutions were 
associated with each of the antigenic cluster transitions. Almost all of these cluster-
difference substitutions were in the antigenic sites (31). Here, we investigate which of 
these substitutions actually caused the antigenic change.
We selected a representative virus from each antigenic cluster. The HA1 
subunit amino acid sequence, which comprises the globular head domain of HA 
including the receptor binding site (RBS), of each representative virus was identical to 
the consensus sequence for all strains from the respective cluster (59). The consensus 
HA genes, representing natural circulating viruses, were used to make recombinant 
viruses in the context of the A/Puerto Rico/8/1934 reference virus (60). We also 
produced chimeric viruses with the full HA1 or with HA1 positions 109-301 of each 
antigenic cluster consensus strain in the context of HA of the Sichuan 1987 cluster 
consensus virus (Fig. S1). The antigenic properties of all viruses were analyzed in 
hemagglutination inhibition (HI) assays using a panel of 8-16 ferret antisera raised 
against A/H3N2 viruses from 1968-2006 (Table S1). The wild type, recombinant, and 
chimeric viruses all had similar antigenic properties in the HI assay (Figs. S2 and S3). 
Thus, HA1 positions 109 - 301 determined the antigenic phenotype of representative 
A/H3N2 strains circulating between 1968 and 2003.
Each of the 54 cluster-difference substitutions within the 109 - 301 HA1 region 
(Table S2) was introduced independently into the corresponding consensus HA and 
tested for antigenic effect. If no single substitution induced the antigenic change 
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to the subsequent cluster, combinations of substitutions were tested. We call 
the subset of cluster-difference substitutions that were responsible for the major 
antigenic change between clusters “cluster-transition” substitutions. The cluster-
transition substitutions were also tested in reverse. For example, each of the 11 
cluster-difference substitutions between the EN72 and VI75 clusters were introduced 
individually in the EN72 consensus virus. We found that substitution 189QK alone 
caused the change in antigenic phenotype from EN72-like to VI75-like. The reverse 
substitution 189KQ was then introduced into the VI75 consensus HA and resulted in 
reversion of the antigenic phenotype to EN72-like (Fig. S4B). 
Surprisingly, seven of the ten cluster transitions were caused by only a single 
amino acid substitution (Fig. 1, Table S3). Two cluster transitions were caused by two 
substitutions, and one by three substitutions. In two of the three cluster transitions 
for which more than one substitution was required for the full antigenic change, 
one substitution was responsible for the majority of the antigenic change and 
the additional substitution(s) had a relatively modest effect on the antigenic 
phenotype (Fig. 1, Figs. S4C and E, Table S2). For the remaining transition the effect 
caused by the single substitution could not be determined (Fig. S4I). We further tested 
the results for all cluster transitions using virus neutralization assays and obtained 
similar results (Figs. S5 and S6, Table S2). In summary, we found that at least 9 of 10 
A/H3N2 cluster transitions over the 35-year period were predominantly caused by 
single amino acid substitutions.
Strikingly, all the cluster-transition substitutions occurred at only seven positions, 
immediately adjacent to the RBS (Fig. 2). Six of seven positions align to form an 
antigenic ridge on the periphery of the RBS, while the other, at position 145, is located 
on a loop that is partly involved in receptor binding. Five of seven key positions were 
involved in a cluster transition at least twice (Fig. 1, Table S3).
Substitutions responsible for major antigenic change were located exclusively in 
antigenic sites A (position 145) and B (positions 155, 156, 158, 159, 189, and 193), 
with none in sites C, D, or E. Our results do not contradict the studies that found 131 
positions that can cause antigenic change and that define sites A-E (32, 33). Rather 
we show that nature has, during 35 years of A/H3N2 virus circulation in humans, 
only selected for the substantial antigenic changes caused by substitutions at only 
seven of these 131 position; this is an important change in our understanding of 
the antigenic evolution of seasonal influenza viruses.
Even though antibodies have been found to bind many regions of the HA, 
the location of the key positions for antigenic change on the periphery of the RBS 
suggests that RBS region specific antibodies play the critical role in neutralizing 
influenza A/H3N2 viruses. 
To test the surprising finding that the antigenic phenotype was determined 
by the amino acids at just seven positions we attempted to change the phenotype of 
the HK68 consensus virus to become FU02-like by introducing only the five cluster-
transition substitutions that differ between the HK68 and FU02 antigenic clusters 
(Table S4). This test compares the effect of substitutions at just five positions (HK68+5) 
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to the 54 substitutions that occurred over 35 years between HK68 and FU02, 47 
of which were in antigenic sites. Remarkably, the HK68+5 mutant is FU02-like 
antigenically: it had an HI titer only 3-fold lower than the FU02 consensus virus 
to a FU02 antiserum (Fig. S7, Table S4). Interestingly, although HK68+5 had 
a substantially (20-fold) reduced titer with the HK68 antiserum, it retained some 
residual low reactivity with the HK68 serum. In a similar experiment we incrementally 
introduced cluster-transition substitutions into the HK68 consensus virus. The antigenic 
properties of the mutants matched those of the consensus viruses from subsequent 
clusters other than in their HI titers to one of the two HK68 sera. After introduction 
of all cluster-transition substitutions between the first five clusters we were unable to 
rescue the mutant virus. In summary, even for highly divergent strains with as many 
as 54 substitutions and 35 years of evolution between them, only the amino acid 
substitutions at key positions determined the majority of the antigenic phenotype.
We next tested the effect of a cluster-transition substitution in HA on the antibody 
response in an infected host. Two groups of three ferrets each were inoculated 
with either the wildtype HK68 consensus virus or HK68 containing cluster-transition 
substitution 155TY, and antisera were collected two weeks later. Each antiserum 
was titrated in the HI assay to 31 viruses belonging to the HK68, EN72, or VI75 
antigenic clusters (31). Antisera to the HK68 consensus virus had a 25-fold (4.6 log2) 
reduction in reactivity to EN72-like strains (compared to its reactivity with HK68-like 
viruses) and had no reactivity to the majority of the VI75-like viruses. In contrast, 
antisera to HK68 155TY had only 4-fold (2.1 log2) reduced titers to EN72-like strains, 
and had substantial titers to the viruses from the VI75 cluster (Fig. 3 and Fig. S9). 
Thus, a single cluster-transition substitution can also substantially increase reactivity of 
the antiserum raised to the mutant virus to strains from subsequent antigenic clusters 
while maintaining reactivity to the antigenic cluster of origin.
The identification of key influential positions in HA and single amino acid 
substitutions responsible for major antigenic changes provides a plausible explanation 
for the previously described punctuated nature of the antigenic evolution of influenza 
A/H3N2 virus (31): 9 out of 10 cluster transitions were predominantly caused by 
a single amino acid substitution.
Although we found that almost 90% of HA substitutions associated with cluster 
transitions had little or no measurable antigenic effect, these findings do not imply 
that substitutions away from the RBS are phenotypically neutral. Some may be neutral 
hitchhikers carried along by chance, but others may collectively add to the decreased 
recognition by antibodies raised to a strain in an earlier cluster (Figs. 3, S7 and S8), or 
may be compensatory mutations necessary to retain function. 
Given the high mutation rate of influenza virus and the observation that single 
amino acid substitutions are sufficient to cause antigenic cluster transitions, it is 
surprising that new antigenic clusters appear as slowly as they do—on average every 
3.3 years (31). One hypothesis is that antigenic change has an intrinsic fitness cost 
that slows down the antigenic evolution of the virus. We found that several mutant 
viruses with substitutions near the RBS could not be rescued (Figs. S4E and I, S8). 
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Fig. 1. Antigenic effect of cluster-transition substitutions. A) Antigenic maps of A/H3N2 virus 
evolution and cluster transition mutants. The central map provides an overview in which antisera 
and epidemic strains are indicated by open squares and colored circles respectively, and consensus 
viruses by larger colored circles. Both vertical and horizontal axes represent antigenic distance. 
The spacing between gridlines is one antigenic unit distance, corresponding to a two-fold difference 
in the HI assay. Cluster names are as indicated in B). Maps I-X show each cluster transition in more 
detail. Diamonds indicate the position of viruses with cluster-transition substitutions. B) Overview 
of cluster-transition substitutions. The clusters are named after the first vaccine strain in the cluster, 
with letters and digits referring to location and year of isolation (HK; Hong Kong, EN; England, 
VI; Victoria, TX; Texas, BK; Bangkok, SI; Sichuan, BE; Beijing, WU; Wuhan, SY; Sydney, FU; Fujian). 
A
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Colored circles indicate the consensus viruses. The gray background shapes indicate the cloud of 
strains that make up an antigenic cluster. The red line represents the evolutionary path from the HK68 
to the FU02 consensus virus. Antigenic distances between consensus viruses are shown in red. Arrows 
indicate antigenic distance and direction of the cluster-transition amino acid substitutions. Antigenic 
distance between the mutant and consensus virus is indicated in parentheses. Substitutions between 
square brackets are accessory substitutions, which changed direction towards the subsequent cluster 
(Figs. 2, S6 and S10, Table S3), and did not significantly add to the antigenic distance.
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Fig. 2. Positions of the cluster-transition amino acid substitutions indicated on an A/Aichi/2/1968 
HA trimer. The three monomers are shown in black, white and grey, the RBS in yellow. A) and B) 
The positions responsible for A/H3N2 cluster transitions are shown in red. An asterisk indicates 
accessory substitutions (Fig. S10). Position 193 is both a cluster-transition and accessory substitution 
(Fig. 1B). C) Positions of amino acid substitutions responsible for antigenic change of influenza 
A/H1N1 and B virus are shown in green and magenta, respectively. The positions responsible for 
cluster transitions of A/H3N2 virus are shown in light brown.
These results suggest that introduction of mutations on the periphery of the RBS 
can affect HA function, and that co-mutations may be crucial to retain viral fitness. 
The requirement for co-mutations that offset the fitness cost of antigenic evolution 
could provide an explanation for the paradox of high mutation rate and slow 
antigenic evolution. 
Almost all substitutions responsible for cluster transitions resulted in substantial 
changes in the biophysical properties of the amino acids involved. For instance, in nine 
cluster transitions at least one charge change was involved, and substantial volume 
changes were involved in three transitions (Table S5). The amino acid composition of 
the key positions seems limited by their exposed nature. Hydrophobic amino acids 
are typically located on the interior of a protein where they can be shielded from 
solvent access. Tyrosine, which is only partially hydrophobic because of the hydroxyl 
group on its aromatic ring, was the only hydrophobic amino acid observed on the key 
positions. The necessity for maintaining a functional HA structure as well as escape 
from neutralizing antibodies may have restricted the range of possible amino acids. 
The number of potential glycosylation sites on the A/H3N2 virus HA has steadily 
increased since 1968 (24), and the presence of carbohydrate side chains has been 
associated with shielding of antibody epitopes (61, 62). A total of 14 HA positions 
are associated with glycosylation of the A/H3N2 viruses that circulated from 
1968 – 2003. Two positions, 133 and 144, are located adjacent to the RBS. However, 
changes in glycosylation did not coincide with cluster transitions and viruses 
belonging to the same antigenic cluster often had different glycosylation states (63). 
In agreement with these observations, the cluster-transition substitutions neither 
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Fig. 3. Effect of a cluster-transition substitution on the antibody response of ferrets. Groups of three 
ferrets were inoculated with HK68 consensus virus or HK68+155TY, and antisera were tested to strains 
from the HK68 (purple), EN72 (cyan) or VI75 (yellow) clusters of Fig. 1. Circles, triangles and diamonds 
mark the three individual antisera. Black horizontal lines show the mean log2 HI titer. DL indicates 
the detection limit of the HI assay at the starting dilution (1/20) we used. Reactivity below detection 
was set to the value of the detection limit to calculate the means; these points are indicated in grey. 
The log2 reduction in mean reactivity to the different strains is indicated between the groups.
introduced nor deleted any glycosylation sites, and glycosylation was therefore not 
directly involved in the antigenic changes between the clusters. The location of 
the majority of the potential glycosylation sites away from the RBS could be 
the reason why changes in glycosylation have not played a major role in the antigenic 
change of A/H3N2 viruses. 
To further expand these results, we examined the most recent antigenic 
cluster transitions in the other human seasonal influenza viruses: the B/Yamagata 
and B/Victoria lineages of the B viruses, and the pre-2009 A/H1N1 viruses 
(the current A/H1N1pdm09 viruses are yet to undergo a cluster transition). We found 
the same results as for the A/H3N2 viruses: The major antigenic change was caused 
by a single amino acid substitution in the corresponding region close to the RBS 
(Fig. 2C, Figs. S11-13). 
We find that although human A/H3N2 seasonal influenza viruses have fixed amino 
acid substitutions at 54 positions in antigenic sites, substitutions at only seven of these 
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locations have been responsible for the major antigenic changes in these viruses 
to date. Moreover, these locations are all near the RBS of the HA, which suggests 
the mechanism for slowing the antigenic evolution of these viruses could be 
a reduction in receptor binding function. This small number of critical positions, and 
restricted amino acid usage involved in antigenic cluster transitions, suggests that 
possibilities for important antigenic change of seasonal influenza viruses may be 
more restricted than previously thought, with potentially far reaching consequences 
for understanding the underlying evolutionary mechanisms governing such viruses. 
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MATERIALS METHODS
Cells 
293T cells were cultured in DMEM (Cambrex, Heerhugowaard, The Netherlands) 
supplemented with 10% FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2mM 
glutamine, 1mM sodiumpyruvate, and non-essential amino acids (MP Biomedicals, 
Europe, Illkirch, France). Madin-Darby Canine Kidney (MDCK) cells were cultured 
in EMEM (Cambrex) supplemented with 10% FCS, 100 IU/ml penicillin, 100 μg/ml 
streptomycin, 2mM glutamine, 1.5 mg/ml sodiumbicarbonate (Cambrex), 10mM 
Hepes (Cambrex), and non-essential amino acids (MP Biomedicals). 
Recombinant, chimeric and mutant virus construction
Full hemagglutinin (HA) genes of the consensus virus of each antigenic cluster were 
cloned in the modified pHW2000 expression plasmid (64, 65), where consensus viruses 
are those viruses with the HA amino acid consensus sequence for that cluster (HK68; 
A/Bilthoven/16190/68, EN72; A/Bilthoven/21793/72, VI75; A/Bilthoven/1761/76, 
TX77; A/Bilthoven/2271/76, BK79; A/Netherlands/233/82 193N, SI87; A/
Netherlands/620/89, BE89; A/Netherlands/823/92, BE92; A/Netherlands/179/93, 
WU95; A/Netherlands/178/95 145K, SY97; A/Netherlands/427/98 and FU02; A/
Netherlands/213/03. Cluster names as defined in Fig. 1). For nine of the eleven 
clusters the HA amino acid consensus sequence was identical to that of a naturally 
occurring virus from that cluster. For two clusters the HA consensus sequences were 
constructed by genetic modification of the HA of a virus from that cluster. The BK79 
cluster consensus virus was genetically engineered to represent the amino acid 
consensus sequence of the BK79 cluster by introducing the 193KN substitution in 
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the A/Netherlands/233/82 HA. The virus representing the WU95 cluster was genetically 
engineered to be antigenically WU95-like by introduction of the 145NK substitution 
in the NL/178/95 HA (31), and differs from the true WU95 consensus sequence by 
two amino acids (135TK and 262SN). A/Netherlands/301/99 was initially selected 
to represent the SY97 cluster. The virus grows to normal TCID50 titers but wildtype, 
recombinant, and mutant viruses had very low HA titers, which potentially affected 
HI assay results. We therefore selected A/Netherlands/427/98 to represent the SY97 
cluster. This virus differs from NL/301/99 by five amino acid substitutions that occur 
only in the SY97-like viruses from 1999 onwards (and that may have been responsible 
for the poor hemagglutination). A/Netherlands/427/98 and A/Netherlands/301/99 
are antigenically very similar and differ by less than one antigenic unit in 
the antigenic map.
HA chimeric constructs were made by digestion of consensus HAs with SalI 
– NdeI  (HA1, amino acids 1-301), SalI – Bsu36I (5’-HA1, amino acids 1-108), 
or Bsu36I – NdeI (3’-HA1, amino acids 109 – 301), and ligation in the pHW2000 
expression plasmid containing the SI87 HA gene (see Fig. S1). SI87 was chosen 
because of its central position in the antigenic map. The NdeI site was not present in 
the A/Netherlands/178/95 HA sequence. Therefore NsiI was used for digestion, 
yielding fragments of slightly different sizes; SalI-NsiI (HA1): amino acids 1-282, and 
Bsu36I-NsiI (3’-HA1): amino acids 109-282. The HA of A/Netherlands/233/82 which, 
except for the Lysine (K) at position 193, has the amino acid consensus sequence for 
the BK79 cluster and was used to construct BK79 chimeric viruses. We were unable to 
rescue the SY97-HA1 chimeric virus. 
Introduction of 50 initial point mutations was outsourced to Baseclear 
(Leiden, The Netherlands). Introduction of mutations for the remaining 70 mutants 
(additional single and combined mutations) was performed using the QuickChange 
multi-site directed mutagenesis kit (Stratagene, Leusden, The Netherlands) according 
to the manufacturers instructions. Modified plasmids were subsequently used to 
generate recombinant viruses consisting of the modified HA gene and remaining 
gene segments of the A/Puerto Rico/8/34 strain by reverse genetics as described 
elsewhere (64). The presence of correct regions/mutations and absence of undesired 
mutations was confirmed by sequence analysis of the HA gene. 
The HA of the A/Singapore/92/05 A/H1N1 virus was genetically modified to match 
the HA1 amino acid sequence of A/Cheju/960/05 (NC99; A/New Caledonia/20/99-
like) and A/Daejeion/1000/05 (SS06; A/Solomon Islands/3/06-like). The recombinant 
viruses were rescued in the context of A/Puerto Rico/8/34 gene segments. All 
influenza B viruses were wildtype strains belonging to the B/Florida/4/06 (FL06) - B/
Wisconsin/1/10 (WN10) antigenic phenotypes (influenza B virus Yamagata-lineage), 
or B/Malaysia/2506/04 (ML04) - B/Brisbane/60/08 (BR08) antigenic phenotypes 
(influenza B virus Victoria-lineage).
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Accession numbers
In addition to the previously published A/H3N2 sequences by Smith et al. (31) 
the sequences of the influenza A/H1N1 and B viruses used in this study are available 
from the GISAID EpiFluTM Database (www.gisaid.org) and selected sequences are 
listed in Table S6.
Virus production
Virus stocks were generated by inoculation of Madin Darby Canine Kidney (MDCK) 
cells with 2mL 293T transfection supernatant. Inoculum was removed after 2 hours 
and replaced by MDCK infection medium, consisting of EMEM (Cambrex), 100 IU/ml 
penicillin, 100 μg/ml streptomycin, 2mM glutamine, 1.5 mg/ml sodium bicarbonate, 
10mM Hepes, non-essential amino acids, and 25 μg/ml trypsin. Subsequently, 
plates were incubated at 37°C / 5% CO2. If hemagglutination titers were below 12 
hemagglutinating units, culture supernatants were subjected to ultracentrifugation to 
concentrate viral particles.
Hemagglutination inhibition assay
Hemagglutination inhibition (HI) assays using a panel of post-infection ferret antisera 
were performed using standard procedures (37). Briefly, ferret antisera were prepared 
upon intranasal inoculation and collecting blood 14 days (A/H3N2 and A/H1N1 
viruses) or 21 days (influenza B viruses) later. An overview of antisera used in this 
study is provided in Table S1. Antisera were pre-treated overnight at 37 °C with 
receptor destroying enzyme (Vibrio cholerae neuraminidase) and incubated at 56°C 
for 1h. Two-fold serial dilutions of the antisera, starting at a 1:20 dilution, were mixed 
with 25 μL of a virus stock containing 4 hemagglutinating units and were incubated 
at 37°C for 30 minutes. Subsequently, 25 μL 1% turkey erythrocytes was added 
and the mixture was incubated at 4°C for 1h. Hemagglutination inhibition patterns 
were read and the HI titer was expressed as the reciprocal value of the highest dilution 
of the serum that completely inhibited agglutination of turkey erythrocytes. 
Virus neutralization assay
Virus neutralization assays were performed as described previously (66). Briefly, 
antisera were heated for 30 minutes at 56°C and twofold serial dilutions 
of the antisera starting at a 1:10 dilution, were mixed 1:1 with 100 tissue culture 
infectious dose50 (TCID50) of the virus stocks. After incubation at 37°C for 2h 
the antiserum – virus mixture was transferred to 96-wells plates containing MDCK 
cells, which were washed twice with PBS prior to inoculation. Plates were incubated 
for 2h at 37°C, and inoculum was replaced by 200 μL infection medium. After seven 
days end-point dilutions were read by hemagglutination assay. 
2SEVEN KEY POSITIONS DICTATE H3N2 VIRUS ANTIGENIC EVOLUTION
32
Plaque reduction assay
Plaque reduction assays were performed essentially similar to the virus neutralization 
assays. Inoculum consisted of antiserum dilutions mixed with 100 plaque-forming 
units of virus, and was replaced after two hours of inoculation by a 1:1 mixture of 2.4% 
Avicell (67) and double strength infection medium. Presence of plaques was read by 
immunostaining of influenza virus nucleoprotein expressed in the MDCK cells two 
days after inoculation. The end-point dilution was defined as the dilution in which 
there was complete inhibition of plaque formation. 
Antigenic cartography
Antigenic map construction was performed as described previously (31). Briefly, 
antigenic cartography is a method to increase the resolution of, resolve paradoxes in, 
and visualize HI data. In an antigenic map, the distance between antiserum point S and 
antigen point A corresponds to the difference between the log2 of the maximum titer 
observed for antiserum S against any antigen and the log2 of the titer for antiserum 
S against antigen A. Thus, each titer in an HI table can be thought of as specifying 
a target distance for the points in an antigenic map. Modified multidimensional 
scaling methods are then used to arrange the antigen and antiserum points in an 
antigenic map to best satisfy the target distances specified by the HI data. The result 
is a map in which the distance between the points represents antigenic distance as 
measured by the HI assay in which the distances between antigens and antisera are 
inversely related to the log2 HI titer. Because antisera are tested against multiple 
antigens, and antigens tested against multiple antisera, many measurements can be 
used to determine the position of the antigen and antiserum in an antigenic map, 
thus improving the resolution of HI data. 
Positions of the cluster-transition amino acid substitutions in the HA structure
The positions identified as responsible for significant antigenic change were plotted 
on the crystal structure of the A/Aichi/2/1968 (A/H3N2) virus HA [PDB accession 
code 5HMG] using MacPyMOL (The PyMOL Molecular Graphics System, Version 1.3, 
Schrödinger, LLC) for visualization of the trimer.
Rationale of substitution choices
Smith et al. (31) previously identified 67 cluster-difference substitutions associated 
with the antigenic evolution of A/H3N2 viruses. An amino acid substitution X to Y at 
location L was considered a cluster-difference substitution between clusters A and B 
if all (or all but one) strains in cluster A have amino acid X at location L, and all (or all 
but one) strains in cluster B have amino acid Y at location L. The analysis shown in 
Figs. S1, S2 and S3 indicated that only the amino acid positions 109 – 301 in HA1 were 
relevant for the antigenic phenotype. Therefore, the 54 substitutions that were within 
region 109 – 301 from the set of 67 were introduced in the appropriate consensus HA. 
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Initially all substitutions were tested individually. If single substitutions did not 
induce the antigenic change necessary for the cluster transition, combinations 
of substitutions were tested. Where possible the substitution(s) responsible for 
a cluster transition were tested both in chronological time order (forward mutant, 
e.g. HK68 – EN72 transition) and in reverse time order (reverse mutant, e.g. 
EN72 – HK68 transition). Fig. S4 describes each cluster transition in detail, motivates 
the choice of mutations introduced, and explains why particular mutants could not 
be tested.
Substitutions responsible for major antigenic change were located exclusively 
in antigenic sites A and B, and generally involved gross changes in the physical 
properties of the amino acids. We tested mutants with cluster-transition substitutions, 
and mutants with cluster-difference substitutions in sites C, D and E (Fig. S6) that had 
large changes in amino acid properties (Table S2) in virus neutralization assays to test 
if results matched those obtained by HI assay (Fig. S5).
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SI87 HAconsensus
HA1 chimera
3’ HA1 chimera
5’ HA1 chimera
Consensus HA
CTTMNCR NCR5’-HA1 3’-HA1
HA1 HA2SP
SalI Bsu36I
(aa 108)
NdeI
(aa 301)
NsiI
(aa 282)
3’-HA1
3’-HA15’-HA1
5’-HA1
Fig. S1. Construction of HA chimeric viruses. The top bar shows the different regions of the HA gene, 
SP: signal peptide, NCR: non-coding region, TM: transmembrane region, and CT: cytoplasmic tail. 
Colors indicate the amino acid positions located in the antigenic sites, yellow: site A, red: site B, 
purple: site C, blue: site D, green: site E. White portions in the lower bars indicate regions derived 
from consensus strains, grey regions are derived from the SI87 consensus virus. Vertical arrows 
indicate the location of restriction sites. Amino acid positions of restriction sites are indicated 
between brackets.
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HK68EN72
VI75TX77
BK79
SI87
BE89 BE92
WU95
SY97
FU02
Fig. S2. Antigenic properties of consensus and chimeric viruses. The colored symbols represent strains, 
open squares represent antisera. Small circles represent wild type viruses, large circles recombinant 
consensus viruses, triangles HA1 chimeric viruses, and diamonds 3’-HA1 chimeric viruses. The viruses 
are color coded by antigenic similarity. Star shapes indicate 5’-HA1 chimeric viruses and are color 
coded by their 5’-HA1 genetic composition (see Fig. S1). Both vertical and horizontal axes represent 
antigenic distance. The spacing between gridlines is one antigenic unit distance, corresponding to 
a two-fold difference in the HI assay.
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Fig. S3. HI data for chimeric 
viruses. Titers reflect the geometric 
average of multiple HI tests. 
The chimeras are grouped and color-
coded by HA1, 3’-HA1 and 5’-HA1 
genotype. The prefix R indicates that 
the chimera is a 7:1 recombinant 
virus, suffixes -H, -3H and -5H specify 
HA1, 3’-HA1 and 5’-HA1 chimeras 
respectively. A dash in the main body 
of the table marks the absence of 
(reliable) HI data for this antigen – 
antiserum combination, which may 
occur when the standard deviation 
of repeat measurements is more 
than one, a black asterisk marks 
the lack of cross-titration for that 
antigen – antiserum set. When 
the highest concentration of antiserum 
did not inhibit hemagglutination, 
the titer is indicated as a threshold 
titer (e.g. <10). 
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Fig. S4
Antigenic maps of cluster transitions. The figure is similar to the small maps in 
Fig. 1, but in addition the positions of all tested mutants is indicated. The larger 
circles represent the consensus viruses for the two clusters shown in the map, small 
circles with arrows indicate mutants, small faint colored circles are wildtype strains, 
and diamonds indicate the mutant with the minimal set of substitutions necessary 
for the cluster transition. Below each map we show the HI titers for the mutants and 
consensus viruses in the map. In the HI tables consensus viruses are indicated in bold 
and with the suffix REC. The tables are subdivided in forward and reverse mutants, 
and occasionally in single and double/triple mutants if more than one substitution 
was necessary for a cluster transition. Only those antiserum columns with at least 
one titer above the detection limit are shown in the tables. A dash in the main body 
of the table marks the absence of (reliable) HI data for this antigen – antiserum 
combination, which may occur when the standard deviation of repeat measurements 
is more than one, a black asterisk indicates that that antigen – antiserum combination 
was not titrated. When the highest concentration of antiserum did not inhibit 
hemagglutination, the titer is indicated as a threshold titer (e.g. <10). The tables can 
be zoomed to show details. All mutants were initially analyzed in small antigenic maps 
constructed using only the HI data obtained from the assays in which the mutants 
were tested. When the mutations responsible for the cluster transitions were identified 
they were integrated into, and re-analyzed in the context of, the larger 35-year map 
(see Smith et al. (31)).
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155TY
207RK
122TN
144GD
155YT
H 68K
EN72
188ND
Fig. S4A. HK68 – EN72 cluster transition. The five cluster-difference substitutions were initially tested 
as forward mutants. Only 155TY induced a significant antigenic change. No antigenic changes were 
observed for the remaining four mutants. The symbols for 144GD and 122TN largely overlap and 
therefore only four forward mutants are visible in the map. Because new batches of antisera were 
raised, the 155TY forward and 155YT reverse mutants as well as the consensus strains were retested, 
as shown in the top and bottom right panels of the table. Hence, we conclude that the single cluster-
transition substitution for the HK68 to EN72 cluster transition was 155TY.
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HK68122TN 2560 1120 640 960 200 * * * *
HK68144GD 2560 3840 1120 1280 280 * * * *
HK68155TY 640 40 640 1280 240 1120 80 800 200
HK68188ND 3200 1280 800 320 240 * * * *
HK68207RK 2560 1280 640 1120 280 * * * *
EN72REC 218 59 1301 1920 240 226 80 2048 363
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EN72REC 226 80 2048 363
EN72155YT 800 1920 960 160
HK68REC 2715 1280 320 86
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188ND
217IV
201RK
137NS
174FS
189QK193SD
189QK
193SD
189KQ193DS
189KQ
EN72
VI75
164LQ
145SN
230IV
278IS
213IV
Fig. S4B. EN72 – VI75 cluster transition. All cluster-difference mutants were initially tested to 
the antisera as shown in the left panel of the table. Out of 11 forward pointmutants only 189QK showed 
substantial antigenic difference compared to the EN72 consensus virus. Substitution 193SD showed 
more than 1 unit antigenic divergence from the consensus virus, and was therefore combined with 
189QK. Both forward and reverse mutants with only the 189 substitution elicited a larger antigenic 
change than the double mutants. Because new batches of antisera were raised, the mutants that were 
antigenically different from the EN72REC strain were re-analyzed (top and bottom right panels of the 
table). Therefore we conclude that the only cluster-transition substitution for the EN72 to VI75 cluster 
transition was 189QK.
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193DN
158GE
137SY
VI75
TX77
Fig. S4C. VI75 – TX77 cluster transition. Nine cluster-difference substitutions were tested as 
single mutants initially, none of which could induce the cluster transition. Three mutants (137SY, 
193DN and 158GE were combined to make double and triple mutants. Both 158GE193DN and 
137SY158GE193DN have a similar phenotype as the TX77 strains. The directionality of the reverse 
mutant 137YS158EG193ND is incorrect and does not revert the phenotype to VI75-like, while 
the double reverse mutant 158EG193ND displays similar antigenic properties as the VI75-like strains. 
Hence, we conclude that 158GE and 193ND together were the cluster-transition substitutions for 
the VI75 – TX77 cluster transition.
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Fig. S4D-I. TX77 – BK79 cluster transition. Because of the limited number of strains in the TX77 cluster, 
which consists of only 3 strains (Smith et al. (31)), there are many cluster-difference substitutions 
between the TX77 and BK79 clusters. All 13 cluster-difference substitutions were initially tested 
as single mutants. Only TX77 156KE was substantially different from the TX77 consensus virus, 
and resembled the BK79 consensus virus antigenically (Fig. S4 D-I and Fig. S 4 D-II). Addition of 
the cluster-difference substitutions with large changes in amino acid properties—e.g. large changes 
in amino acid volume and/or charge changes—or substitutions near the receptor binding site to 
the TX77 156KE mutant did not induce additional antigenic change. Similarly, BK79 156EK reverted 
the antigenic phenotype to TX77-like and additional substitutions did not change the antigenic 
the antigenic properties as compared to 156EK alone. Thus, we conclude that 156KE alone was 
responsible for the antigenic difference between the TX77 and BK79 clusters.
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144DV156KE
156KE
156KE159SY
156KE163VA
TX77
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Fig. S4D-II. Antigenic change within the BK79 antigenic cluster. The viruses representing 
the antigenic clusters have an HA1 amino acid sequence that is the consensus sequence of all strains 
from the respective cluster. Such a virus is usually an adequate representative of the antigenic 
consensus of the cluster, however for the BK79 cluster this is not the case. We added to the TX77 
156KE cluster-transition mutant three substitutions that occurred within the BK79 cluster and which 
were different for BK79 strains located above or below the dashed line: 144DV, 163VA and 159SY. 
All three TX77 mutants are BK79-like, and 159SY and 144DV changed antigenically as compared to 
156KE alone and are located near the main body of the BK79 cluster. The addition of substitutions 
144DV or 159SY to the TX77 156KE cluster transition mutant thus resulted in viruses with antigenic 
properties that represented the BK79 cluster better than the amino acid consensus virus of the BK79 
cluster that does not have these substitutions. 
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Fig. S4E. BK79 – SI87 cluster transition. Three cluster-difference substitutions were associated with 
the BK79 to SI87 cluster transition: 124GD, 155YH and 189KR. These mutations were initially 
introduced in the wildtype HA of NL/233/82, which has the amino acid consensus sequence of 
the BK79 cluster except for 193NK. Both 155YH and 189KR changed antigenically but did not induce 
the full transition to SI87-like, and also combination of 155YH and 189KR did not entirely change 
the virus to SI87-like. Because BK79 193K viruses reacted with low titers to available antisera in HI 
tests, we introduced 193KN in the HA of A/Netherlands/233/82 to obtain the exact BK79 cluster 
genetic consensus. HA position 159 changed from Serine (S) to Tyrosine (Y) during the period that 
the BK79-like strains circulated, and structural analysis of HA suggested that this substitution could 
have a major impact on the antigenic properties of BK79-like viruses. The combination 
155YH159SY189KR induced a 5.8 antigenic unit change, and had the same phenotype as the SI87 
consensus virus. Interestingly, the 155HY159YS189RK reverse mutant was constructed, but we 
were unable to rescue this virus. Thus, we conclude that three substitutions were responsible for 
the antigenic difference between the BK79 and SI87 clusters: 155YH, 159SY and 189KR.
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Fig. S4F. SI87 – BE89 cluster transition. Only one cluster-difference substitution occurs between 
the SI87 and BE89 clusters. This substitution, 145NK, has been described previously by 
Smith et al. (31). The 135GE and 193NS substitutions, which have few exceptions to the cluster-
difference substitution criterion, were added to 145NK to test if these have additional significance to 
145NK alone. The 145NK135GE mutant did not change antigenically compared to 145NK.  Addition 
of 193NS did not affect the distance from the SI87 consensus virus, but better resembles the antigenic 
properties of the BE89 consensus virus than 145NK alone (see Fig. S10 for details). The reverse 
145KN and 145KN193SN mutants, although located on the interface of the SI87 and BE89 clusters, 
are 1.7 and 1.5 units away from the SI87 consensus virus, respectively. Hence we conclude that 
the cluster-transition substitution for the SI87 to BE89 cluster transition was 145NK.
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Fig. S4G. SI87 – BE92 cluster transition. Given that from phylogenetic analysis the most likely 
ancestor of the BE92 cluster was a SI87-like strain rather than a BE89-like strain (31), cluster- difference 
substitutions as defined by Smith et al. (31) were redefined comparing SI87 and BE92-clusters 
(Table S2). None of the cluster-difference substitutions 133SD, 190ED or 193NS, alone or as double or 
triple mutants, caused the antigenic change from the SI87 to the BE92 cluster. The reverse mutants were 
also tested, but similarly none could revert the antigenic phenotype to SI87-like. We therefore tested 
three additional substitutions that had few exceptions to the cluster-difference substitution criterion. 
Substitution 156EK resulted in a substantial antigenic difference from the SI87-like strains, but did not 
match the strains of the BE92 cluster antigenically. It was therefore combined with substitutions that 
induced more than 1 unit antigenic change from either SI87 or BE92. The combinations with the 156 
substitution resulted in an antigenic change that was at least 2 units larger than any other combination 
(between 3.8 – 6.3 antigenic units for combinations with the 156 substitution, between 1.4 – 1.8 for 
any other combination). For the reverse mutants no significant changes were observed by addition 
of other substitutions to 156KE. The addition of 133SD to 156EK in the forward mutant, however, 
skewed the phenotype to BE92-like, without affecting antigenic distance from the SI87 consensus 
virus. Since 133SD alone, or combined with all other substitutions except 156KE, did not result in 
evident antigenic change, we conclude that 133SD is considered to be accessory to the 156EK for 
this cluster transition (see Fig. S10 for details). We therefore conclude that 156EK was the cluster-
transition substitution for the SI87 to BE92 cluster transition.
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145KN
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Fig. S4H. BE92 – WU95 cluster transition. Smith et al. (31) previously showed that the 145NK 
substitution is responsible for the BE92 – WU95 cluster transition. For this study we additionally tested 
the reverse mutant WU95145KN, which reverts the phenotype to BE92-like. Thus, we conclude that 
the single cluster-transition substitution for the BE92 to WU95 cluster transition was 145NK.
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Fig. S4I. WU95 – SY97 cluster transition. Four cluster-difference substitutions occur between 
the WU95 and SY97 clusters. We were unable to rescue the 158EK mutant, and therefore could not 
test it as single mutant. The combination of 156KQ and 158EK induced an antigenic change of 3.6 
antigenic units from WU95REC, which is similar to specific strains of the SY97 antigenic phenotype. 
Its position, however, is away from the main body of the SY97 cluster. Addition of the remaining 
cluster-difference mutations to this double mutant did not result in a position more similar to 
the majority of the SY97-like strains. To test if substitutions that do not fit the cluster-difference 
criterion were involved in this cluster transition we combined the 156KQ158EK mutant with five 
additional substitutions. Four (121TN, 124GS, 133DN, and 142GR) had few exceptions to the criterion 
for a cluster-difference substitution and may therefore be involved in the antigenic change, and one 
(135KT) is typical for late WU95-like strains and is present in the majority of strains from the WU95 
cluster. Furthermore, the 133DN135KT combination was added because it introduces a glycosylation 
pattern. Addition of 121TN, 124GS, 133DN, or 142GR did not result in a position closer to 
the main body of the SY97 cluster. Addition of 135KT skewed the phenotype towards that typical of 
the majority of SY97-like strains without increasing antigenic distance from WU95REC (see Fig. S10 
for details). Addition of both 133DN and 135KT further increased the distance from WU95REC but 
within the SY97 cluster. The reverse mutant SY97 156QK158KE reverted the phenotype to WU95-like. 
We therefore conclude that the cluster-transition substitutions for the WU95 to SY97 cluster transition 
were 156KQ and 158EK.
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155TH156HQ
156HQ
155TH 156QH
155HT156QH
155HT
SY97
FU02
Fig. S4J. SY97 – FU02 cluster transition. Four cluster-difference substitutions occur between 
the SY97 and FU02 clusters, each of which was constructed and tested as a single mutation. The panel 
of 16 antisera used in the analysis did not recognize the 155HT, 156QH or the double 155HT156QH 
mutants. Each mutant was extensively tested to exclude contamination and sequence anomalies. 
The remaining two mutants, 131AT and 225GD, reacted normally but were SY97-like antigenically 
(data not shown). Jin et al. (48) reported that a combination of 155HT and 156QH, but not the single 
substitutions, reverted the phenotype from FU02 to SY97-like and concluded that both 155HT and 
156QH were required for the SY97 to FU02 transition, but also could not test the single forward 
mutants. The consensus virus that represents SY97 was replaced because both the consensus virus 
as well as mutants made from the consensus HA grew to very low HA titers, which may have caused 
the unexpected results (see materials and methods for details). We rescued and tested the three 
forward and reverse mutants in the new consensus virus. The phenotypes of the 155HT156QH double 
and 156QH single mutants were very similar, also for the reverse mutants, and both the induced 
the cluster transition. The directionality of the 155HT alone was more towards earlier clusters. Thus, 
155HT did not contribute to the antigenic effect of 156QH. Hence, we conclude that the cluster-
transition substitution for the SY97 to FU02 cluster transition was 156QH.
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Fig. S5. Correlation between hemagglutination inhibition and virus neutralization assays. A) Consensus 
viruses and their associated forward and reverse cluster-transition mutants (black symbols), and 
non-cluster-transition mutants in sites C, D and E (open symbols), were tested in both the HI and 
micro neutralization (MN) assays. Titers are expressed as the log2 of the resulting value found in each 
assay. R2 = 0.65, 95% CI = 0.64 – 0.90, P-value (two-tailed) < 0.0001. B) Consensus viruses used in 
the analysis of cluster-defining substitutions were tested in both the HI and plaque reduction 
(PR) assays. Titers are expressed as the log2 of the resulting value found in each assay. R
2 = 0.96, 
95% CI = 0.83 – 0.99, P value (two-tailed) < 0.0001.
B
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Fig. S7. Effect of exchanging amino acids on key positions in the HK68 and FU02 consensus viruses. 
Solid purple and yellow lines show the log2 HI titers for the HK68 and FU02 consensus viruses to 
a set of antisera that are representative of the antigenic clusters. DL indicates the detection limit 
of the HI assay used. Vertical arrows denote the fold difference from homologous titers with HK68 
and FU02 consensus viruses. A) The dashed yellow line shows the log2 HI titers for HK68+5, which is 
genetically fully HK68 consensus except for the five substitutions on the seven key positions that differ 
between the HK68 and FU02 viruses. B) The dashed purple line indicates the log2 HI titers for FU02-5 
(FU02 minus 5) that has the five amino acids typical of the HK68 consensus virus on the seven key 
positions, but is otherwise genetically fully FU02 consensus. The amino acid substitutions in HK68+5 
and FU02-5 compared to the HK68 and FU02 consensus viruses, as well as the HI titers, are listed 
in Table S4. The antisera used in this experiment were raised to viruses from the following antigenic 
clusters: HK/1A/68; HK68, BI/21793/72; EN72, VI/3D/75; VI75, NL/209B/80; BK79, SH/11A/87; 
SI87, LY/1149/91; BE89, JO/33A/94; BE92, LY/2279/95; WU95; NL/118/01; SY97, FU/411/02; 
FU02.  The data in this figure are an extreme test of the findings for ‘natural’ cluster transitions 
(cluster transitions between neighboring clusters) by incorporating only the cluster-transition 
substitutions for nine consecutive cluster transitions from HK68 to FU02 into a single virus.  Interestingly, 
the forward mutant virus in panel A retains some binding to the HK68 antiserum (HK/1A/68), gains 
titers to the latest antisera (NL/118/01 and FU/441/02) and has undetectable titers to the other 
antisera in the panel—other than residual titers to the HK/1A/68 antiserum, this highly artificial virus 
is essentially FU02-like. 
Fig. S6. Structure of an A/Aichi/2/1968 HA trimer. Accessory substitutions and cluster-difference amino 
acid substitutions tested in both hemagglutination inhibition and virus neutralization assays indicated 
on an A/Aichi/2/1968 HA trimer. The three monomers are shown in black, white and grey, the RBS in 
yellow. For reference, panel C shows the positions of antigenic sites A-E. A) Positions of accessory 
substitutions (blue) and cluster-difference amino acid substitutions tested in virus neutralization 
assays (magenta). Mutants tested were: EN72 53ND; site C, EN72 201RK; site D, VI75 50KR; site 
C, VI75 82EK; site E, VI75 174SF; site D, WU95 62KE; site E, WU95 276NK; site C, SY97 50RG; 
site C, and SY97 75HQ; site E. B) Zoomed in on the area around the RBS. Position 193 is a cluster-
transition substitution in the VI75 to TX77 antigenic cluster transition, but is an accessory substitution 
in the SI87 to BE89 cluster transition (Fig. S10). Position 201 is located on the trimer interface behind 
the dark monomer in this figure and is therefore not visible. C) Position of antigenic sites A-E (32, 33). 
Site A; red, site B; light blue, site C; blue, site D; orange, and site E; green.
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Fig. S8. Incremental addition of cluster-transition substitutions. A) Solid purple and cyan lines indicate 
log2 HI titers for HK68 and EN72 consensus viruses, respectively. The dashed cyan line shows log2 HI 
titers for HK68 155TY, which has the substitution responsible for the major antigenic change between 
the HK68 to EN72 cluster but not the remaining four cluster-difference substitutions. In all panels, DL 
indicates the detection limit of the HI assay used. B) Solid purple and yellow lines indicate log2 HI 
titers for the HK68 and VI75 consensus viruses, respectively. The dashed yellow line shows the log2 HI 
titers for HK68 155TY189QK—the cluster-transition substitutions responsible for the HK68 to EN72 
and EN72 to VI75 cluster transitions, but not the remaining 14 cluster-difference substitutions. C) 
Solid purple and brown lines indicate log2 HI titers for HK68 and TX77 consensus viruses, respectively. 
The dashed brown line shows log2 HI titers for HK68 155TY189QK158GE193DN that has the cluster-
transition substitutions for the HK68 to EN72, EN72 to VI75 and VI75 to TX77 cluster transitions, 
but not the remaining 21 cluster-difference substitutions. We constructed the HK68 consensus HA 
with all cluster-transition substitutions between HK68 and BK79, but could not rescue this mutant. 
The antisera used in this experiment were raised to viruses from the following antigenic clusters: 
HK/1A/68; HK68, HK/107A/71; HK68, BI/21793/72; EN72, PC/1B/73; EN72, VI/3D/75; VI75, BK/2/79; 
BK79, NL/209B/80; BK79. Panels B and C test the extremities of the findings for ‘natural’ cluster 
transitions (cluster transitions between neighboring clusters) by incorporating the cluster-transition 
substitutions for multiple (two and three respectively) consecutive cluster transitions into a single virus. 
Interestingly, the mutant viruses retain some binding to the earliest HK68 antiserum (HK/1A/68), but 
have mostly similar titers as the consensus viruses to the other HK68 antiserum (HK/107A/71) and to 
the other antisera in the panel.
2SEVEN KEY POSITIONS DICTATE H3N2 VIRUS ANTIGENIC EVOLUTION
69
B
I/2
17
93
A/
72
H
K/
1A
/6
8
H
K/
10
7A
/7
1
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
A
H
K/
1A
/6
8
H
K/
10
7A
/7
1
B
I/2
17
93
A/
72
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
B
H
K/
1A
/6
8
H
K/
10
7A
/7
1
B
I/2
17
93
A/
72
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
C
lo
g
2
H
I
ti
te
r
B
I/2
17
93
A/
72
H
K/
1A
/6
8
H
K/
10
7A
/7
1
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
A
H
K/
1A
/6
8
H
K/
10
7A
/7
1
B
I/2
17
93
A/
72
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
B
H
K/
1A
/6
8
H
K/
10
7A
/7
1
B
I/2
17
93
A/
72
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
C
lo
g
2
H
I
ti
te
r
B
I/2
17
93
A/
72
H
K/
1A
/6
8
H
K/
10
7A
/7
1
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
A
H
K/
1A
/6
8
H
K/
10
7A
/7
1
B
I/2
17
93
A/
72
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
B
H
K/
1A
/6
8
H
K/
10
7A
/7
1
B
I/2
17
93
A/
72
P
C
/1
B
/7
3
V
I/3
D
/7
5
B
K/
2/
79
N
L/
20
9B
/8
0
DL
1
2
3
4
5
6
7
8
9
10
C
lo
g
2
H
I
ti
te
r
A
B
2SEVEN KEY POSITIONS DICTATE H3N2 VIRUS ANTIGENIC EVOLUTION
70
HK68
E 72N
V 75I
wt-A
wt-B
wt-C
mut-A
mut-B
mut-C
wt-A
wt-B
wt-C
2.6
mut-A mut-B mut-C
3.7 3.7
2.2 3.3 3.3
1.5 2.1 2.1
Distance between antisera
(antigenic units)
Fig. S9. Antigenic map of antisera raised to the wildtype or a mutant HK68-like virus. The map 
shows the positions of antisera raised to the HK68 consensus virus (red squares) and to HK68 
155TY (red stars). The position of the HK68, EN72 and VI75-like strains are indicated by purple, 
cyan and yellow outlines, respectively. The inset table shows the distances between the antiserum 
positions. The average distance between the wildtype and mutant antisera is 2.7 antigenic units 
(a 6.5-fold dilution difference). This distance is similar to the distance between the HK68 consensus 
virus and the HK68 155TY mutant, and the distance between the HK68 and EN72 consensus viruses 
(2.6 and 3.1 antigenic units. Fig. 1 and Table S3).
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Fig. S10. Antigenic effect of accessory substitutions. For three cluster transitions an accessory 
amino acid substitution was required to change the antigenic phenotype to that characteristic 
of the subsequent cluster. The larger circles represent the consensus viruses for the two clusters 
shown in the map, small faint colored circles are wildtype strains, small filled circles indicate 
the cluster-transition mutant without the accessory substitution, diamonds indicate the cluster-
transition mutant with the accessory substitution. The distances in antigenic units between 
the consensus virus and mutants are indicated in the figures. A) The accessory substitution for 
the SI87 – BE89 transition was 193NS. B) The accessory substitution for the SI87 – BE92 transition 
was 133SD. C) The accessory substitution for the WU95 – SY97 transition was 135KT. Addition 
of the accessory substitutions did not result in increased antigenic distance from the consensus virus 
in which the substitution was introduced, but corrected for directionality towards the subsequent 
antigenic phenotype in the antigenic maps. Because no additional antigenic distance is acquired by 
addition of an accessory substitution, we did not consider these to be essential molecular determinants 
of the major antigenic change between clusters.
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Fig. S11. Antigenic change of epidemic A/H1N1 viruses. NC99; A/New Caledonia/20/99, SS06; 
A/Solomon Islands/3/06. The strains are colored according to the amino acid at position 140 
(H1 numbering); red circles have a Lysine (K) at position 140, whereas blue circles have a Glutamic 
acid (E) at this position. There are no other substitutions that are consistently different between 
viruses of the NC99 and SS06 phenotypes. No sequence information was available for the grey filled 
circles. The larger circles represent recombinant viruses that have the HA1 amino acid sequence from 
A/Cheju/960/05 and A/Daejeion/1000/05. The HA1 amino acid sequence of these viruses 
differs only by 140KE. Therefore, 140KE alone is sufficient to induce the antigenic transition 
from NC99 to SS06-like. 
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Fig. S12. Antigenic change of influenza B/Victoria-lineage viruses (7). ML04; B/Malaysia/2506/04, 
BR08; B/Brisbane/60/08. The strains are colored according to the amino acid at position 165 
(B/Victoria numbering): Blue circles have 165 Asparagine (N), orange circles have a Lysine (K) at this 
position. The HA1 amino acid sequences of the large blue and orange circles differ only by the 165NK 
substitution. Thus, change of an N to a K at position 165 was responsible for the antigenic change 
between the ML04 and BR08 antigenic phenotypes.
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Fig. S13. Antigenic change of influenza B/Yamagata-lineage viruses (7). FL06; B/Florida/4/06, 
WN10; B/Wisconsin/1/10. The strains are colored according to the amino acid at position 166 
(B/Victoria numbering): strains that have an Asparagine (N) at position 166 are shown in magenta, 
those with 166 Tyrosine (Y) in green. The HA1 amino acid sequences of the large magenta and green 
circles differ by only 166NY. We conclude that the 166NY substitution was solely responsible for 
the antigenic difference between the FL06 and WN10 antigenic phenotypes.
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Table S1. Ferret antisera used in this study. Each antiserum was raised in ferrets as described in 
Supplementary Methods. When antisera were raised to the same strain multiple times the repeat 
antisera were labeled A, B, C, etc., additional to the virus strain name to which the serum was raised 
(e.g. A/Hong Kong/1/68, A/Hong Kong/1A/68, A/Hong Kong/1B/68). Data obtained using different 
antisera raised to the same strain were treated as individual antisera, i.e. data from A/Hong Kong/1/68 
and A/Hong Kong/1A/68 were not averaged. aInfluenza B virus Yamagata-lineage (7). bInfluenza B virus 
Victoria-lineage (7).
Antigenic 
cluster
Subtype  
or lineage Antisera
HK68 A/H3N2 A/Hong Kong/1/68 A/Hong Kong/107/71
EN72 A/H3N2 A/Bilthoven/21793/72 A/Port Chalmers/1/73 A/Scotland/840/74
VI75 A/H3N2 A/Victoria/3/75
TX77 A/H3N2 -
BK79 A/H3N2 A/Netherlands/209/80 A/Philippines/2/82 A/Netherlands/233/82
A/Netherlands/241/82 A/Stockholm/10/85
SI87 A/H3N2 A/Sichuan/2/87 A/Shanghai/11/87 A/Hong Kong/34/90
BE89 A/H3N2 A/Beijing/353/89 A/Victoria/2/90 A/Lyon/1149/91
A/Paris/548/92 A/Netherlands/823/92
BE92 A/H3N2 A/Beijing/32/92 A/Shangdong/9/93 A/Johannesburg/33/94
WU95 A/H3N2 A/Wuhan/359/95 A/Nanchang/933/95 A/Lyon/2279/95
A/Brisbane/8/96
SY97 A/H3N2 A/Sydney/5/97 A/Netherlands/118/01 A/Netherlands/88/03
FU02 A/H3N2 A/Fujian/411/02 A/Netherlands/22/03 A/Wellington/1-
IVR-139/04
A/Wisconsin/67/05 A/Netherlands/42/06
NC99 A/H1N1 A/New Caledonia/20/99 A/Netherlands/271/99 A/Netherlands/300/00
A/Netherlands/352/02 A/Netherlands/128/04 A/Netherlands/239/06
A/Netherlands/364/06 A/St.Petersburg/10/07
SS06 A/H1N1 A/Solomon Islands/3/06 A/Fukushima/97/06 A/Netherlands/361/06
A/Brisbane/59/07 A/Netherlands/345/07 A/Netherlands/165/08
FL06 B Yama B/Florida/4/06 B/Brisbane/3/07 B/South Australia/6/12
B/Malaysia/412/12
WN10 B Yama B/Bangladesh/3333/07 B/Indiana/1/08 B/South Australia/5/08
B/Brisbane/9/08 B/Hubei/
Wujiagang/158/09
B/Wisconsin/1/10
B/Brisbane/2/12
ML04 B Vicb B/Malaysia/2506/04 B/Darwin/40/06 B/Singapore/616/08
B/Philippines/6363/09 B/Cambodia/30/11
BR08 B Vicb B/Brisbane/33/08 B/Brisbane/60/08 B/Hong Kong/90/08
B/Sydney/508/10 B/South Australia/11/12
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Table S3. Cluster-transition substitutions and distance between mutant and consensus virus into which 
the substitutions were introduced. Cluster-transition amino acid substitutions as defined in the main 
text. Substitutions between brackets are accessory substitutions. The addition of these substitutions 
corrected for directionality towards the consensus virus of the subsequent cluster only and did not 
significantly add to the antigenic distance from the consensus virus in which the substitutions were 
introduced (Fig. S10).
Cluster 
transition
Cluster-transition substitutions Distance 
between 
consensus viruses
(antigenic units)
Distance 
mutant from 
consensus virus
(antigenic units)Antigenic Site A Antigenic Site B
HK68-EN72 155TY 3.1 2.6
EN72-VI75 189QK 4.7 4.1
VI75-TX77 158GE 193DN 1.3 1.6
TX77-BK79 156KE 2.1 1.2
BK79-SI87 155YH 159SY 189KR 6.9 5.8
SI87-BE89 145NK (193NS) 3.9 3.1
SI87-BE92 (133SD) 156EK 7.3 6.3
BE92-WU95 145NK 3.3 2.2
WU95-SY97 (135KT) 156KQ 158EK 5.5 3.6
SY97-FU02 156QH 2.4 1.1
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Table S4B.
HI titer from antisera to
HK68 EN72 VI75 BK79 SI87 BE89 BE92 WU95 SY97 FU02
  H
K
/1
A
/6
8
B
I/
21
79
3A
/7
2
V
I/
3D
/7
5
N
L/
20
9B
/8
0
SH
/1
1A
/8
7
LY
/1
14
9A
/9
1
JO
/3
3A
/9
4
LY
/2
27
9B
/9
5
N
L/
11
8/
01
FU
/4
11
/0
2
HK68 consensus 2506 640 30 <10 <20 <10 <10 <10 <10 <10
HK68+5 127 <10 <10 <10 <20 <10 <10 <10 15 497
FU02+5 40 20 <10 <10 <20 <10 <10 <10 20 80
FU02 consensus <10 <10 <10 <10 <20 <10 <10 <10 1920 1421
Table S4. Effect of exchanging amino acids on key positions in the HK68 and FU02 consensus viruses. 
Table S4A shows the positions responsible for the major antigenic change between the HK68 and FU02 
clusters. The HK68+5 virus is genetically fully HK68-like and, vice versa, the FU02-5 (FU02 minus 5) is 
genetically fully FU02 like, except for the five introduced cluster-transition substitutions. The HI titers in 
Table S4B are a measure of cross-reactivity of serum antibodies with the tested viruses, where a high value 
indicates good reactivity. When the highest concentration of antiserum did not inhibit hemagglutination, 
the titer is indicated as a threshold titer (e.g. <10). The viruses were tested to a set of antisera that are representative 
of the clusters shown in the antigenic map in Fig. 1. Titers shown are the geometric mean value of 
multiple independent experiments.
Table S4A.
HA position
145 155 156 158 159 189 193
HK68 consensus S T K G S Q S
HK68+5 K . H K Y S .
FU02-5 S . K G S Q .
FU02 consensus K . H K Y S .
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Table S5. Charge changes induced by cluster-transition and cluster-difference substitutions. Cluster-
transition and cluster-difference amino acid substitutions as defined in the main text and Smith et al. (31). 
Substitutions between brackets are accessory substitutions (Fig. S10). Neutr, pos and neg: uncharged, 
positively or negatively charged at physiological pH, respectively. vSubstantial change in amino acid 
volume after substitution. aInfluenza A/H1N1 virus. bInfluenza B virus Yamagata-lineage (7). cInfluenza 
B virus Victoria-lineage (7). N.D. not determined.
Cluster transition
Cluster  
transition- 
substitution
Change by cluster-
transition substitution
Total charge change 
cluster-transition 
substitution(s)
Total charge change 
cluster-difference 
substitution(s) 
HK68-EN72 155TY -v 0 -2
EN72-VI75 189QK neutr – pos +1 -1
VI75-TX77 158GE neutr – negv 0 +3
193DN neg – neutr
TX77-BK79 156KE pos – neg -2 +3
BK79-SI87 155YH neutr – pos +1 0
159SY -v
189KR -
SI87-BE89 145NK neutr - pos +1 +1
(193NS) -
SI87-BE92 156EK neg - pos +2 +1
(133SD) neutr – neg
BE92-WU95 145NK neutr – pos +1 +1
WU95-SY97 156KQ pos – neutr +1 0
158EK neg – pos
(135KT) pos – neutr
SY97-FU02 156QH neutr – pos +1 0
NC99-SS06a 140KE pos – neg -2 N.D.
FL06-WN10b 166NY -v 0 N.D.
ML04-BR08c 165NK neutr – pos +1 N.D.
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3ANTIGENIC VARIATION OF CLADE 2.1 H5N1 VIRUS  IS DETERMINED BY FEW AMINO ACID SUBSTITUTIONS IMMEDIATELY ADJACENT TO THE RECEPTOR BINDING SITE
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ABSTRACT
Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype are genetically 
highly variable and have diversified into multiple phylogenetic clades over the past 
decade. Antigenic drift is a well-studied phenomenon for seasonal human influenza 
viruses, but much less is known about the antigenic evolution of HPAI H5N1 viruses 
that circulate in poultry. We hypothesized that the molecular basis for antigenic 
change of avian H5N1 viruses circulating in poultry is similar to that of seasonal 
influenza viruses circulating in humans. In this study we focused on HPAI H5N1 clade 
2.1 viruses, which are enzootic to Indonesia. We selected a set of representative 
viruses from genetically distinct lineages that are currently circulating and determined 
their antigenic properties by hemagglutination inhibition assays. At least six antigenic 
variants have circulated between 2003, when H5N1 clade 2.1 viruses were first detected 
in Indonesia, and 2011. During this period, multiple antigenic variants co-circulated in 
the same geographic regions. Tests with mutant viruses constructed by site-directed 
mutagenesis revealed that antigenic differences between clade 2.1 viruses were due 
to single, double, or quadruple amino acid substitutions immediately adjacent to 
the receptor binding site. Antigenic variants of H5N1 virus evaded recognition by 
both ferret and chicken antibodies. The molecular basis for antigenic change of clade 
2.1 viruses closely resembled that of seasonal human influenza viruses, indicating 
that the hemagglutinin of influenza viruses from different hosts and subtypes may be 
similarly restricted to evade antibody recognition. 
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IMPORTANCE
HPAI H5N1 viruses are responsible for severe outbreaks in both commercial and 
backyard poultry, causing considerable economic losses and regular zoonotic 
transmissions to humans. Vaccination is a primary method to reduce the burden of 
HPAI H5N1 virus in poultry. Influenza viruses can escape from recognition by antibodies 
induced upon vaccination or infection through genetic changes in the hemagglutinin 
protein. The evolutionary patterns and molecular basis of antigenic change of HPAI 
H5N1 viruses are poorly understood, hampering formulation of optimal vaccination 
strategies. We show that HPAI H5N1 viruses in Indonesia diversified into multiple 
antigenic variants, that antigenic differences were due to one or very few substitutions 
near the receptor binding site and that the molecular basis for antigenic change was 
remarkably similar to that of seasonal human influenza viruses. These findings have 
consequences for future vaccination and surveillance considerations, and contribute 
to the understanding of the antigenic evolution of influenza viruses.
INTRODUCTION
Since their first detection in Southeast Asia in 1997, highly pathogenic avian influenza 
(HPAI) viruses of subtype H5N1 have spread to numerous countries of the Eastern 
hemisphere where they caused outbreaks in poultry and diversified into multiple 
distinct genetic lineages or clades (17-19). In Indonesia, HPAI H5N1 viruses were first 
detected in Central Java in August 2003 (17). The viruses were classified to belong 
to clade 2.1, and from early 2004 onwards, multiple persistent genetic lineages 
within this clade have emerged in Indonesia (68). Within the first two years after 
initial detection, the clade 2.1 viruses spread over large parts of the country (69) and 
frequently caused severe outbreaks in both backyard flocks and commercial poultry 
farms. Economic losses resulting from HPAI H5N1 virus outbreaks in poultry were 
estimated at US$ 470 million by 2008 (70). Indonesia’s first human case of H5N1 virus 
infection was identified in 2005 (71). Further zoonotic transmissions resulted in 193 
reported human cases of infection, 161 of which were fatal (72).
The Indonesian government launched a mass vaccination program in poultry in 
February 2004 using A/Chicken/Legok/2003 as the recommended vaccine strain, 
though imported vaccines — often of different clades or subtypes (e.g. clade 1 or 
subtype H5N2 and H5N9) — were used by the poultry industry initially. Emergence of 
antigenic variants to which the vaccines did not provide protection was detected in 
poultry already in 2005. After a series of HPAI H5N1 virus outbreaks from 2006 until 
2008, and as a result of monitoring avian influenza virus variants by the Indonesian 
OFFLU project (73), the poultry vaccine recommendation was updated to contain 
an A/Chicken/West Java/30/07 (A/Chicken/Nagrak/30/07) -like strain. With time, 
vaccination intensified in commercial poultry farms with nearly 100% vaccine coverage 
in breeders and layers, while broilers were vaccinated only during the rainy season. 
However, implementing a vaccination campaign for backyard poultry appeared to 
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be more challenging and vaccination coverage by 2008 was estimated to be less 
than 40% of the standing backyard and commercial poultry population in Indonesia 
(74). Despite vaccination campaigns, improved hygiene measures, movement 
controls, and pre-emptive culling of infected flocks, the virus is still enzootic in large 
parts of Indonesia. 
In 2007, an international consultative group of scientists convened by the World 
Health Organization (WHO), the World Organization for Animal Health (OIE), and 
the Food and Agriculture Organization of the United Nations (FAO), reported on 
the diversification of clade 2.1 into clades 2.1.1, 2.1.2, and 2.1.3. Since 2007, clades 
2.1.1 and 2.1.2 seemed to have gone out of circulation, while clade 2.1.3 viruses 
were further reported to have diversified into fourth order clades; 2.1.3.1, 2.1.3.2, 
and 2.1.3.3 (17-19, 75). Given the large genetic diversity of clade 2.1 viruses and 
continuing outbreaks in vaccinated poultry, we anticipated that clade 2.1 viruses also 
changed — and possibly diversified — antigenically over time.
Antibodies targeting the hemagglutinin (HA) surface glycoprotein are a critical 
component of the immune defense against influenza virus infections in both humans 
and animals (32). In humans, amino acid substitutions in HA have been shown to 
lead to escape from antibody-mediated neutralization. Studies performed in 
the 1980s defined five antigenic sites in the globular head of HA that contain 
the amino acid positions associated with antigenic change of seasonal human 
influenza viruses (32-34). Similar sites have been identified for HPAI H5N1 viruses 
(35, 36) and a recent study suggested that antigenic change of HPAI H5N1 viruses 
in poultry could be attributed to amino acid substitutions in antigenic sites similar to 
those defined for human influenza viruses (76). However, it was recently shown that 
antigenic change of seasonal human influenza viruses is primarily caused by amino 
acid substitutions in a small dominant antigenic domain immediately adjacent to 
the HA receptor binding site (RBS), rather than across nearly the entire globular head 
of HA (77). Here, we mapped the antigenic diversity of clade 2.1 viruses and identified 
the substitutions responsible for antigenic differences, to test the hypothesis that 
the molecular basis for antigenic change of avian clade 2.1 viruses circulating in poultry 
is similar to that of seasonal influenza viruses circulating in humans. Analysis of a subset 
of viruses that represented genetically distinct lineages within clade 2.1 revealed that 
at least six antigenically diverse variants circulated in Indonesia from 2003 – 2011. 
Naturally occurring single, double, or quadruple amino acid substitutions were found 
to determine all major antigenic differences between antigenically distinct viruses. 
These substitutions occurred at positions immediately adjacent to the RBS, indicating 
that clade 2.1 viruses evolved to evade neutralization by antibodies directed to 
the RBS region. These findings imply that avian clade 2.1 H5N1 viruses and seasonal 
human influenza viruses can escape antibody neutralization in a similar way. 
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RESULTS
Phylogenetic analysis and selection of representative viruses
The HA sequences of 96 avian clade 2.1 viruses isolated between 2003 and 2011 
during HPAI H5N1 virus outbreaks in commercial poultry farms and backyard 
flocks in Indonesia were determined as part of ongoing surveillance studies 
(Table S1). Of these 96 HA sequences, 79 were from viruses isolated during 
the currently underreported period since 2008. To evaluate recent genetic variation 
of clade 2.1 viruses we constructed a maximum-likelihood phylogenetic tree using 
the sequences described in the present study and publically available clade 2.1 
sequences  (17-19, 78) (Figs. 1 and S1).
In general, viruses isolated between 2008 and 2011 were genetically more diverse 
than those isolated prior to 2008. Almost 85% of the viruses isolated since 2008 
belonged to clade 2.1.3.2. Of the 92 clade 2.1.3.2 viruses isolated since 2008, 77 
grouped in a single branch that forms the lower part of clade 2.1.3.2 and 94% of the 
2010 and 2011 viruses grouped in this part of the tree. Viruses belonging to the other 
presently circulating clades were much less prevalent in recent years; only seven clade 
2.1.3.1 viruses and five clade 2.1.3.3 viruses were isolated since 2008. Two viruses, 
A/Chicken/West Java/34/2008 and A/Chicken/West Java/6-1/2008, belong to 
a group of viruses that did not fit in any of the defined clades and are most closely 
related to clade 2.1.3.  
Analysis of antigenic diversity
We next investigated the antigenic diversity of clade 2.1 viruses. We selected viruses 
from each of the genetically distinct lineages that circulated since 2008, including 
multiple viruses from the most prominent lineage, to represent the recent genetic 
diversity of clade 2.1 viruses (Fig. 1, Table 1). Two additional representative viruses 
were included; A/Chicken/West Java/30/07, which has been used as poultry vaccine 
strain since 2010, and A/Indonesia/5/05, which is the current clade 2.1.3.2 candidate 
vaccine virus for human use (79). The HA genes of the selected viruses were cloned 
without a multi-basic cleavage site and used to make 6:2 recombinant viruses in 
the context of the A/Puerto Rico/8/1934 reference virus with the neuraminidase 
gene segment of an H5N1 virus (60). We were unable to construct A/Chicken/West 
Java/6-1/08. 
To select a panel of antisera that covered the antigenic variation between 
the representative viruses, we initially prepared antisera against a subset of 
the representative viruses that were genetically most divergent. The antisera were 
subsequently tested in hemagglutination inhibition (HI) assays using all representative 
viruses, and additional antisera were generated against the viruses that showed 
a divergent HI pattern from the viruses used for generation of the initial antiserum 
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Fig. 1. Maximum likelihood phylogenetic tree for 
the HA gene of clade 2.1 viruses. HA sequences 
of 1600 nucleotides in length were used, with 
A/Goose/Guangdong/1/1996 as outgroup. 
The clades as defined previously are specified 
(17-19). The tree contains sequences from 
the present study from 2008 – 2011 (in blue) 
and publically available sequences (17-19, 
78). Red bars indicate viruses selected for 
antigenic characterization (Table 1), including 
the recommended poultry vaccine strain 
(A/Chicken/West Java/30/07), and the candidate 
vaccine strain for human use (A/Indonesia/5/05). 
An asterisk indicates the position of 
A/Indonesia/5/05. The full tree is available 
as Fig. S1.
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A/SWINE/BANTEN/UT2071/2005
A/CHICKEN/WESTJAVAPURWAKARTADARANGDAN/20/2009
A/CHICKEN/KULONPROGO/BBVWTSCIAR667_605/20
A/CHICKEN/WESTJAVASUKABUMISINAGAR/033
A/CHICKEN/PEKANBARU/BPPV-II/2005
A/CHICKEN/INDONESIA/AC-X6/2009
A/CHICKEN/PADANGPARIAMAN/BPPV_BKTB/2007
A/CHICKEN/BANGLI_BBVET_DPS/575/2007
A/DUCK/BALIBADUNG/05/2005
A/CHICKEN/PEKALONGAN/BBVW_208/2007
A/INDONESIA/CDC7/2005
A/CHICKEN/INDONESIA/AC-BL/2003
A/CHICKEN/INDONESIA/AC7/2008
A/CHICKEN/EASTJAVATOYOMARTO/03/2005
A/CHICKEN/PAYAKUMBUH/BPPV_BKT/2007
A/CHICKEN/DENPASAR_BBVET_DPS/145/2007
A/CHICKEN/INDONESIAGARUT/1631-51/2006
A/CHICKEN/INDONESIA/AC97/2010
A/CHICKEN/INDONESIA/AC084/2010
A/CHICKEN/PALEMBANG/BPPV-III/2005
A/INDONESIA/CDC610/2006
A/CHICKEN/BBVET_DPS/560/2007
A/INDONESIA/CDC1032/2007
A/INDONESIA/TLL008/2006
A/INDONESIA/175H/2005
A/MUSCOVYDUCK/BUKITTINGGI/BPPV_BKT/2007
A/CHICKEN/DENPASAR_BBVET_DPS/331/2007
A/CHICKEN/BALI/UT2091/2005
A/CHICKEN/WESTJAVASUKABUMI-PAT/2006
A/SWINE/SOUTHKALIMANTAN/UT6015/2006
A/CHICKEN/PADANG/BBPVII/2006
A/INDONESIA/304H/2006
A/CHICKEN/INDONESIA/AC097/2010
A/CHICKEN/TEBINGTINGGI/BPPVRI_72/2008
A/CHICKEN/INDONESIAAGAM/1631-3/2006
A/DUCK/PADANG/BPPV_BKT/2007
A/CHICKEN/MEDAN/BBPV1-571/2005
A/INDONESIA/CDC699/2006
A/CHICKEN/INDONESIA/AC-PA/2003
A/CHICKEN/MEDAN/BBPV1-576/2005
A/CHICKEN/CIAMIS/BBVW_463/2007
A/CHICKEN/INDONESIA/AC129/2007
A/CHICKEN/INDONESIAREJANGLEBONG/1631-22
A/INDONESIA/CDC644T/2006
A/CHICKEN/DENPASAR_BBVET_DPS/494/2007
A/INDONESIA/TLL006/2006
A/CHICKEN/MAGELANG/BBVW_308/2007
A/INDONESIA/TLL009/2006
A/CHICKEN/WONOSOBO/BPPV4/2003
A/CHICKEN/INDONESIA/AC034/2009
A/CHICKEN/SRAGEN/BPPV4/2003
A/INDONESIA/CDC742/2006
A/CHICKEN/INDONESIA/AC12/2006
A/INDONESIA/245H/2005
A/PIGEON/INDONESIA/ROKHIT1631-6/2006
A/INDONESIA/CDC194P/2005
A/CHICKEN/INDONESIA/AC146/2011
A/CHICKEN/INDONESIA/AC125/2010
A/CHICKEN/BUKITTINGGI/BPPV_BKT/2007
A/CHICKEN/INDONESIABANDUNG/1631-49/2006
A/QUAIL/TASIKMALAYA/BPPV4/2004
A/CHICKEN/INDONESIA/4/2004
A/CHICKEN/EASTJAVA/UT1006/2003
A/CHICKEN/INDONESIA/AC007/2007
A/CHICKEN/BANGLI_BBVET_DPS/387AB/2007
A/CHICKEN/WESTJAVASUBANG/08B/2006
A/CHICKEN/CILEGON/BBVW_361/2007
A/CHICKEN/JEPARA/BBVW_244/2007
A/CHICKEN/INDONESIAWATES/126/2005
A/CHICKEN/PALOPO/BBV_MAROS/2007
A/CHICKEN/MADIUN/BBVW_485/2007
A/CHICKEN/INDONESIA/AC159/2011
A/CHICKEN/WESTJAVASUBANG/29/2007
A/INDONESIA/6/2005
A/CHICKEN/TABANAN_BBVET_DPS/307/2007
A/CHICKEN/INDONESIA/AC131/2010
A/CHICKEN/WAJO/BBVM/2005
A/CHICKEN/ROKANHULU/BPPV_BKT/2007
A/CHICKEN/PIDIE/BPPV1/2005
A/CHICKEN/INDONESIA/AC-X2/2008
A/CHICKEN/INDONESIA/AC053/2009
A/CHICKEN/INDONESIA/5/2004
A/INDONESIA/CDC582/2006
A/INDONESIA/CDC370T/2006
A/INDONESIA/CDC634T/2006
A/CHICKEN/INDONESIA/AC081/2010
A/CHICKEN/KARO/BBPVII/2006
A/CHICKEN/INDONESIA/AC-A/2003
A/CHICKEN/TAPANULIUTARA/BBPV1-576/2005
A/INDONESIA/7261/2008
A/CHICKEN/MEDAN/BPPVRI_15/2008
A/CHICKEN/INDONESIASEMARANG/1631-62/2007
A/CHICKEN/SOUTHSULAWESI/UT2093/2005
A/CHICKEN/WESTJAVAPURWAKARTADARANGDAN/20/2007
A/CHICKEN/INDONESIA/AC75/2010
A/CHICKEN/BATAM/BPPV_BKT/2007
A/CHICKEN/INDONESIAPEKANBARU/1631-11/200
A/DUCK/INDONESIA/MS/2004
A/CHICKEN/INDONESIAWATES/130/2005
A/CHICKEN/MALANG/BBVW_412/2007
A/CHICKEN/SALATIGA/BBVET-I/2005
A/CHICKEN/INDONESIA/AC128/2009
A/INDONESIA/TLL010/2006
A/CHICKEN/SOUTHPESISIR/BPPV_BKT/2007
A/CHICKEN/INDONESIA/AC091/2010
A/CHICKEN/SIAK/BPPV-II/2005
A/CHICKEN/INDONESIAKULON/1631-47/2006
A/CHICKEN/WESTJAVAGARUT/2006
A/INDONESIA/CDC329/2006
A/CHICKEN/INDONESIA/AC145/2010
A/CHICKEN/ACEHBESAR/BPPVRI_012/2007
A/INDONESIA/CDC836/2006
A/DUCK/TABANAN/BPPV1/2005
A/CHICKEN/ACEHBARAT/BPPVRI_327/2007
A/CHICKEN/INDONESIA/AC123/2010
A/CHICKEN/PEKALONGAN/BPPV4/2003
A/CHICKEN/DENPASAR_BBVET_DPS/435/2007
A/CHICKEN/PONOROGO/BBVW_197B/2007
A/INDONESIA/CDC326T/2006
A/PEACEFULDOVE/DENPASAR_BBVET_DPS/480/20
A/CHICKEN/INDONESIA/AC130/2007
A/QUAIL/YOGYAKARTA/UT1023/2004
A/INDONESIA/583H/2006
A/DUCK/KULONPROGO/BBVW_196/2007
A/QUAIL/BOYOLALI/BPPV4/2004
A/CHICKEN/INDONESIA/AC84/2010
A/MUSCOVYDUCK/INDONESIAKEDIRI/1631-24/20
A/CHICKEN/KLATEN/BBVW_290/2007
A/CHICKEN/REMBANG/BBVW_258/2007
A/QUAIL/CENTRALJAVASEMARANG/2006
A/INDONESIA/567H/2006
A/CHICKEN/INDONESIA/AC015B/2009
A/CHICKEN/INDONESIA/AC7/2003
A/CHICKEN/BALIBANGLI/BPPV6-2/2004
A/CHICKEN/PADANG/BPPV_BKT/2007
A/INDONESIA/CDC523E/2006
A/CHICKEN/JAMBIMUAROJAMBI/BBPV-II/2005
A/CHICKEN/WESTJAVASUKABUMI-ENDRI2/2006
A/CHICKEN/SAWAHLUNTO/BPPV_BKT/2007
A/CHICKEN/INDONESIAWATES/77/2005
A/CHICKEN/AGAM/BPPV_BKT/2007
A/CHICKEN/WESTJAVASUBANG/10/2006
A/CHICKEN/INDONESIA/AC090/2010
A/CHICKEN/DELI/BPPVRI_238_2/2008
A/CHICKEN/INDONESIA/AC20/2007
A/DUCK/EASTJAVA/UT1107/2004
A/INDONESIA/7/2005
A/CHICKEN/INDONESIA/AC049/2009
A/CHICKEN/PADANGPANJANG/BPPV_BKT/2007
A/CHICKEN/BANTUL/BBVW_218/2007
A/CHICKEN/INDONESIAWATES/83/2005
A/CHICKEN/GUNUNGKIDUL/BBVW_531/2007
A/SWINE/BANTEN/UT3081/2005
A/CHICKEN/EASTJAVA/UT6044/2007
A/CHICKEN/INDONESIA/AC59A/2009
A/CHICKEN/INDONESIA/AC134/2010
A/CHICKEN/INDONESIA/AC198/2011
A/CHICKEN/EASTJAVA/UT6017/2006
A/CHICKEN/INDONESIA/AC195/2011
A/CHICKEN/SLEMAN/BBVWTSCIAR626_233/200
A/CHICKEN/INDONESIA/AC139/2010
A/CHICKEN/INDONESIA/AC052/2009
A/SWINE/EASTJAVA/UT6012/2007
A/CHICKEN/EASTFLORES_BBVET_DPS/256/200
A/CHICKEN/INDONESIA/AC142/2010
A/INDONESIA/CDC287E/2005
A/CHICKEN/INDONESIA/AC051/2009
A/CHICKEN/INDONESIA/AC145/2011
A/CHICKEN/EASTJAVA/UT6031/2007
A/QUAIL/JAKARTA/JU1/2006
A/CHICKEN/KARO/BPPVRI_320/2007
A/SWINE/BANTEN/UT3062/2005
A/CHICKEN/INDONESIA/AC093/2010
A/CHICKEN/BANTAENG/BBV_MAROS/2008
A/CHICKEN/TABANAN_BBVET_DPS/142/2007
A/INDONESIA/542H/2006
A/CHICKEN/BADUNG_BBVET/DPS/532/2007
A/INDONESIA/TLL005/2006
A/CHICKEN/INDONESIA/AC6-2/2009
A/CHICKEN/EASTKALIMANTAN/UT1035/2004
A/CHICKEN/AGAM/BPPV_BKT2/2007
A/CHICKEN/SUKOHARJO/BBVW_243/2007
A/CHICKEN/WESTJAVASUBANG/08A/2006
A/CHICKEN/TANAHDATAR/BPPV_BKT/2007
A/CHICKEN/INDONESIASOUTHBANGKA/1631-2
A/INDONESIA/CDC940/2006
A/CHICKEN/HONGKONG/YU324/2003
A/INDONESIA/CDC184/2005
A/CHICKEN/INDONESIA/11/2003
A/CHICKEN/NTTMANGGARAI/BPPV6/2004
A/INDONESIA/TLL012/2006
A/CHICKEN/INDONESIA/AC-X5/2006
A/CHICKEN/DENPASAR_BBVET_DPS/456/2007
A/CHICKEN/INDONESIA/AC075/2010
A/CHICKEN/SOUTHSULAWESI/UT2094/2005
A/SWINE/BANTEN/UT3063/2005
A/DUCK/PAREPARE/BBVM/2005
A/CHICKEN/KLUNGKUNG_BBVET_DPS/484/2007
A/CHICKEN/PIDIE/BPPVRI_015/2007
A/CHICKEN/KULONPROGO/BBVWTSCIAR453_11055/
A/INDONESIA/CDC326N/2006
A/INDONESIA/CDC370/2006
A/CHICKEN/WESTJAVASUKABUMISINAGAR/059/2009
A/CHICKEN/WONOSOBO/BBVW_601/2007
A/CHICKEN/MAROS_1/BBV_MAROS/2008
A/INDONESIA/CDC938/2006
A/CHICKEN/PADANGPARIAMAN/BPPV_BKTA/2007
A/INDONESIA/CDC1046T/2007
A/CHICKEN/GUNUNGKIDUL/BBVW_193/2007
A/CHICKEN/WONOGIRI/BBVW_198/2007
A/CHICKEN/PATI/BBVW_247/2007
A/CHICKEN/INDONESIA/AC120A/2010
A/INDONESIA/CDC1031/2007
A/CHICKEN/BIREUEN/BPPVRI_079/2007
0.01
2.1.3
2.1.1
2.1.3.2
2.1.3.3
2.1.3.1
2.1.2
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Table 1. Representative viruses selected for mapping the antigenic diversity of clade 2.1 viruses.
Strain Clade
A/Indonesia/5/05 2.1.3.2
A/Chicken/West Java/30/07 2.1.3.2
A/Chicken/West Java/6-1/08 2.1.3.2
A/Chicken/North Sumatra/27/09 2.1.3.2
A/Chicken/West Java/47/09 2.1.3.2
A/Chicken/Central Java/51/09 2.1.3.2
A/Chicken/Central Java/52/09 2.1.3.2
A/Chicken/West Java/59/09 2.1.3.2
A/Chicken/North Sumatra/72/10 2.1.3.3
A/Chicken/West Java/90/10 2.1.3.2
A/Chicken/West Java/119/10 2.1.3.2
A/Chicken/East Java/121/10 2.1.3.2
A/Chicken/South Sulawesi/157/11 2.1.3.1
panel. The antigenic properties of all representative viruses were analyzed in HI assays 
using a panel of 8 – 16 ferret antisera (Table S2). 
The representative viruses differentiated into six distinct antigenic variants (Fig. 2). 
A/Indonesia/5/05, A/Chicken/Central Java/51/09 and A/Chicken/North Sumatra/27/09 
that belong to clade 2.1.3.2 were antigenically similar. Three other antigenic variants 
were distinguished within clade 2.1.3.2; A/Chicken/West Java/30/07, A/Chicken/West 
Java/119/10, and A/Chicken/East Java/121/10. The latter was antigenically similar 
to four other representative viruses of clade 2.1.3.2: A/Chicken/West Java/47/09, 
A/Chicken/Central Java/52/09, A/Chicken/West Java/59/09, and A/Chicken/West 
Java/90/10. The representative viruses for clades 2.1.3.1 and 2.1.3.3, A/Chicken/
South Sulawesi/157/11 and A/Chicken/North Sumatra/72/10, respectively, were 
antigenically distinct from each other and all other representative viruses. 
Surprisingly, A/Chicken/South Sulawesi/157/11 (clade 2.1.3.1) and A/Chicken/
North Sumatra/72/10 (clade 2.1.3.3) were antigenically more closely related to 
A/Indonesia/5/05 (clade 2.1.3.2) than other antigenic variants of clade 2.1.3.2 (Fig. 2). 
Vice versa, A/Chicken/West Java/30/07 was genetically very similar to A/Indonesia/5/05 
(Fig. S1), yet it was antigenically substantially more distinct from A/Indonesia/5/05 
than A/Chicken/Central Java/51/09 and A/Chicken/North Sumatra/27/09, A/Chicken/
South Sulawesi/157/11, and A/Chicken/North Sumatra/72/10 (Fig. 2). The correlation 
between the antigenic distance of the representative viruses from A/Indonesia/5/05 
and the number of HA1 amino acid substitutions from A/Indonesia/5/05 was 0.4828, 
but was not statistically significant (p = 0.1325) (Table S3, Pearson correlation). 
Mapping the molecular basis of antigenic change of clade 2.1 viruses
To gain insight in the molecular basis of antigenic change of clade 2.1 viruses we next 
performed site-directed mutagenesis of the HA of A/Indonesia/5/05 and generated 
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Fig 2. Antigenic map of selected clade 2.1 viruses. Filled circles and open squares indicate 
the positions of viruses and antisera, respectively. Both axes represent antigenic distance. The spacing 
between gridlines is one antigenic unit distance, which equals a two-fold difference in the HI assay. 
Positions of viruses and antisera in the map were generated using antigenic cartography methods as 
described previously (31). Briefly, the distance between a virus—antiserum pair is inversely related 
to the HI titer of the virus to that antiserum. Modified multidimensional scaling methods were used 
to arrange the relative positions of virus and antiserum points in the map such that they reflect 
the HI titers with minimal error. The viruses are color-coded to indicate the different antigenic variants: 
A/Indonesia/5/05; green, A/Chicken/West Java/30/07; blue, A/Chicken/North Sumatra/72/10; 
purple, A/Chicken/East Java/121/10; yellow, A/Chicken/West Java/119/10; red, and A/Chicken/
South Sulawesi/157/11; pink. We considered viruses to be substantially antigenically different if 
the distance between them is at least two antigenic units. Abbreviations in the virus names are as 
follows: Ck, Chicken; CJ, Central Java; EJ, East Java; ID, Indonesia; NS, North Sumatra; SS, South 
Sulawesi; WJ, West Java. 
ID/5/05
2.1.3.2
Ck/EJ/121/10
2.1.3.2
Ck/WJ/119/10
2.1.3.2 Ck/WJ/30/07
2.1.3.2
Ck/NS/72/10
2.1.3.3
Ck/SS/157/11
2.1.3.1Ck/WJ/59/09
ID/5/05
Ck/WJ/47/09
Ck/EJ/121/10
Ck/WJ/90/10
Ck/CJ/52/09
Ck/CJ/51/09
Ck/NS/27/09
recombinant viruses that were tested by HI assay. It was shown recently that all 
major antigenic changes of seasonal human influenza viruses were due to amino 
acid substitutions immediately adjacent to the RBS (77), and we hypothesized that 
the same would apply to H5N1 viruses. To test this hypothesis, the amino acid 
differences between HA of A/Indonesia/5/05 and the representative viruses from 
the remaining five antigenic variants were plotted on an H5N1 HA crystal 
structure to identify the amino acid substitutions that occurred near the RBS 
(Figs. S2 and S3). Subsequently, each of these substitutions was introduced 
independently into the A/Indonesia/5/05 HA gene and HI assays were performed 
with the mutant viruses to test if the substitution could fully explain the antigenic 
difference between A/Indonesia/5/05 and the strain in which the substitution was 
observed. Combinations of substitutions were tested when single substitutions did 
not fully explain the antigenic difference.
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Fig 3. Summary of substitutions responsible for antigenic differences between representative viruses 
and A/Indonesia/5/05. The mutants were analyzed in the context of the antigenic map shown in 
Fig. 2. Panels A – E display a detail of the antigenic map and show the mutants with the substitutions 
responsible for the antigenic change from A/Indonesia/5/05 to: (A) A/Chicken/West Java/30/07, (B) 
A/Chicken East Java/121/10, (C) A/Chicken/West Java/119/10, (D) A/Chicken/South Sulawesi/157/11, 
and (E) A/Chicken/North Sumatra/72/10. A representative virus for each antigenic variant is shown as 
a large colored circle, the remaining representative viruses are shown as smaller faint colored circles. 
Mutants are indicated by green diamond shapes, A/Indonesia/5/05 as large green circles. Gridlines 
and antigenic map construction as in Fig. 1. Antigenic maps with all mutants made to investigate 
the molecular basis of antigenic change from A/Indonesia/5/05 are shown in Fig. S4. The antigenic 
distances between A/Indonesia/5/05, representative viruses and mutants are listed in Table S4.
Ck/WJ/30/07
133SA185AE
129SL
Ck/SS/157/11
129151IT183DN189RM
Ck/WJ/119/10
183DN189RM
189RK
Ck/NS/72/10
A B
C
D
E
Ck/EJ/121/10
A/Indonesia/5/05 and A/Chicken/West Java/30/07 differed by five amino acids 
in the HA1 region (Fig. S2), of which substitutions 133SA and 185AE were located 
adjacent to the RBS. Single mutants of A/Indonesia/5/05 with either 133SA or 185AE 
in HA did not have the same antigenic properties as A/Chicken/West Java/30/07 
(Fig. S4A). However, introduction of both 133SA and 185AE in A/Indonesia/5/05 
resulted in a virus with antigenic properties that were similar to A/Chicken/
West Java/30/07 (Figs. 3A and S4A). Thus, the antigenic difference between 
A/Indonesia/5/05 and A/Chicken/West Java/30/07 was due to substitutions 
133SA and 185AE.
The five viruses that were antigenically A/Chicken/East Java/121/10-like (Fig. 2) 
shared six amino acids in the HA1 region that were different from A/Indonesia/5/05 
(Fig. S2), four of which were located adjacent to the RBS; 155SN, 183DN, 184AE 
and 189RM. When introduced individually, none of these substitutions changed 
the antigenic properties of A/Indonesia/5/05 to become A/Chicken/East Java/121/10-
like. However, substitutions 183DN and 189RM each had a substantial impact 
on the antigenic properties of A/Indonesia/5/05 (Fig. S4B), and we therefore 
constructed a double mutant virus. A/Indonesia/5/05 with substitutions 183DN and 
189RM in HA was antigenically similar to the A/Chicken/East Java/121/10-like viruses, 
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indicating that the combination of substitutions 183DN and 189RM was responsible for 
the antigenic difference between A/Indonesia/5/05 and A/Chicken/East Java/121/10-
like viruses (Figs. 3B and S4B). 
A/Chicken/West Java/119/10 displayed 17 amino acid differences in HA1 as 
compared to A/Indonesia/5/05 (Fig. S2), of which 5 occurred at positions adjacent 
to the RBS: 136, 151, 159, 183, and 189. In addition, A/Chicken/West Java/119/10 
HA had a deletion of the amino acid at position 129 as compared to the HA of 
A/Indonesia/5/05. These six amino acid changes were introduced individually 
in the HA of A/Indonesia/5/05, but none resulted in a change in antigenic properties 
to become A/Chicken/West Java/119/10-like (Fig. S4C). The ∆129151IT combination 
was previously shown to cause conformational changes around the RBS (22), which 
could affect antibody recognition. Mutations ∆129151IT in HA of A/Indonesia/5/05 
indeed had a substantial effect on the antigenic properties of the virus (Fig. S4C). 
Since substitutions 183DN and 189RM were collectively responsible for the antigenic 
difference between A/Indonesia/5/05 and A/Chicken/East Java/121/10 (Fig. 3B), and 
both substitutions were also present in A/Chicken/West Java/119/10, we constructed 
a virus to combine ∆129151IT with 183DN and 189RM. This quadruple mutant virus 
was antigenically similar to A/Chicken/West Java/119/10 (Figs. 3B and S4C). Thus, 
we concluded that the deletion at position 129 and substitutions 151IT, 183DN, and 
189RM were responsible for the antigenic difference between A/Indonesia/5/05 and 
A/Chicken/West Java/119/10.
A/Chicken/South Sulawesi/157/11 displayed 15 amino acid differences to 
the HA1 of A/Indonesia/5/05 (Fig. S2). Positions 129, 155 and 184 were located close 
to the RBS, and the corresponding substitutions were introduced individually into 
the HA of A/Indonesia/5/05. Substitutions 155SN and 184AE had no antigenic effect 
(Fig. S4D). Introduction of substitution 129SL into A/Indonesia/5/05 changed it 
antigenically to A/Chicken/South Sulawesi/157/11 (Figs. 3D and S4D).
There were 10 amino acid differences between HA1 of A/Indonesia/5/05 and 
A/Chicken/North Sumatra/72/10 (Fig. S2). We constructed pointmutants of the two 
substitutions that were located close to the RBS; 155SN and 189RK. Substitution 
155SN did not have an antigenic effect (Fig. S4E). Introduction of 189RK was sufficient 
to change the antigenic properties of A/Indonesia/5/05 to become A/Chicken/North 
Sumatra/72/10-like (Fig. 3E and S4E).
To summarize these results, the amino acid changes responsible for antigenic 
change among all selected representative clade 2.1 viruses occurred at six key 
positions; 129, 133, 151, 183, 185 and 189. Five positions form a nearly continuous 
ridge located on the periphery of the RBS. The sixth, position 133, is located in 
the 130-loop that includes positions that are part of the RBS (Fig. 4).
Seven of the eight amino acid changes responsible for the antigenic differences 
from A/Indonesia/5/05 involved a large change in the biophysical properties 
of the amino acids (Table S5). Seven changes resulted in a modification 
of the hydrophilicity of the amino acids, five in a charge change, and a single 
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Fig 4. Amino acid positions responsible for antigenic change of clade 2.1 viruses plotted on an 
A/Indonesia/5/05 HA crystal structure. (A) Monomers are shown in black, grey and white, the RBS 
in yellow, and amino acid positions responsible for antigenic change in green. (B) Zoomed in on 
the area around the RBS. The amino acid positions are based on H5 numbering. (C) Amino acid 
positions responsible for antigenic change of seasonal human H3N2 viruses shown for comparison 
(77). Key positions are plotted on an A/Aichi/2/68 HA trimer and are indicated in red. The amino 
acid positions are based on H3 numbering. H5 amino acid positions 133, 151, 183, 185, and 189 
correspond to H3 positions 137, 155, 187, 189, and 193, respectively. There is no equivalent of H5 
amino acid position 129 in H3N2 viruses.
substitution involved a substantial increase in volume of the amino acid side chain. 
The A/Indonesia/5/05 HA amino acid sequence contains six predicted N-linked 
glycosylation sites (N-X-S/T-X) but these sites were not affected by the substitutions 
responsible for the antigenic changes, nor were any new glycosylation sites introduced 
by these substitutions. 
We next marked the amino acid substitutions that were responsible for antigenic 
change of clade 2.1 viruses in the phylogenetic tree of Fig. 1 and analyzed in which 
years and geographic regions the antigenic variants identified in this study may have 
circulated (Fig. 5). The single substitutions responsible for the antigenic change 
to A/Chicken/North Sumatra/72/10 or A/Chicken/South Sulawesi/157/11 were 
detected in viruses of all third and fourth order clades of clade 2.1. These viruses 
were isolated intermittently between 2004 and 2011. Viruses that contained the 2 - 4 
substitutions responsible for the antigenic change to A/Chicken/West Java/30/07, 
A/Chicken/East Java/121/10, and A/Chicken/West Java/119/10 were more confined 
to specific regions of the tree. The quadruple change that was responsible for 
the antigenic change to A/Chicken/West Java/119/10 was found in two unique 
sequences only, both of which were isolated in 2010.
Viruses with the substitutions typical for the A/Chicken/South Sulawesi/157/11, 
A/Chicken/East Java/121/10, A/Chicken/North Sumatra/72/10, and A/Indonesia/5/05 
antigenic variants were isolated from multiple geographic regions of Indonesia 
(Fig. 5). The A/Chicken/West Java/119/10-like and A/Chicken/West Java/30/07-like 
viruses from our dataset were exclusively isolated on the island of Java. Co-circulation 
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in the same geographic region of two or more viruses that had the substitutions 
typical for the antigenic variants identified here was noticed from 2005 onwards. 
Antigenic effect of substitutions tested using chicken sera
Ferret antisera obtained after inoculation with influenza viruses under laboratory-
controlled conditions are the most sensitive reagents for detection of antigenic 
variation of influenza viruses. We next examined if substitutions leading to antigenic 
variation as tested by ferret antisera also lead to evasion of recognition by antibodies 
in antisera of vaccinated chickens. Ten chickens were vaccinated with a vaccine 
prepared from A/Indonesia/5/05. Three weeks post-vaccination the antisera were 
harvested and tested in HI assays using the same protocol as for HI tests using 
ferret antisera.
The HI antibody titers against A/Chicken/West Java/30/07 were at least 
4-fold lower than the HI antibody titers against A/Indonesia/5/05 with all ten 
A/Indonesia/5/05 antisera (Fig. 6A). Of the ten A/Indonesia/5/05 antisera, four had 
also at least four-fold lower HI titers against the 133SA185AE mutant as compared to 
A/Indonesia/5/05, five had two-fold or less lower HI titers, and the remaining antiserum 
had the same HI titers against the wildtype and mutant viruses (Fig. 6B). The HI 
antibody titers against A/Chicken/East Java/121/10 were also at least four-fold lower 
than the HI antibody titers to A/Indonesia/5/05 for eight of the ten A/Indonesia/5/05 
antisera. The remaining two antisera had either a 2.7-fold lower HI titer against 
A/Chicken/East Java/121/10 as compared to A/Indonesia/5/05 or had the same HI titers 
(Fig. 6C). The HI antibody titers against the 183DN189RM mutant virus were at least 
4-fold lower than against A/Indonesia/5/05 with all ten chicken antisera (Fig. 6D). 
These data thus show that two amino acid substitutions near the RBS can also be 
sufficient to substantially decrease recognition by chicken antibodies. 
We next tested the effect of the same amino acid substitutions - 133SA185AE and 
183DN189RM – on the antibody response of chickens upon vaccination. To this end, 
we vaccinated chickens with A/Indonesia/5/05 with substitutions 133SA185AE or 
A/Indonesia/5/05 with substitutions 183DN189RM. These post-vaccination antisera 
were compared with antisera raised against wildtype A/Indonesia/5/05 vaccine upon 
titration in HI assays against A/Indonesia/5/05 and A/Chicken/West Java/30/07 or 
A/Chicken/East Java/121/10. Antisera prepared by vaccination with the 133SA185AE 
mutant had on average 2.5-fold (1.2 log2) higher HI antibody titers against A/Chicken/
West Java/30/07 than antisera prepared with A/Indonesia/5/05 vaccine (Fig. 7A). 
Antisera prepared by vaccination with the 183DN189RM mutant had on average 
8.3-fold (3.2 log2) higher titers to A/Chicken/East Java/121/10 than antisera prepared 
with A/Indonesia/5/05 vaccine (Fig. 7B). We then tested if antisera prepared against 
the 133SA185AE vaccine inhibited the binding of A/Chicken/West Java/30/07 in HI 
assays, and did the same for 183DN189RM antisera and A/Chicken/East Java/121/10. 
Using the antisera raised against 133SA185AE vaccine, HI antibody titers against 
A/Chicken/West Java/30/07 were two to four-fold lower than to the homologous 
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virus for five of ten antisera, four-fold lower for four antisera, and six-fold lower for 
one antiserum (Fig. 7C). Using the antisera raised against the 183DN189RM vaccine, 
the HI antibody titers against A/Chicken/East Java/121/10 and homologous 
virus were the same for three of the ten antisera, less than two-fold lower than to 
the homologous virus for six of the ten antisera, and three-fold lower for one 
antiserum (Fig. 7D). Thus, amino acid substitutions responsible for antigenic change 
as defined with ferret antisera substantially affected the reactivity of chicken antisera 
upon vaccination. 
DISCUSSION
Following the initial detection of H5N1 clade 2.1 viruses in 2003 in Central Java, 
the viruses diversified into three distinct genetic lineages (clades 2.1.1, 2.1.2, 2.1.3) 
from 2004 onwards and became enzootic in most parts of Indonesia (17-19, 69, 78). 
Since 2004, the ongoing genetic diversification of clade 2.1.3 viruses necessitated 
further classification into fourth order clades (2.1.3.1, 2.1.3.2, 2.1.3.3), while viruses 
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Fig 5. Identification of years and geographic region of isolation of clade 2.1 virus antigenic variants. 
(A) Geographical regions of Indonesia defined for this study. (B) Colored bars specify the years in 
which viruses with the substitutions that define the antigenic variants were isolated. The letters 
S, J, K, U, and N correspond to the geographical region from which isolates were obtained in 
a given year, and are as defined in panel A. An asterisk indicates the years in which multiple antigenic 
variants circulated in the same geographical region. Abbreviations in the virus names are provided 
in the legend to Fig. 2. (C) The phylogenetic tree of Fig. 1 color-coded for the substitutions that define 
the antigenic variants (Fig. 3). Color-coding corresponds to the antigenic variants specified in panel 
B. The positions of the representative viruses in the tree are indicated by a black dot. Sequences that 
did not contain the identified (combinations of) substitutions responsible for antigenic variation are 
shown in light grey.
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of clades 2.1.1 and 2.1.2 have apparently disappeared. However, data has been 
extremely sparse since 2008, which has hampered further analysis of clade 2.1 virus 
evolution. The present study shows that viruses from clades 2.1.3.1, 2.1.3.2, and 
2.1.3.3 have circulated between 2008 and 2011, while viruses that belong to clades 
2.1.1 or 2.1.2 were not detected. This finding further substantiates the suggestion that 
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Fig 6. Reactivity of viruses with wildtype or mutant HAs to A/Indonesia/5/05 chicken antisera. 
Antisera obtained from chickens vaccinated with A/ Indonesia/5/05 were tested in HI assays to 
A/Indonesia/5/05 and Ck/West Java/30/07 (A), A/Indonesia/5/05 and A/Indonesia/5/05 + 133SA185AE 
(B), A/Indonesia/5/05 and Ck/East Java/121/10 (C), or A/Indonesia/5/05 and 
A/Indonesia/5/05 + 183DN189RM (D). Solid lines connect the log2 HI titers obtained for viruses 
tested to the same chicken antiserum. Dashed lines connect log2 HI titers obtained from HI assays 
using ferret antisera. DL indicates the detection limit of the HI assay at the 1:20 starting dilution that 
was used.
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Fig 7. Effect of substitutions responsible for antigenic change on the antibody response of 
chickens. Antisera obtained from chickens vaccinated with A/Indonesia/5/05, A/Indonesia/5/05 with 
substitutions 133SA185AE, or A/Indonesia/5/05 with substitutions 183DN189RM were titrated in HI 
assays to A/Indonesia/5/05 and A/Chicken/West Java/30/07 (A), or A/Indonesia/5/05 and A/Chicken/
East Java/121/10 (B). Each point represents the log2 HI titer for an individual antiserum. Horizontal 
lines show the mean log2 HI titer. The mean log2 HI titer difference is indicated between the groups. 
Antisera obtained from chickens vaccinated with A/Indonesia/5/05 with substitutions 133SA185AE 
or A/Indonesia/5/05 with substitutions 183DN189RM were titrated in HI assays to homologous virus 
and A/Chicken/West Java/30/07 (C), or homologous virus and A/Chicken/East Java/121/10 (D). Solid 
lines connect the log2 HI titers obtained for viruses tested to the same chicken antiserum. DL indicates 
the detection limit of the HI assay at the 1:20 starting dilution that was used.
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viruses of these latter clades are no longer circulating in poultry. Although viruses from 
clades 2.1.3.1 and 2.1.3.3 were isolated, the majority of viruses belonged to clade 
2.1.3.2 indicating that this was the dominant genotype in recent years. The dataset 
used in this study contains sequences from viruses isolated throughout Indonesia, but 
the majority of samples originate from outbreaks on the island of Java. This 
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geographical bias is (at least in part) explained by the poultry population densities 
within Indonesia; 70% of the commercial poultry population and poultry production 
is on the island of Java. 
We selected viruses to represent the most prominent recently circulating lineages 
and used these viruses to map the antigenic diversity of clade 2.1 viruses. Using 
antigenic cartography methods, we show that at least six antigenically distinct variants 
circulated in Indonesia since 2003. Representative viruses that belonged to different 
phylogenetic clades, or to distinct lineages within the same clade, were generally also 
antigenically distinct. However, antigenic distances between the variants correlated 
poorly with distances in the phylogenetic tree or with the number of amino acid 
differences in HA1. As was suggested previously (35), antigenic differences between 
clade 2.1 viruses are therefore not necessarily predictable from (phylo)genetic 
information alone. Antigenic analysis of the representative viruses also indicated 
that new antigenic variants emerged with time, but that these new variants did not 
replace previously circulating viruses per se, and existing antigenic variants continued 
to circulate alongside newly emerged, antigenically distinct, viruses. However, 
the predominance of isolates with the 183DN189RM substitutions that define 
the A/Chicken/East Java/121/10 antigenic variant in recent years may also 
signal ongoing directional selection towards viruses of this antigenic phenotype 
or genotype. 
Previously, we reported that major antigenic changes during the evolution of 
seasonal human H3N2, H1N1, and influenza B viruses were caused by very few amino 
acid substitutions that occurred exclusively at positions immediately adjacent to 
the RBS (77). Although amino acid substitutions that affect the antigenic properties 
of H3N2 and H1N1 influenza viruses can occur on positions distributed over large 
parts of the HA globular head (32-34) nature has selected for major antigenic change 
of these subtypes caused by substitutions at only few positions located adjacent to 
the RBS. In the present study we tested the hypothesis that the molecular basis for 
antigenic change of clade 2.1 viruses resembles that of seasonal human influenza 
viruses. Indeed, antigenic differences from A/Indonesia/5/05 were due to single, 
double, or, in a single case, quadruple amino acid substitutions only. Each of these 
substitutions occurred at a small set of amino acid positions located immediately 
adjacent to the RBS. Five key positions are located on the membrane distal periphery 
of the RBS and form a nearly continuous antigenic ridge, while the sixth position is 
located on the membrane proximal part of the RBS and is located in the 130-loop that 
is involved in receptor binding. 
The location of substitutions responsible for antigenic change of clade 2.1 
viruses is thus remarkably similar to that of seasonal human influenza viruses. 
The key substitutions structurally map to positions comparable to those responsible 
for antigenic change of human H3N2 virus (Fig. 4) (77), and a single or very few 
substitutions near the RBS were responsible for the antigenic differences. Interestingly, 
antigenic change of a clade 2.2.1 virus from Egypt was also due to substitutions 
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near the RBS (76). The combination of ∆129 and 151IT involved in the antigenic 
change from A/Indonesia/5/05 to A/Chicken/West Java/119/10 was observed in 
clade 2.2.1 viruses isolated between 2007 and 2009 (80). Consistent with the finding 
that ∆129151IT results in a conformational change of the area around the RBS, we 
found that combination of these amino acid changes resulted in reduced antibody 
recognition of clade 2.1 viruses. 
We previously found that large changes in the biophysical properties were involved 
in all major antigenic changes of H3N2 viruses (77). The antigenic changes of clade 2.1 
viruses similarly involved substitutions with large changes in the biophysical properties 
of the amino acids responsible for the antigenic difference from A/Indonesia/5/05 to 
four of the five antigenic variants. Charge changes of the amino acids seemed to 
play an important role in antigenic change of clade 2.1 viruses as well as human 
H3N2 viruses. Interestingly, substitutions that involved hydrophilicity changes were 
common in clade 2.1 virus, but were almost completely absent among substitutions 
that led to antigenic change of H3N2 viruses. Variation in the number of carbohydrate 
side chains on HA has been associated with changes in the antigenic properties of 
influenza A viruses because they can mask antibody epitopes (61, 62), but changes 
in glycosylation sites were not involved in the major antigenic changes of clade 2.1 
viruses. The location of the amino acid positions involved in antigenic change of 
clade 2.1 viruses exclusively in the periphery of the RBS implies that clade 2.1 viruses, 
like seasonal human influenza viruses, evolved to specifically evade the antibodies 
directed at the RBS region. Follow-up studies looking into the effect of substitutions 
involved in antigenic change on receptor binding could help to understand potential 
limitations of influenza virus antigenic change.
Evolutionary patterns that become noticeable after extensive periods of 
virus circulation may not yet be clear in the relatively short period of HPAI H5N1 
virus circulation in Indonesia. However, we observed some distinct differences in 
the antigenic evolution of clade 2.1 H5N1 and seasonal human influenza viruses. 
Human influenza viruses accumulate antigenically important substitutions over 
time. To avoid neutralization by antibodies raised to an earlier strain, antigenic 
evolution is typically away from previously circulating antigenic variants and shows 
a somewhat linear pattern (31). Moreover, antigenic variants are periodically replaced 
by newly emerging variants that can better evade population immunity. In contrast, 
the substitutions responsible for antigenic change of clade 2.1 viruses did typically 
not accumulate over time, and antigenic evolution did not follow a clear pattern away 
from earlier viruses. Additionally, multiple antigenic variants co-circulated in the same 
geographical region during multiple consecutive years. A plausible explanation for 
the different evolutionary patterns of seasonal human influenza viruses and clade 2.1 
viruses is the difference in selective pressures acting on these viruses. The short life 
span of chickens, approximately 28 – 35 days for broilers and 18 months for breeders 
and layers in commercial poultry farms, prevents build up of immunity to multiple 
antigenic variants in the poultry population. Similar to what was described by de Jong 
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et al. for H3N2 viruses in pigs (30), the necessity to evade population immunity that 
was acquired through infection or vaccination with consecutive antigenic variants is 
absent in poultry. Population immunity is therefore unlikely to be a major driving force 
of clade 2.1 virus antigenic evolution, in contrast to seasonal human influenza virus. 
Moreover, whereas antigenic variants of seasonal human influenza viruses can spread 
around the globe in a matter of months (81), the limited spatial and temporal mixing of 
chicken populations limits competition among antigenic variants, and therefore may 
allow co-existence of multiple antigenically different viruses in the same geographic 
region of Indonesia.
Vaccination can be an efficient method to reduce the burden of HPAI H5N1 viruses 
in poultry (82-84). The current poultry vaccine strain recommendation for Indonesia is 
A/Chicken/West Java/30/07 or an antigenically similar strain. Viruses of this antigenic 
phenotype circulated until at least 2009. However, our analyses indicate that 
A/Chicken/East Java/121/10-like viruses have become the major antigenic variant 
in more recent years. Jadhao et al. (83) showed that chickens vaccinated with an 
antigenically poorly matched vaccine are fully protected from morbidity and mortality, 
but shed virus at much higher levels than those vaccinated with an antigenically 
matched strain. Reduced virus shedding decreases the probability of further spread 
between poultry flocks and zoonotic events. It is therefore advantageous to pursue 
the use of vaccine strains that match the antigenic variants in circulation, if vaccination 
is chosen as one of the approaches to stop or limit the spread of HPAI viruses.
Antigenic analysis of clade 2.1.3.2 viruses isolated from humans in 2011 and 2012 
indicated that these viruses were antigenically different from A/Indonesia/5/05, which 
is the current candidate vaccine strain for human use. An updated vaccine based 
on an A/Indonesia/NIHRD11771/2011-like virus, which has the 183DN and 189RM 
substitutions typical for the A/Chicken/East Java/121/10-like viruses, is currently 
in preparation (85).  
Updating the vaccines for poultry or human use to a contemporary strain that 
matches the major antigenic variant is an important measure that helps to ensure 
optimal vaccine efficacy. Given that one or two amino acid substitutions near 
the RBS can already substantially decrease recognition by ferret and chicken 
antibodies, the long-term efficacy of vaccines that target a single antigenic variant 
is questionable. We here show that vaccination of chickens with a recombinant 
virus that only contains two key substitutions for antigenic change can be sufficient 
to substantially change the reactivity of chicken antisera to antigenic variants. 
Recombinant viruses can be designed to contain the key amino acids necessary to 
match an antigenic variant while maintaining the growth characteristics endowed by 
other parts of the virus genome, and can be constructed without multi basic cleavage 
site. Although the efficacy of such vaccines should be evaluated in in vivo models, 
antigenically engineered viruses may provide a means to quickly adapt the vaccine 
to emerging antigenic variants. However, antigenic variants have co-circulated in 
the same geographic region of Indonesia from 2005 onwards. These variants were 
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isolated from chickens, thus excluding that they circulated exclusively in different 
host-species. Therefore, any vaccine that is designed to neutralize a single antigenic 
variant may be of only limited use. The identification of persistent co-circulation of 
antigenic variants stresses the need for more potent, broadly reactive, next generation 
vaccines. At the same time, this study underscores the need for continued monitoring 
of circulating influenza viruses in poultry, certainly when vaccines are employed to 
contribute to control outbreaks.  
Analysis of the amino acid sequence variation immediately adjacent to the RBS 
region of HA can be applied as a proxy to identify the most prominent antigenic 
phenotypes, and could provide an early indication of emerging antigenic variants. 
Such genetic data should be complemented with antigenic data and vaccination-
challenge experiments with the circulating viruses, to ensure that the vaccines 
continue to match the circulating viruses associated with outbreaks.  
MATERIALS AND METHODS
Sample collection and virus isolation
Samples were collected during the investigations of outbreaks in both commercial 
and backyard poultry flocks from 2003 onwards. From 2008 onwards, samples were 
collected during outbreaks in commercial farms and backyard poultry throughout 
Indonesia as part of ongoing surveillance studies. Tracheal and oropharyngeal 
swabs and organ samples—typically the brain, trachea, lung, spleen, pancreas, and 
intestines—were used to inoculate specific pathogen free embryonated chicken 
eggs and allantoic fluids were tested for viral presence by hemagglutination assay. 
Subsequently, virus isolates were subject to H5N1 virus specific reverse-transcription 
polymerase chain reaction followed by sequencing of the full HA gene. 
Construction of phylogenetic trees
The HA sequences of 96 H5N1 viruses isolated in Indonesia that were obtained as 
described above were combined with the publically available clade 2.1 HA sequences 
(17-19, 78). Phylogenetic tree construction of HA sequences was performed using 
the maximum likelihood method available from the PAUP* package 
(version 4.0b10) (86) under the GTR + I + Γ4 model (the general time-reversible model 
 with the proportion of invariant sites and the gamma distribution of among-
site rate variation with four categories estimated from the empirical data) as 
determined by ModelTest (87). Global optimization of the tree topology was 
performed by tree bisection–reconnection branch swapping. The tree was rooted to 
A/Goose/Guangdong/1/1996.
Cells 
293T cells were cultured in DMEM (Cambrex, Heerhugowaard, The Netherlands) 
supplemented with 10% fetal calf serum (FCS), 100 μg/ml streptomycin, 100 IU/ml 
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penicillin, 2mM glutamine, 1mM sodiumpyruvate, and non-essential amino acids 
(MP Biomedicals, Europe, Illkirch, France). Madin Darby Canine Kidney (MDCK) cells 
were cultured in EMEM (Cambrex) supplemented with 10% FCS, 100 IU/ml penicillin, 
100 μg/ml streptomycin, 2mM glutamine, 1.5 mg/ml sodiumbicarbonate (Cambrex), 
10mM Hepes (Cambrex), and non-essential amino acids (MP Biomedicals). 
Plasmid construction and site-directed mutagenesis
A/Indonesia/5/05 was isolated from a human case of HPAI virus infection (71), 
and passaged once in embryonated chicken eggs followed by a single passage 
in MDCK cells before amplification of the HA segment by reverse transcription 
polymerase chain reaction. The HA gene of A/Chicken/North Sumatra/27/09 was 
synthesized by Life Technologies Corporation (Carlsbad, CA, USA), while full HA 
genes of other representative viruses (Table S1) were synthesized by BaseClear 
(Leiden, The Netherlands). All HA genes were synthesized without multi basic 
cleavage site and were cloned into the modified pHW2000 expression plasmid as 
described previously (64, 65). We were unable to construct the HA of A/Chicken/West 
Java/6-1/08. Mutations were introduced into the HA gene of A/Indonesia/5/05 using 
the QuickChange multi-site directed mutagenesis kit (Agilent Technologies, Santa 
Clara, CA, USA) according to the manufacturers instructions.
Generation of recombinant viruses
Plasmids containing wildtype or modified HA genes were used to generate 
recombinant viruses by reverse genetics as described elsewhere (64). Briefly, one 
day prior to transfection 293T cells were seeded in 100 mm gelatinized culture 
dishes. Cells were transfected overnight with 40 µg of plasmid DNA. Subsequently, 
transfection medium was replaced by fresh medium supplemented with 2% FCS. 
After incubation for 72 hours at 37°C / 5% CO2 the supernatant was harvested. Virus 
stocks were propagated by inoculation of MDCK cells with 2mL 293T transfection 
supernatant. Inoculum was removed after 2 hours and replaced by MDCK 
infection medium, consisting of EMEM (Cambrex), 100 IU/ml penicillin, 100 μg/ml 
streptomycin, 2mM glutamine, 1.5 mg/ml sodium bicarbonate, 10mM Hepes, non-
essential amino acids, and 25 μg/ml trypsin. Viruses were harvested after incubation 
at 37°C / 5% CO2 for 72 hours. All viruses were rescued as 6:2 viruses and contained 
six segments of A/Puerto Rico/8/1934 (A/H1N1), the neuraminidase (NA) gene of 
A/Hong Kong/156/1997 (H5N1), and the HA gene of the appropriate clade 2.1 
viruses, except for A/Indonesia/5/05 and A/Chicken/West Java/30/07 that contained 
the NA from A/Indonesia/5/05. Absence of undesired mutations and presence of 
introduced substitutions was confirmed by sequence analysis.
Antisera
Ferret antisera were prepared by intranasal inoculation with 500 µl recombinant virus 
stock. Fourteen days post inoculation ferrets were boosted using 500 µL of a 1:1 
mix of concentrated virus (>2048 HAU) and Titermax Gold Adjuvant (Sigma-Aldrich, 
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St. Louis, MO, USA). Antisera were collected four weeks later. Chicken antisera were 
prepared by subcutaneous vaccination of 4-week old SPF White Leghorn chickens 
(Charles River Laboratories, Wilmington, MA) with 0.5 mL of a 1:1 mix of 512 HAU of 
virus and Montanide ISA50V (Seppic, France). Antisera were collected three weeks 
post-vaccination. All antisera were pre-treated overnight at 37°C with receptor 
destroying enzyme (Vibrio cholerae neuraminidase) followed by inactivation for 1h at 
56°C before use in hemagglutination inhibition (HI) assays.
Serological assays
HI assays were performed following standard procedures (37). Briefly, two-fold 
serial dilutions of the antisera, starting at a 1:20 dilution, were mixed with 25 μL of 
a virus stock containing 4 hemagglutinating units and were incubated at 37°C for 30 
minutes. Subsequently, 25 μL 1% turkey erythrocytes was added and the mixture was 
incubated at 4°C for 1h. The HI titer is expressed as the reciprocal value of the highest 
serum dilution that completely inhibited hemagglutination.
Antigenic cartography
Analysis of antigenic properties was performed using antigenic cartography methods 
as described previously (31). Briefly, antigenic cartography is a method to increase 
the resolution of, solve paradoxes in, and visualize HI assay data or other binding 
assay data. In an antigenic map, the distance between antigen point A and antiserum 
point S corresponds to the difference between the log2 of the maximum observed 
titer to antiserum S from any antigen and the titer of antigen A to antiserum S. 
The titers in an HI table can be thought of as specifying target distances between 
the antigens and the antisera. Modified multidimensional scaling methods are then 
used to arrange the antiserum and antigen points in an antigenic map to best satisfy 
the target distances specified by the HI data. The distances between the points in 
an antigenic map represent antigenic distance as measured by the HI assay, in which 
the distances between antigens and antisera are inversely related to the log2 HI titer. 
Because antigens are tested against multiple antisera, and antisera are tested against 
multiple antigens, many measurements can be used to determine the position of the 
antigens and antisera in an antigenic map, thus improving the resolution of HI data. 
Structural analysis
The amino acid positions responsible for antigenic change were plotted on 
the crystal structure of the A/Indonesia/5/2005 virus HA (PDB accession code 4K62 
(88)). MacPyMOL (The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, 
LLC) was used to visualize the trimer. 
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the author’s organizations. Ferrets were housed and experiments were conducted in 
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approved by the independent animal experimentation ethical review committee 
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was performed under light anesthesia (ketamine) to minimize animal discomfort. 
Studies that involved the use of chickens were conducted under ABSL-3 conditions 
approved by USDA and performed according to the protocol R-12-51 “Inactivated 
vaccines against antigenic variants of highly pathogenic H5N1 influenza viruses” 
approved by the Institutional Animal Care and Use Committee of the University of 
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Fig. S1. Phylogenetic tree for the HA gene of 
clade 2.1 viruses. The tree is the same nucleotide 
maximum-likelihood tree as shown in Fig. 1 
of the main text, but shows full virus names. 
Representative viruses are indicated in red. The 
clades as defined previously are specified in the 
tree (17-19). 
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A/INDONESIA/CDC836/2006
A/DUCK/TABANAN/BPPV1/2005
A/CHICKEN/ACEHBARAT/BPPVRI_327/2007
A/CHICKEN/CENTRAL JAVA/123/2010
A/CHICKEN/PEKALONGAN/BPPV4/2003
A/CHICKEN/DENPASAR_BBVET_DPS/435/2007
A/CHICKEN/PONOROGO/BBVW_197B/2007
A/INDONESIA/CDC326T/2006
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Fig. S2. HA1 amino acid sequence alignment of the representative 
viruses selected for mapping the antigenic diversity of clade 2.1 
viruses. The sequences are grouped and color-coded according to 
their antigenic phenotype (Fig. 2). The top row indicates the amino 
acid positions where substitutions from A/Indonesia/5/05 occurred. 
Consensus amino acid positions are excluded from the alignment.   
3ANTIGENIC EVOLUTION OF H5N1 CLADE 2.1 VIRUSES
110
Fig. S3. Amino acid sequence variation of representative clade 2.1 viruses plotted on an 
A/Indonesia/5/05 crystal structure. Monomers are shown in black, grey and white, the receptor 
binding site in yellow. The amino acid positions on which differences from A/Indonesia/5/05 were 
observed in the representative viruses (Fig. S2) are indicated in orange. Panels A, B and C show 
different angles of the same crystal structure.
A B C
Fig. S4. 
Antigenic maps for the analysis of mutants constructed to identify the molecular basis 
for antigenic differences from A/Indonesia/5/05. The antigenic maps are similar to 
those shown in Fig. 2, but in addition the positions of all tested mutants is indicated. 
A representative virus for each antigenic variant is shown as a larger colored circle, 
A/Indonesia/5/05 is indicated as a larger green circle, and the remaining 
representative viruses from Fig. 2 are shown as smaller faint colored circles. A diamond 
shape indicates the mutant with the minimal set of substitutions that determined 
the antigenic difference between A/Indonesia/5/05 and the respective representative 
virus. The remaining mutants are indicated as smaller green filled circles. Antisera are 
represented by open squares. The spacing between gridlines is one antigenic unit 
distance, which equals a two-fold difference in the HI assay. A table below each map 
shows the HI titers for the representative viruses and mutants. Antisera are named 
according to the viruses that were used to prepare the antisera. Suffices A, B, C, 
etcetera, in the antisera names (e.g. ID/5B/05) indicate that multiple antisera were 
raised to the same antigen. Only those serum columns with at least one titer above 
the detection limit of the assay (typically a 1/10 dilution of the antiserum) are shown. 
HI titers below the detection limit are shown as threshold values (e.g. <10). NT 
indicates that the antigen – antiserum combination was not tested. Abbreviations 
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FIG S4 A. A/Indonesia/5/05 - A/Ck/West Java/30/07.  
 
 
 
 
!
FIG S4 B. A/Indonesia/5/05 - A/Ck/East Java/121/10.  
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Fig. S4A. A/Indonesia/5/05 - A/Ck/West Java/30/07. 
in the virus names are as follows: Ck, Chicken; CJ, Central Java; EJ, East Java; ID, 
Indonesia; NS, North Sumatra; SS, South Sulawesi; WJ, West Java.
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FIG S4 B. A/Indonesia/5/05 - A/Ck/East Java/121/10.  
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Fig. S4B. A/Indonesia/5/05 - A/Ck/East Java/121/10. 
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FIG S4 C. A/Indonesia/5/05 - A/Ck/West Java/119/10 
 
 
 
 
 
FIG S4 D. A/Indonesia/5/05 - A/Ck/South Sulawesi/157/11. 
  
Ck/WJ/119/10
129151IT183DN189RM
129136PS151IT189RM
129151IT
183DN
129
159TK
136PS
151IT189RM
Ck/ID/5A/05 Ck/ID/5B/05 Ck/WJ/30A/07 Ck/CJ/51A/09 Ck/CJ/051B/09 Ck/NS/72/10 Ck/WJ/119A/10 Ck/WJ/119B/10 Ck/EJ/121A/10 Ck/EJ/121B/10 Ck/SS/157A/11 Ck/SS/157B/11
ID/5/05 256 2136 <80 446 1126 158 <40 <40 <40 146 193 200
Δ129 160 1280 30 320 640 80 160 <40 10 60 NT NT
136PS 320 1920 40 480 1280 160 <10 <40 30 160 NT NT
151IT 480 2560 80 640 1280 320 20 <40 10 80 NT NT
159TK 640 3840 60 640 1920 320 10 <40 30 60 NT NT
183DN 320 2560 40 640 1280 240 80 40 240 320 NT NT
189RM <10 240 60 320 160 640 30 <40 1280 2560 NT NT
Δ129151IT NT 320 <10 120 240 80 320 320 <10 <10 NT NT
Δ129136PS151IT189RM <30 80 <10 60 <80 320 1280 320 160 320 NT NT
Δ129151IT183DN189RM NT <20 <10 <10 <60 <80 2240 1600 480 640 <10 <10
Ck/WJ/119/10 <10 <120 <10 <10 <10 <20 2537 1674 177 73 <10 <10
129SL
155SN
184AE
Ck/SS/157/11
ID/5A/05 ID/5B/05 ID/5D/05 AC30A/07 AC30B/07 AC51A/09 AC051B/09 AC72/10 AC119A/10 AC119B/10 AC121A/10 AC121B/10 AC157A/11 AC157B/11
ID/5/05 256 2136 160 <80 <80 446 1126 158 <40 <40 <40 146 193 200
155SN 320 1810 * 24 NT 480 1109 277 <10 <40 * 240 320 640
184AE 320 1810 * 35 NT 960 1109 160 <30 <40 * 240 640 240
129SL 80 423 <40 <40 <80 200 113 24 <10 NT <10 120 453 599
AC157/11 <80 80 * <10 <80 126 124 <20 <10 NT <20 45 1016 784
ID/5A/05 ID/5B/05 Ck/WJ/30A/07 Ck/CJ/51A/09 Ck/CJ/051B/09 Ck/NS/72/10 Ck/EJ/121B/10 Ck/SS/157A/11 Ck/SS/157B/11
ID/5/05 256 2136 <80 446 1126 158 146 193 200
155SN 320 1810 24 480 1109 277 240 320 640
184AE 320 1810 35 960 1109 160 240 640 240
129SL 80 423 <40 200 113 24 120 453 599
Ck/SS/157/11 <80 80 <10 126 124 <20 45 1016 784
ID
/5
A
/0
5
ID
/5
B
/0
5
C
k/
W
J/
30
A
/0
7
C
k/
C
J/
51
A
/0
9
C
k/
C
J/
05
1B
/0
9
C
k/
N
S/
72
/1
0
C
k/
W
J/
11
9A
/1
0
C
k/
W
J/
11
9B
/1
0
C
k/
E
J/
12
1A
/1
0
C
k/
E
J/
12
1B
/1
0
C
k/
SS
/1
57
A
/1
1
C
k/
SS
/1
57
B
/1
1
ID/5/05 256 2136 <80 446 1126 158 <40 <40 <40 146 193 200
136PS 320 1920 40 480 1280 160 <10 <40 30 160 NT NT
151IT 480 2560 80 640 1280 320 20 <40 10 80 NT NT
159TK 640 3840 60 640 1920 320 10 <40 30 60 NT NT
∆129 160 1280 30 320 640 80 160 <40 10 60 NT NT
∆129151IT NT 320 <10 120 240 80 320 320 <10 <10 NT NT
∆129136PS151IT189RM <30 80 <10 60 <80 320 1280 320 160 320 NT NT
∆129151IT183DN189RM NT <20 <10 <10 <60 <80 2240 1600 480 640 <10 <10
Ck/WJ/119/10 <10 <120 <10 <10 <10 <20 2537 1674 177 73 <10 <10
Fig. S4C. A/Indonesia/5/05 - A/Ck/West Java/119/10
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FIG S4 D. A/Indonesia/5/05 - A/Ck/South Sulawesi/157/11. 
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ID/5A/05 ID/5B/05 Ck/WJ/30A/07 Ck/CJ/51A/09 Ck/CJ/051B/09 Ck/NS/72/10 Ck/EJ/121B/10 Ck/SS/157A/11 Ck/SS/157B/11
ID/5/05 256 2136 <80 446 1126 158 146 193 200
155SN 320 1810 24 480 1109 277 240 320 640
184AE 320 1810 35 960 1109 160 240 640 240
129SL 80 423 <40 200 113 24 120 453 599
Ck/SS/157/11 <80 80 <10 126 124 <20 45 1016 784
Fig. S4D. A/Indonesia/5/05 - A/Ck/South Sulawesi/157/11. 
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Fig. S4E. A/Indonesia/5/05 - A/Ck/North Sumatra/72/10. 
 
 
FIG S4 E. A/Indonesia/5/05 - A/Ck/North Sumatra/72/10. 
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Table S1. Clade 2.1 viruses sequenced for the present study. Accession numbers refer to sequences 
in the GISAID database (http://gisaid.org) and were shared with kind permission of the government of 
the Republic of Indonesia. Representative viruses as defined in Figs. 1 and S1 are indicated in bold.
Strain Accession number URL
A/Chicken/Indonesia/2A/2003 EPI533371 http://gisaid.org/EPI/533371
A/Chicken/Indonesia/7/2003 EPI115476* http://gisaid.org/EPI/115476
A/Chicken/Indonesia/BL/2003 EPI533370 http://gisaid.org/EPI/533370
A/Chicken/Indonesia/PA/2003 EPI533369 http://gisaid.org/EPI/533369
A/Chicken/West Java/A/2003 EPI533400 http://gisaid.org/EPI/533400
A/Chicken/West Java/028/2006 EPI533426 http://gisaid.org/EPI/533426
A/Chicken/West Java/12/2006 EPI533442 http://gisaid.org/EPI/533442
A/Chicken/West Java/8/2006 EPI533443 http://gisaid.org/EPI/533443
A/Chicken/West Java/CSLK-EC/2006 EPI533451 http://gisaid.org/EPI/533451
A/Chicken/West Java/PWT-WIJ/2006 EPI224605* http://gisaid.org/EPI/224605
A/Chicken/Lampung/007/2007 EPI533455 http://gisaid.org/EPI/533455
A/Chicken/West Java/129/2007 EPI533420 http://gisaid.org/EPI/533420
A/Chicken/West Java/130/2007 EPI533419 http://gisaid.org/EPI/533419
A/Chicken/West Java/132/2007 EPI533418 http://gisaid.org/EPI/533418
A/Chicken/West Java/20/2007 EPI533414 http://gisaid.org/EPI/533414
A/Chicken/West Java/29-002/2007 EPI533441 http://gisaid.org/EPI/533441
A/Chicken/West Java/30/2007 EPI533406 http://gisaid.org/EPI/533406
A/Chicken/Lampung/7/2008 EPI533454 http://gisaid.org/EPI/533454
A/Chicken/West Java/028/2008 EPI533425 http://gisaid.org/EPI/533425
A/Chicken/West Java/32-031/2008 EPI533440 http://gisaid.org/EPI/533440
A/Chicken/West Java/34/2008 EPI533439 http://gisaid.org/EPI/533439
A/Chicken/West Java/6-1/2008 EPI533450 http://gisaid.org/EPI/533450
A/Chicken/West Java/X2/2008 EPI533438 http://gisaid.org/EPI/533438
A/Chicken/Banten/019/2009 EPI533412 http://gisaid.org/EPI/533412
A/Chicken/Central Java/51/2009 EPI533397 http://gisaid.org/EPI/533397
A/Chicken/Central Java/52/2009 EPI533395 http://gisaid.org/EPI/533395
A/Chicken/Central Java/053/2009 EPI533394 http://gisaid.org/EPI/533394
A/Chicken/Central Java/056/2009 EPI533387 http://gisaid.org/EPI/533387
A/Chicken/East Java/013/2009 EPI533381 http://gisaid.org/EPI/533381
A/Chicken/East Java/029/2009 EPI533383 http://gisaid.org/EPI/533383
A/Chicken/East Java/035/2009 EPI533379 http://gisaid.org/EPI/533379
A/Chicken/East Java/6/2009 EPI533380 http://gisaid.org/EPI/533380
A/Chicken/North Sumatra/27/2009 EPI533461 http://gisaid.org/EPI/533461
A/Chicken/Riau/071/2009 EPI533368 http://gisaid.org/EPI/533368
A/Chicken/South Kalimantan/070/2009 EPI533378 http://gisaid.org/EPI/533378
A/Chicken/West Java/59/2009 EPI533448 http://gisaid.org/EPI/533448
A/Chicken/West Java/015/2009 EPI533407 http://gisaid.org/EPI/533407
A/Chicken/West Java/034/2009 EPI533410 http://gisaid.org/EPI/533410
A/Chicken/West Java/47/2009 EPI533424 http://gisaid.org/EPI/533424
A/Chicken/West Java/049/2009 EPI533423 http://gisaid.org/EPI/533423
A/Chicken/West Java/068/2009 EPI533437 http://gisaid.org/EPI/533437
A/Chicken/West Java/127/2009 EPI533399 http://gisaid.org/EPI/533399
A/Chicken/West Java/128/2009 EPI533411 http://gisaid.org/EPI/533411
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Table S1. (continued)
Strain Accession number URL
A/Chicken/West Java/2/2009 EPI533435 http://gisaid.org/EPI/533435
A/Chicken/West Java/20/2009 EPI533413 http://gisaid.org/EPI/533413
A/Chicken/West Java/59A/2009 EPI533444 http://gisaid.org/EPI/533444
A/Chicken/Central Java/59/2009 EPI533396 http://gisaid.org/EPI/533396
A/Chicken/West Java/6-2/2009 EPI533449 http://gisaid.org/EPI/533449
A/Chicken/West Java/X3/2009 EPI533436 http://gisaid.org/EPI/533436
A/Chicken/Central Java/075/2010 EPI533390 http://gisaid.org/EPI/533390
A/Chicken/Central Java/099/2010 EPI533388 http://gisaid.org/EPI/533388
A/Chicken/Central Java/123/2010 EPI533393 http://gisaid.org/EPI/533393
A/Chicken/Central Java/139/2010 EPI533392 http://gisaid.org/EPI/533392
A/Chicken/Central Java/75/2010 EPI533391 http://gisaid.org/EPI/533391
A/Chicken/Central Java/99/2010 EPI533389 http://gisaid.org/EPI/533389
A/Chicken/East Java/121/2010 EPI533384 http://gisaid.org/EPI/533384
A/Chicken/Lampung/092/2010 EPI533453 http://gisaid.org/EPI/533453
A/Chicken/North Sumatra/072/2010 EPI533459 http://gisaid.org/EPI/533459
A/Chicken/North Sumatra/72/2010 EPI533460 http://gisaid.org/EPI/533460
A/Chicken/South Sulawesi/140/2010 EPI533377 http://gisaid.org/EPI/533377
A/Chicken/West Java/081/2010 EPI533405 http://gisaid.org/EPI/533405
A/Chicken/West Java/084/2010 EPI533409 http://gisaid.org/EPI/533409
A/Chicken/West Java/090/2010 EPI533404 http://gisaid.org/EPI/533404
A/Chicken/West Java/091/2010 EPI533434 http://gisaid.org/EPI/533434
A/Chicken/West Java/093/2010 EPI533422 http://gisaid.org/EPI/533422
A/Chicken/West Java/094/2010 EPI533447 http://gisaid.org/EPI/533447
A/Chicken/West Java/097/2010 EPI533402 http://gisaid.org/EPI/533402
A/Chicken/West Java/119/2010 EPI533433 http://gisaid.org/EPI/533433
A/Chicken/West Java/120/2010 EPI533432 http://gisaid.org/EPI/533432
A/Chicken/West Java/125/2010 EPI533421 http://gisaid.org/EPI/533421
A/Chicken/West Java/125A/2010 EPI533417 http://gisaid.org/EPI/533417
A/Chicken/West Java/126/2010 EPI533446 http://gisaid.org/EPI/533446
A/Chicken/West Java/131/2010 EPI533416 http://gisaid.org/EPI/533416
A/Chicken/West Java/134/2010 EPI533431 http://gisaid.org/EPI/533431
A/Chicken/West Java/138/2010 EPI533415 http://gisaid.org/EPI/533415
A/Chicken/West Java/142/2010 EPI533398 http://gisaid.org/EPI/533398
A/Chicken/West Java/145/2010 EPI533430 http://gisaid.org/EPI/533430
A/Chicken/West Java/84/2010 EPI533408 http://gisaid.org/EPI/533408
A/Chicken/West Java/90/2010 EPI533403 http://gisaid.org/EPI/533403
A/Chicken/West Java/97/2010 EPI533401 http://gisaid.org/EPI/533401
A/Chicken/West Java/X4/2010 EPI533428 http://gisaid.org/EPI/533428
A/Chicken/Central Java/146/2011 EPI533386 http://gisaid.org/EPI/533386
A/Chicken/East Java/151/2011 EPI533382 http://gisaid.org/EPI/533382
A/Chicken/Jambi/184/2011 EPI533457 http://gisaid.org/EPI/533457
A/Chicken/Lampung/153/2011 EPI533452 http://gisaid.org/EPI/533452
A/Chicken/North Sumatra/198/2011 EPI533458 http://gisaid.org/EPI/533458
A/Chicken/South Sulawesi/156/2011 EPI533376 http://gisaid.org/EPI/533376
A/Chicken/South Sulawesi/157/2011 EPI533375 http://gisaid.org/EPI/533375
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Table S1. (continued)
Strain Accession number URL
A/Chicken/South Sulawesi/188/2011 EPI533374 http://gisaid.org/EPI/533374
A/Chicken/South Sulawesi/195/2011 EPI533373 http://gisaid.org/EPI/533373
A/Chicken/South Sulawesi/196/2011 EPI533372 http://gisaid.org/EPI/533372
A/Chicken/South Sumatra/170/2011 EPI533456 http://gisaid.org/EPI/533456
A/Chicken/West Java/145/2011 EPI533429 http://gisaid.org/EPI/533429
A/Chicken/West Java/148/2011 EPI533445 http://gisaid.org/EPI/533445
A/Chicken/West Java/200/2011 EPI533427 http://gisaid.org/EPI/533427
A/Chicken/Yogyakarta/159/2011 EPI533385 http://gisaid.org/EPI/533385
Table S2. Ferret antisera used in this study. Antisera were prepared as described in Materials and 
Methods. Antisera prepared to the same virus were labeled A, B, C, etcetera, additional to the isolation 
number in the virus name (e.g. A/Indonesia/5A/05, A/Indonesia/5B/05). Data obtained from antisera 
prepared to the same virus were treated as individual antisera, i.e. HI titers from these sera were 
not averaged.
Antigenic variant Clade Antisera
A/Indonesia/5/05 2.1.3.2 A/Indonesia/5A/05 A/Indonesia/5B/05
A/Indonesia/5D/05 A/Chicken/Central 
Java/51A/09
A/Chicken/Central Java/51B/09
A/Chicken/West Java/30/07 2.1.3.2 A/Chicken/West Java/30A/07 A/Chicken/West 
Java/30B/07
A/Chicken/North 
Sumatra/72/10
2.1.3.3 A/Chicken/North 
Sumatra/72/10
A/Chicken/West 
Java/119/10
2.1.3.2 A/Chicken/West Java/119A/10 A/Chicken/West 
Java/119B/10
A/Chicken/East Java/121/10 2.1.3.2 A/Chicken/East Java/121A/10 A/Chicken/East 
Java/121B/10
A/Chicken/South 
Sulawesi/157/11
2.1.3.1 A/Chicken/South 
Sulawesi/157A/11
A/Chicken/South 
Sulawesi/157B/11
N.A. 0 A/Hong Kong/156A/97 A/Hong Kong/156B/97
1 A/Vietnam/1194A/04 A/Vietnam/1194B/04
2.2 A/Turkey/Turkey/1A/2005 A/Turkey/Turkey/1B/2005
2.3 A/Anhui/1A/05 A/Anhui/1A/05
Classic A/Mallard/Netherlands/3B/99
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Table S3. Amino acid changes and antigenic distances from A/Indonesia/5/05. Antigenic distance 
is expressed as antigenic units in the antigenic maps, where 1 unit equals a two-fold difference in 
the HI titer. * Number of HA1 amino acid differences from A/Indonesia/5/05. ** Not including 
a deletion of position 129.
Strain
Number of substitutions from 
A/Indonesia/5/05*
Antigenic distance from 
A/Indonesia/5/05 (units)
A/Ck/North Sumatra/27/09 3 1.3
A/Ck/West Java/30/07 4 5.0
A/Ck/Central Java /51/09 5 0.8
A/Ck/Central Java/59/09 7 7.4
A/Ck/West Java/47/09 7 7.5
A/Ck/East Java/121/10 8 8.5
A/Ck/North Sumatra/72/10 10 3.0
A/Ck/Central Java/52/09 10 7.1
A/Ck/West Java/90/10 12 7.5
A/Ck/South Sulawesi/157/11 15 3.2
A/Ck/West Java/119/10 17** 10.6
Table S4. Amino acid substitutions responsible for the antigenic differences from A/Indonesia/5/05 
and antigenic distance of representative and mutant viruses from A/Indonesia/5/05. The antigenic 
distances are derived from the antigenic maps shown in Fig. 3. One antigenic unit equals a two-fold 
difference in HI titer. We considered viruses to be substantially antigenically different if the distance 
between them is at least two antigenic units.
Antigenic change from  
A/Indonesia/5/05 to Substitution(s)
Antigenic distance (units)
A/Indonesia/5/05 
to representative
A/Indonesia/5/05 
to mutant
Mutant  
to representative
A/Ck/West Java/30/07 133SA 185AE 4.7 3.4 1.3
A/Ck/East Java/121/10 183DN 189RM 8.4 7.7 0.7
A/Ck/West Java/119/10 ∆129151IT 
183DN 189RM
10.6 9.5 1.2
A/Ck/North Sumatra/72/10 189RK 3.0 3.2 0.5
A/Ck/South Sulawesi/157/11 129SL 3.6 2.6 1.3
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Table S5. Biophysical properties of the amino acid substitutions responsible for antigenic differences 
from A/Indonesia/5/05. Amino acid charges are at physiological pH. V Substantial change in amino 
acid volume after substitution.
Antigenic change to Substitutions Biophysical change
A/Ck/West Java/30/07 133SA 
185AE
hydrophilic – hydrophobic
neutral hydrophobic – negative hydrophilic V
A/Ck/East Java/121/10 183DN
189RM
negative – neutral
positive hydrophilic – neutral hydrophobic
A/Ck/West Java/119/10 S129∆
151IT 
183DN
189RM
loss of neutral hydrophilic
hydrophobic – hydrophilic
negative – neutral
positive hydrophilic – neutral hydrophobic
A/Ck/North Sumatra/72/10 189RK –
A/Ck/South Sulawesi/157/11 129SL hydrophilic – hydrophobic
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ABSTRACT
Single amino acid substitutions at seven positions in hemagglutinin were 
recently shown to determine major antigenic change of influenza H3N2 virus. 
Here, the impact of two such substitutions was tested in eleven prototype H3 
hemagglutinins to investigate context-dependence effects. The data indicate that 
the amino acid context in which a substitution occurs may determine the magnitude of 
the antigenic effect, but not the ability of the substitution to cause antigenic change. 
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Influenza viruses of the H3N2 subtype have been circulating in humans since 1968 
and are a major cause of annual epidemics. Antibodies against the hemagglutinin 
(HA) surface glycoprotein can neutralize the virus and are a critical component of 
our immune defense against influenza viruses (40). However, the HA changes over 
time to escape from such neutralizing antibodies present in the human population. 
Smith et al. used hemagglutination inhibition (HI) assay data spanning a 35-year 
period to map H3N2 virus antigenic evolution (31). During this period, 11 antigenic 
clusters that comprise viruses of high antigenic similarity emerged, each of which was 
consecutively replaced by a new cluster of antigenically distinct viruses. Antigenic 
cluster transitions, the major antigenic changes between clusters, were subsequently 
shown to be predominantly caused by single amino acid substitutions on seven 
key positions adjacent to the receptor binding site (RBS), and most positions were 
involved in cluster transitions multiple times ((77), and Fig. 1A and 1B). An important 
question that remained is whether these single substitutions could have comparable 
impact on antigenic properties independent of the HA context.
Here we investigated if the amino acid context in which a substitution occurs 
determines its antigenic effect. Cluster-transition substitutions 155TY and 145NK 
were introduced in the HA genes of viruses representing the 11 antigenic clusters 
(Fig. 1C). Both substitutions substantially change the biophysical properties of 
the amino acids on these positions and were, as single substitutions, responsible 
for antigenic cluster transitions during H3N2 virus antigenic evolution (Fig. 1A). 
Substitution 155TY was responsible for the first antigenic cluster transition of H3N2 
virus (77). Substitution 145NK caused an antigenic cluster transition after 21 years 
of H3N2 virus evolution and was responsible for another cluster transition six years 
later (31, 77). The substitutions were introduced as single mutations into the 11 HA 
genes. Depending on the amino acid at position 155 or 145 we introduced either 
155Y or T, or 145K or N in the HA genes (Fig. 1C). When representative viruses had 
145S we introduced 145K, but not 145N as this results only in a small biophysical 
change. For viruses with 155H two modified HA genes, containing 155T or 155Y, 
were constructed. All substitutions resulted in substantial changes in the biophysical 
properties of the amino acids. Plasmids containing wildtype or modified HA genes 
were used to generate recombinant viruses consisting of the (modified) HA gene 
and remaining genes of A/Puerto Rico/8/34 by reverse genetics (64). Subsequently, 
the antigenic properties of recombinant viruses were analyzed in HI assays using 
a previously defined panel of ferret antisera (37, 77).
Most mutant HAs with substitutions at position 155 were substantially antigenically 
different from the respective wildtype HAs, with up to 64-fold differences in HI titers 
(Fig. 2A). A subset of the antisera yielded similar HI titers (i.e. < 4-fold different) to 
viruses with wildtype and mutant HA. In the context of some HAs (e.g. SI87, BE89, 
BE92), substitutions at position 155 had a modest effect, with up to 4-fold differences 
in HI titers. For the BE92 mutants, only a single antiserum showed 4-fold different HI 
titers compared to the wildtype virus. Thus, although the magnitude of the antigenic 
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Fig. 1. Experimental background and viruses used in this study. (A) Substitutions responsible for 
antigenic cluster transitions as defined in (77). Letters and digits in antigenic cluster names refer 
to the location and year of isolation of the first vaccine strain in that cluster (HK, Hong Kong; EN, 
England; VI, Victoria; TX, Texas; BK, Bangkok; SI, Sichuan; BE, Beijing; WU, Wuhan; SY, Sydney; FU, 
Fujian). (B) Amino acid positions responsible for major antigenic change during H3N2 virus antigenic 
evolution plotted on an A/Aichi/2/68 HA trimer (PDB accession code 5HMG). Monomers are shown in 
black, grey, and white, the RBS in yellow. Amino acid positions 145 and 155 are indicated in red and 
blue, while the remaining key positions are indicated in orange. (C) Mutants constructed for this study. 
Cluster representative viruses had the amino acid consensus sequence of all viruses in that cluster 
(described in (77)). BI: Bilthoven, NL; The Netherlands.
A B
C
change caused by the substitution of T/Y at position 155 was variable, this substitution 
caused a large antigenic change in the majority of HA contexts that were tested.
Viruses with a substitution on position 145 of HA were each antigenically distinct 
from the respective wildtype viruses (Fig. 2B), with HI titer differences up to 128-fold. 
Also here, a subset of the antisera yielded similar HI titers to viruses with wildtype 
and mutant HA. The antigenic change caused by the substitution of K/N at position 
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145 in HA was even less affected by the HA context as compared to substitution T/Y 
at position 155. 
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Fig. 2. HI titer differences between viruses with wildtype and mutant HAs. (A) Each symbol represents 
the log2 HI titer difference for an individual antiserum between a representative virus and a mutant 
with 155TY or 155YT, or between mutants with 155HT and 155HY (indicated as 155TY for SI87, BE89, 
BE92, WU95, and SY97). (B) Log2 HI titer differences between viruses with wildtype HA and 145K or 
145N mutants. Symbols as in panel (A).
Substitution 145NK was responsible for the cluster transition from SI87 to BE89 
(Fig. 1A). When 145K was introduced in viruses representing the antigenic clusters 
that circulated prior to the SI87 cluster, this caused similar escape from inhibition 
by antisera to contemporary or previously circulating strains as 145K in the SI87 
representative virus (Fig. 2B). We next tested if 145K affected the antigenic properties 
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to similar levels as the cluster-transition substitutions that were taken naturally before 
1989 (Fig. 1A). In this analysis only antisera to strains from the same or previous 
antigenic clusters as the representative virus were included, thus testing escape from 
antibodies induced to previously circulating strains. Antigenic differences caused by 
145K were similar to those caused by the substitutions that were responsible for the 
“natural” antigenic cluster transitions (Fig. 3). Thus, if viruses with 145K had appeared 
before the BE89 antigenic cluster, they would have been sufficiently antigenically 
different from earlier H3N2 viruses to provide antibody escape. These results suggest 
that antibody escape only partially determines the evolutionary success of an 
emerging antigenic variant.
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Fig. 3. HI titer differences between cluster representatives, 145K mutants, and cluster-transition 
mutants. Each symbol represents the log2 HI titer difference for an individual antiserum between 
viruses with wildtype and 145K mutant HA or between the wildtype and cluster-transition mutant 
virus. Only antisera to strains from the same or preceding antigenic clusters as the representative virus 
were included in the analyses.
The differences in magnitude of the antigenic effect of 155T and 155Y substitutions 
versus the context independent antigenic change caused by the 145N and 145K 
substitutions in different amino acid backgrounds may be due to differences in local 
HA structure.  Position 155 is located in the depression between the 190-helix that 
contains conserved position 195Y and a loop that contains conserved position 153W 
(Fig. 4), which are fundamental components of the RBS (24, 33). Although adjacent to 
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RBS positions 135 - 137, position 145 is located on a protruding loop that may have 
fewer structural constraints. The substitutions introduced at position 145 therefore 
possibly have a larger impact on the local HA structure than the substitutions 
introduced at position 155, resulting in the more pronounced antigenic changes of 
the mutants with a substitution at position 145 observed here. 
Fig. 4. Cartoon representation of the A/Aichi/2/68 RBS area. Positions 155 and 145 are indicated in 
blue and red, respectively. Positions 195Y and 153W, which are conserved among influenza A virus 
subtypes (24, 33), are indicated in pink.
In summary, the ability of cluster-transition substitutions to cause antibody 
escape was found to be largely independent of the amino acid context, although 
the magnitude of antigenic change may be context-dependent. In agreement with 
the observed repeated substitution at the 7 key antigenic positions during influenza 
H3N2 virus antigenic evolution (77), these results emphasize the potential importance 
of the key positions for future antigenic change. 
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ABSTRACT 
The majority of currently circulating influenza A(H1N1) viruses are antigenically similar 
to the virus that caused the 2009 influenza pandemic. However, antigenic variants 
are expected to emerge as population immunity increases. Amino acid substitutions 
in the hemagglutinin protein can result in escape from neutralizing antibodies, affect 
viral fitness, and change receptor preference. Here we constructed mutants with 
substitutions in the hemagglutinin of A/Netherlands/602/09 in an attenuated backbone 
to explore amino acid changes that may contribute to emergence of antigenic variants 
in the human population. Our analysis revealed that single substitutions affecting 
the 151 – 159 loop located adjacent to the receptor binding site caused escape from 
ferret and human antibodies elicited after primary A(H1N1)pdm09 virus infection. 
The majority of these substitutions resulted in similar or increased replication efficiency 
in vitro compared to the virus carrying the wildtype hemagglutinin, and did not result 
in a change of receptor preference. However, none of the substitutions was sufficient 
to escape from the antibodies in sera from individuals that experienced both seasonal 
and pandemic A(H1N1) virus infections. These results suggest that antibodies directed 
against epitopes on seasonal A(H1N1) viruses contribute to neutralization of A(H1N1)
pdm09 antigenic variants, thereby limiting the number of possible substitutions that 
could lead to escape from population immunity.
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IMPORTANCE
Influenza A viruses can cause significant morbidity and mortality in humans. Amino 
acid substitutions in the hemagglutinin protein can result in escape from antibody-
mediated neutralization. This allows the virus to re-infect individuals that have 
acquired immunity to previously circulating strains through infection or vaccination. 
To date, the vast majority of A(H1N1)pdm09 strains remain antigenically similar to 
the virus that caused the 2009 influenza pandemic. However, antigenic variants are 
expected to emerge as a result of increasing population immunity. We show that 
single amino acid substitutions near the receptor binding site were sufficient to 
escape from antibodies specific for A(H1N1)pdm09 viruses, but not from antibodies 
elicited in response to infections with seasonal A(H1N1) and A(H1N1)pdm09 viruses. 
This study identifies substitutions in A(H1N1)pdm09 viruses that support escape from 
population immunity, but also suggests that the number of potential escape variants 
is limited by previous exposure to seasonal A(H1N1) viruses.
INTRODUCTION
Influenza pandemics occur when a novel influenza A virus is introduced in the human 
population and spreads around the globe. Since existing antibody responses are 
typically not cross-reactive with the antigenically novel virus, the virus encounters 
little pre-existing humoral immunity and can cause severe outbreaks. Three influenza 
pandemics occurred during the 20th century: A(H1N1) virus in 1918, A(H2N2) virus 
in 1957, and A(H3N2) virus in 1968 (89). In each case the newly introduced subtype 
replaced the previous subtype. In 1977 an A(H1N1) virus that caused epidemics in 
the early 1950s was reintroduced in the human population (90), and continued to co-
circulate with A(H3N2) until 2009. In April 2009 a swine-origin A(H1N1) virus A(H1N1)
pdm09) caused the first influenza A virus pandemic of the 21th century (91). It replaced 
the previously circulating seasonal A(H1N1) virus, but continues to co-circulate with 
seasonal A(H3N2) virus (92).
A prerequisite for the influenza virus to infect the host cell is the binding of 
the hemagglutinin (HA) surface protein to sialylated glycan receptors on the host 
cell through its receptor-binding site (RBS). HA is the main target of neutralizing 
antibodies and is therefore a critical component of influenza vaccines (40). Influenza 
viruses continually escape antibody-mediated neutralization by variation of the amino 
acids in the HA protein. This process is referred to as antigenic drift, and allows the 
virus to infect individuals that are immune to contemporary or previously circulating 
antigenic variants.
Studies from the 1980s identified four immunodominant antigenic regions 
within the HA of A(H1N1) virus (34, 93). Similar antigenic regions were identified for 
A(H3N2) (33) and A(H5N1) viruses (35, 36). Amino acid substitutions in these so called 
antigenic sites, which cover much of the HA globular head, can result in escape from 
antibody recognition. More recently it was shown that major antigenic change during 
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evolution of A(H3N2) and A(H5N1) viruses and recent antigenic change of seasonal 
A(H1N1) and influenza B viruses were predominantly caused by single substitutions 
that occurred near the RBS (77, 94).
Antigenic change may also be a secondary effect of substitutions in HA that 
facilitate more efficient replication in the human host. HA is pivotal in adaptation of 
zoonotic influenza A viruses to a new host because of its function in receptor binding 
(95). Human influenza viruses bind to sialic acids (SAs) linked to the galactose in an 
α2,6-linkage, avian influenza viruses have a preference for α2,3-linked SAs, while swine 
viruses bind either α2,6 or both α2,3 and α2,6 linked SAs (27). We hypothesized that 
substitutions that modify or fine-tune receptor specificity, thereby altering host range 
and tissue tropism, may result in escape from antibodies directed at the RBS area. 
Finally, addition or removal of carbohydrate side chains on HA has been associated 
with changes in the antigenic properties of influenza viruses (61, 62).
The HA of A(H1N1)pdm09 viruses is antigenically most similar to that of recent 
classical and triple reassortant swine A(H1N1) viruses (96, 97). The HA of these 
swine viruses descended from the 1918 pandemic influenza virus but in contrast to 
the human lineage did not undergo extensive antigenic drift, as was reported 
for A(H3N2) swine viruses (30). Structural analyses suggested high antigenic 
similarity between the A(H1N1)pdm09 virus and A(H1N1) viruses that circulated 
in the first decades after the 1918 pandemic (98, 99). Accordingly, age groups 
that experienced A(H1N1) virus infection before 1950 were partially immune to 
the A(H1N1)pdm09 virus (100). 
During the five years after its emergence multiple antigenic variants of A(H1N1)
pdm09 virus have been detected, but the vast majority of recently isolated viruses 
remain antigenically similar to the A/California/7/2009 vaccine virus (92). However, 
as population immunity to A(H1N1)pdm09 virus builds up it becomes beneficial 
for the virus to be antigenically different from the pandemic strain. Therefore, the goal 
of the present study was to explore molecular changes that contribute to antibody 
escape of A(H1N1)pdm09 virus.  
We selected 25 single and five double substitutions based on substitutions that 
were shown to be important for antigenic change in other subtypes, changes in 
receptor specificity, or genetic differences between A(H1N1)pdm09, swine A(H1N1) 
and seasonal A(H1N1) viruses. The substitutions were introduced into the HA gene 
of influenza virus A/Netherlands/602/09 in an attenuated virus backbone, and 
their antigenic effect was tested in hemagglutination inhibition (HI) assays using 
a ferret antiserum prepared to A/Netherlands/602/09. Mutants that displayed altered 
antigenic properties were further tested to a larger panel of ferret antisera and human 
sera. In addition, the impact of these substitutions on replication kinetics and receptor 
specificity was evaluated. 
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MATERIALS AND METHODS
Cells
293T cells were cultured in DMEM (Lonza, Breda, The Netherlands) supplemented 
with 10% FCS (Sigma-Aldrich, Zwijndrecht, The Netherlands), 100 IU/ml penicillin, 
100 μg/ml streptomycin, 2 mM glutamine, 1mM sodiumpyruvate, non-essential amino 
acids (Lonza, Breda, The Netherlands), and 500 µg/mL geneticin (Life Technologies, 
Bleiswijk, The Netherlands). Madin-Darby Canine Kidney (MDCK) cells were cultured 
in EMEM (Lonza) supplemented with 10% FCS, 100 IU/ml penicillin, 100 μg/ml 
streptomycin, 2mM glutamine, 1.5 mg/ml sodiumbicarbonate (Lonza), 10mM Hepes 
(Lonza), and non-essential amino acids. 
Plasmid construction
A/Netherlands/602/09 was isolated from a patient in the Netherlands during 
the 2009 influenza pandemic (101), and was used in this study to represent 
the antigenic properties of A(H1N1)pdm09 viruses. The full HA gene was cloned in 
the modified pHW2000 expression plasmid as previously described (64, 65, 102). 
Mutations were introduced with the minimal number of nucleotide substitutions 
necessary to change the amino acid. When more than one single nucleotide change 
could lead to the desired substitution, the codon change observed in naturally 
occurring amino acid substitutions was selected (e.g. genetic differences between 
human A(H1N1) viruses). If the desired amino acid substitution did not occur previously 
in A(H1N1) viruses, the mutation was introduced using a codon observed in A(H3N2) 
viruses. Mutations were introduced in the HA gene using the QuickChange multi-
site directed mutagenesis kit (Agilent Technologies, Amstelveen, The Netherlands) 
according to the manufacturers instructions. The presence of introduced mutations 
and absence of undesired additional mutations was confirmed by sequence analysis 
of the modified HA gene. 
Construction of recombinant virus stocks
Plasmids containing wildtype or modified A/Netherlands/602/09 HA genes were 
used to generate recombinant viruses consisting of the (modified) HA gene and 
seven remaining gene segments of A/Puerto Rico/8/34, as described previously (64). 
Briefly, 293T cells were seeded in 100mm dishes one day prior to transfection. Cells 
were transfected overnight with 40 µg of plasmid DNA. Transfection medium was 
subsequently replaced with medium containing 2% FCS. Cells were incubated for 72 
hours at 37°C and 5% CO2 before harvesting the supernatant. The virus stocks were 
propagated by inoculation of MDCK cells with 2 mL of supernatant of transfected 
cells. After 2 hours the inoculum was replaced by MDCK infection medium consisting 
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of EMEM, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2mM glutamine, 1.5 mg/ml 
sodium bicarbonate, 10mM Hepes, non-essential amino acids, and 25 μg/ml trypsin. 
Viruses were harvested after incubation for 72 hours at 37°C and 5% CO2. The culture 
supernatants were subjected to ultracentrifugation to increase the viral particle 
concentration if hemagglutination titers were below 12 hemagglutinating units (HAU). 
The presence of introduced mutations and absence of unwanted additional mutations 
was confirmed by sequencing of the HA gene. Work with recombinant viruses was 
performed under biosafety level 2 conditions under a permit from the Ministry of 
Infrastructure and the Environment.
Antisera
Ferret antisera were prepared by intranasal inoculation with 500 µL virus stock. Antisera 
were collected fourteen days after inoculation. Ferrets were housed and experiments 
were conducted in strict compliance with European guidelines (EU directive on 
animal testing 86/609/EEC) and Dutch legislation (Experiments on Animal Act, 1997). 
The protocol was approved by an independent animal experimentation ethical 
review committee ‘stichting DEC consult’. Animal welfare was monitored daily and 
all animal handling was performed under light anesthesia (ketamine) to minimize 
animal discomfort. 
Human serum samples were selected from the serum bank of the Viroscience 
department. Sera from patients in whom the possibility of non-naturally obtained 
antibody responses to A(H1N1)pdm09 virus (e.g. vaccination, intravenous 
immunoglobulin administration) existed or sera from patients with immune 
deficiencies (e.g. auto-immune disease, HIV-positive status, use of immunosuppressive 
medication) were excluded from use in this study. In addition, only sera of patients 
who, or of whom the caregivers, did not object to scientific use of leftover materials 
were included in this study. The study protocol was reviewed and approved by 
the medical ethics board of the Erasmus University Medical Center (study number 
MEC-2012-181). Informed consent was waived because patient inclusion was 
performed retrospectively and anonymously. 
HI assay
HI assays were performed using standard procedures (37). Briefly, ferret antisera or 
human sera were pre-treated overnight with the receptor destroying enzyme Vibrio 
cholerae neuraminidase (VCNA) at 37°C followed by inactivation for 1 hour at 56°C. 
2-fold serial dilutions of the pre-treated sera, starting at a 1:20 dilution, were mixed 
with 25 µL virus stock containing 4 HAU and the mixture was incubated at 37°C for 30 
minutes. Subsequently, 25 µL 1% turkey erythrocytes was added and hemagglutination 
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patterns were read after a 1 hour incubation at 4°C. The HI titer is expressed 
as the reciprocal value of the highest serum dilution that completely inhibited 
agglutination of turkey erythrocytes.
Plaque assay
The assay was performed as described (67). In brief, MDCK cells were seeded in a 6 
well plate to reach 90% confluency the following day. One hour after inoculation with 
virus, the inoculum was replaced with a 1:1 mixture of 2.4% Avicel (FMC biopolymers, 
Brussels, Belgium) with 2xEMEM infection medium. After 36 hours, cells were washed 
with PBS and incubated with 80% Aceton for at least 30 minutes at -20°C. Fixed and 
permeabilized cells were washed 3 times with PBS, and incubated for 1 hour at 37°C 
with mouse-anti-NP monoclonal antibody (1 mg/ml HB65, ATCC). Following three 
washes with PBS, cells were incubated for 1 hour at 37°C with rabbit-anti-mouse-
FITC (Life Technologies, Bleiswijk, The Netherlands). Cells were washed with PBS 
and allowed to air dry. Plaques were scanned on a Typhoon 9410 variable mode 
imager (GE Healthcare, Diegem, Belgium). This data was analysed with ImageQuant 
TL Colony counter & Image feature measurement (Amersham Biosciences, Freiburg, 
Germany). Plaque size was plotted as the radius of the plaques.
Modified turkey red blood cell hemagglutination assay
The modified turkey red blood cell (TRBC) assay was performed as described 
previously (103) with modifications. Briefly, SAs were removed from the turkey 
erythrocyte surface by incubating 20% turkey erythrocytes in a total volume of 62,5 
µL phosphate-buffered saline supplemented with 50mU of VCNA (Roche, Almere, 
The Netherlands) in 8 mM calcium chloride at 37°C for 1 hour. The removal of SAs 
was confirmed by absence of hemagglutination of the treated turkey erythrocytes by 
control viruses. Turkey erythrocytes stripped of SAs were resialylated to contain only 
α2,3- or α2,6-linked SAs using either 0.5 mU α2,3-(N)-sialyltransferase (Calbiochem, 
CA) or 2 mU of α2,6-(N)- sialyltransferase (Japan Tobacco, Inc., Shizuoka, Japan), and 
1.5 mM cytidine monophospho-N-acetylneuraminic (CMP) sialic acid (Sigma-Aldrich, 
Zwijndrecht, Netherlands) at 37°C for 2 hours in a total volume of 75 µl. Subsequently, 
resialylated turkey erythrocytes were washed with PBS and were resuspended to 
a final concentration of 0.5% in PBS containing 1% bovine serum albumin. Standard 
hemagglutination assays were performed to confirm correct resialylation using control 
viruses with known receptor specificities for α2,3- and α2,6-linked SAs. The receptor 
specificity of mutant viruses was tested by conventional hemagglutination assay with 
the modified TRBCs using cell culture supernatants. 
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Structural analysis
Amino acid positions were plotted on the HA crystal structure of the A/California/04/09 
virus [PDB accession code 3LZG (42)] using MacPyMOL (The PyMOL Molecular 
Graphics System, Version 1.3, Schrödinger, LLC) to visualize the trimer.
RESULTS
Selection of substitutions
The antigenic regions of seasonal A(H1N1) virus have previously been mapped 
(34, 93), but the substitutions that caused antigenic change during A(H1N1) virus 
evolution remain almost entirely unknown. Additionally, fine-grain differences in 
receptor specificity beyond the coarse distinction for α2,3-SA or α2,6-SA preference 
that allow more efficient replication in the human host and that may change the virus 
antigenically are currently incompletely understood (95, 104). Because of the limited 
insight in the molecular basis for previous antigenic change of A(H1N1) viruses we 
selected substitutions to introduce into the A/Netherlands/602/09 representative 
virus HA gene based on the following three approaches. 
First, we aligned the HA sequences of 28 viruses representing pre-1957 and 
post-1977 seasonal A(H1N1) viruses, swine A(H1N1) viruses and A(H1N1)pdm09 
viruses, and selected substitutions based on genetic differences between these 
viruses (Table 1). We hypothesized that part of the substitutions that became fixed 
during A(H1N1) virus evolution had a selective advantage because of their role in 
immune escape.  In addition, amino acid differences between swine or A(H1N1)
pdm09 viruses and pre-2009 human A(H1N1) viruses may contribute to adaptation to 
the human host and potentially change the virus antigenically as a secondary effect. 
Previous work indicated a critical role for antibodies targeting the RBS area in virus 
neutralization (77, 94) and we therefore focused primarily on amino acid differences 
in this region of the HA. Substitution 84SN is located away from the RBS, but was 
consistently different between A(H1N1)pdm09 viruses and all swine and human 
A(H1N1) viruses (H1 numbering is used throughout, unless indicated otherwise). 
A second approach was based on information regarding the molecular basis for 
antigenic change during evolution of other influenza virus subtypes. Substitutions 
at seven positions (145, 155, 156, 158, 159, 189, and 193, H3 numbering) were 
entirely responsible for the major antigenic changes during evolution of A(H3N2) 
virus (77), three of which (151, 185, and 189, H5 numbering) were also identified as 
key positions for antigenic change of A(H5N1) clade 2.1 virus (94). The corresponding 
A(H1N1)pdm09 virus positions were identified and where possible the substitution 
responsible for the observed antigenic change was introduced (Table 1). Multiple 
mutants were made if it was not possible to introduce the desired substitution. For 
example, 156QH was responsible for a major antigenic change during A(H3N2) virus 
evolution and we therefore generated mutants with 153KQ and 153KH. 
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Third, we selected substitutions shown or predicted to affect receptor binding 
specificity of influenza viruses of the A(H1N1), A(H3N2) or A(H5N1) subtypes (Table 1). 
A(H1N1)pdm09 viruses containing the substitutions 222DE and 222DG were previously 
tested for their effects on receptor binding and antigenic properties by Chutinimitkul 
et al. (102). That work additionally suggested that amino acid differences at positions 
142, 187, 222, and 224 were responsible for differences in receptor binding between 
a 1918 A(H1N1) virus and A/Netherlands/602/09 (26, 102). Mutants with these 
substitutions, or combinations thereof, were included in the current more extensive 
analyses. Substitutions 222QL and 224GS (223QL and 225GS in H1 numbering) were 
previously shown to affect the receptor specificity of A(H5N1) virus (105). 
Recombinant viruses with the modified A/Netherlands/602/09 HA gene and 
the seven remaining gene segments of A/Puerto Rico/8/34 were rescued by 
reverse genetics. We were unable to rescue the 127DN and 186AK mutants. 
The mutant with 187DE did not agglutinate turkey erythrocytes even upon 
concentration of the virus and was therefore omitted from the antigenic analyses. After 
MDCK passaging, we found addition of substitution 153KE to mutant 222DG224EA 
and this mutant was therefore excluded from this study. Figure 1A indicates 
the positions of introduced substitutions on an A/California/04/09 HA crystal structure.
Analysis of antigenic properties using ferret antisera
HI assays with a ferret antiserum prepared to A/Netherlands/602/09 were performed 
to test if the mutant viruses could escape recognition by antibodies against 
the wildtype virus. When comparing HI titers obtained to an individual antiserum, 
viruses were considered substantially antigenically different from the reference virus if 
the HI titer was at least 4-fold (2 log2) lower. Ten of the 27 mutants were substantially 
antigenically different from A/Netherlands/602/09 (Fig. 2): 224EA, 127DT, 155GE, 
156ND, 156NG, 153KE, 156NY, 156NS, 152VT156NS, and 155GE224EA. 
Two groups of mutants were further tested in HI assays to a panel of ferret 
A(H1N1)pdm09 antisera. One group contained the ten viruses that were substantially 
antigenically different from A/Netherlands/602/09, the second group contained 
seven mutants; 84SN, 152VT, 190SN, 222DE, 222DG, 223QL, and 223QR that 
were antigenically similar to A/Netherlands/602/09 (Fig. 1B and 2). These groups 
are hereafter referred to as escape mutants and non-escape mutants, respectively. 
The panel of 14 ferret antisera was prepared to seven A(H1N1)pdm09 viruses 
isolated between 2009 and 2011. Of these, six wildtype viruses were antigenically 
similar to A/Netherlands/602/09, in agreement with the fact that these viruses did not 
have any of the substitutions present in the mutants. However, A/Netherlands/219/11 
contains the 155GE substitution and had a more than 8-fold (3 log2) lower mean HI 
titer (data not shown). 
The mean HI titers of the non-escape mutants and 224EA were less than 2-fold 
lower than that of A/Netherlands/602/09 to the panel of ferret antisera (Fig. 3). 
Escape mutants 156ND, 127DT, 155GE, and 156NG had 3 to 4-fold lower mean 
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A B
Fig. 1. Position of amino acid substitutions indicated on an A/California/04/09 HA crystal structure. 
(A) The three HA monomers are indicated in white, gray, and black; the RBS is in yellow. Amino acid 
positions that were mutated in this study are indicated in orange. (B) Zoom image of the globular 
head of HA. Amino acid substitutions in mutants that were substantially antigenically different from 
A/Netherlands/602/09 (escape mutants) are indicated in red; substitutions in mutants that were 
antigenically similar to A/Netherlands/602/09 and that were included in further antigenic analyses 
(non-escape mutants) are indicated in blue.
HI titers than A/Netherlands/602/09 (4-fold for 155GE when antisera prepared to 
A/Netherlands/219/11 were not included). The mean HI titers of 156NS, 152VT156NS, 
156NY, 155GE224EA, and 153KE were up to 14-fold (3.8 log2) lower than 
A/Netherlands/602/09 HI titers. These results indicate that the amino acid 
substitutions in all escape mutants except 224EA caused evasion of recognition 
by antisera raised to this panel of A(H1N1)pdm09 viruses. Mutants 156NS and 
152VT156NS were antigenically similar, as were 152VT and A/Netherlands/602/09, 
thus indicating that 156NS was solely responsible for the antigenic change of this 
double mutant. Introduction of 224EA as single substitution had only minor effects on 
HI titers to most antisera. The 155GE224EA double mutant displayed a mean HI titer 
decrease of 12-fold (3.6 log2), indicating that these substitutions had a cumulative 
antigenic effect. 
Analysis of antigenic properties using human infant sera
Antibodies in sera obtained from infants that experienced a primary A(H1N1)pdm09 
virus infection were elicited in response to a single antigenic variant of influenza virus, 
as is the case for the antibody repertoire of inoculated ferrets. We next examined if 
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FIG 2 HI titer differences between viruses with wildtype or mutant HAs against 
an A/Netherlands/602/09 ferret antiserum. Viruses with either wildtype or 
mutant A/Netherlands/602/09 HAs were tested in HI assays to a ferret 
antiserum prepared to the A/Netherlands/602/09 wildtype virus. Each point 
represents the log2 HI titer difference between a mutant and 
A/Netherlands/602/09. Mutants with HI titers at least 4-fold (2 log2) lower than 
A/Netherlands/602/09 (dashed line) were considered substantially 
antigenically different. The viruses are ordered by the log2 HI titer difference 
from A/Netherlands/602/09.!
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Fig. 2. HI titer differences between viruses with wild-type or mutant HAs against an A/Netherlands/602/09 
ferret antiserum. Viruses with either wild- type or mutant A/Netherlands/602/09 HAs were tested in HI 
assays with a ferret antiserum pr pared against the A/Nethe lands/602/09 wild-type vir s. Each point 
represents the log2 HI titer difference between a mutant and A/Netherlands/602/09. Mutants with HI 
titers at least 4-fold (2 log2) lower than that of A/Netherlands/602/09 (dashed line) were considered 
substantially antigenically different. The viruses are ordered by the log2 HI titer difference from 
A/Netherlands/602/09.
the substitutions that led to antigenic variation as tested by ferret antisera were 
sufficient to escape recognition by human antibodies. 49 surplus sera from unvaccinated 
infants were tested in HI assays for the presence of antibodies to A(H1N1)pdm09 virus. 
Six sera from infants born in 2009 or 2010 that were between 6 and eleven months 
of age at the time of sampling had detectable HI titers to A/Netherlands/602/09. 
HI titers to A/Brisbane/59/07 (seasonal A(H1N1)) were below the detection limit 
of the HI assay at a starting dilution of 1/40. This suggested that the infants experienced 
a primary infection and that maternal antibodies potentially present in the sera did 
not influence our results. Escape and non-escape mutants were tested in HI assays to 
sera 6, 11, 14 and 16. Non-escape mutants were not included in HI assays with sera 
7 and 25 because of insufficient material available for these sera.
Escape and non-escape mutants had 3.5 – 14-fold lower mean HI titers than 
A/Netherlands/602/09 (Fig. 4A). The variation in HI titers between the different 
infant sera was larger than for ferret antisera and contradicting results were 
obtained with different sera. For example, mutant 222DE was antigenically similar to 
A/Netherlands/602/09 using ferret sera and infant serum 14, yet the HI titer to serum 
16 was more than 10-fold lower. Sera 6, 7 and 16 poorly discriminated between 
the mutants. Serum 7 had a low HI titer of 160 to A/Netherlands/602/09 and HI titers 
of the mutants tested to this serum were similarly low or up to 4-fold higher. The HI 
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FIG 3 HI titer differences between viruses with wildtype or mutant HAs against 
ferret antisera. Each point in panel (A) represents the log2 HI titer difference 
between a mutant and A/Netherlands/602/09 for an individual ferret 
antiserum. The viruses are ordered by the mean log2 HI titer difference from 
A/Netherlands/602/09, which is indicated as red horizontal lines. Names of 
escape and non-escape mutants are shown in black and grey, respectively. 
Ferret antisera are indicated in the left most column panel (B), and are 
ordered top to bottom by a decreasing ability of the serum to inhibit the test 
viruses in the HI assay. Two antisera (labeled A and B) were prepared to 
each virus. HI titers are color coded for the difference from 
A/Netherlands/602/09 (NL602): orange; equal to or higher than 
A/Netherlands/602/09, yellow; up to 2-fold lower, green; 2 to 4-fold lower, 
cyan; 4 to 8-fold lower, blue; 8 to 16-fold lower, purple; 16 to 32-fold lower, 
magenta; at least 32-fold lower.!
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Fig. 3. HI titer differences between viruses with wild-type or mutant HAs in ferret antisera. Each point 
in panel A represents the log2 HI titer difference between a mutant and A/Netherlands/602/09 for 
an individual ferret antiserum. The viruses are ordered by the mean log2 HI titer difference from A/
Netherlands/602/09, which is indicated as red horizontal lines. Names of escape and nonescape 
mutants are shown in black and gray, respectively. Ferret antisera are indicated in the leftmost column 
of panel B and are ordered from top to bottom by a decreasing ability of the serum to inhibit the test 
viruses in the HI assay. Two antisera (labeled A and B) were prepared against each virus. HI titers are 
color-coded for the difference from A/Netherlands/602/09 (NL602): orange, equal to or higher than 
that of A/Netherlands/602/09; yellow, up to 2-fold lower; green, 2- to 4-fold lower; cyan, 4- to 8-fold 
lower; blue, 8- to 16-fold lower; purple, 16- to 32-fold lower; and magenta, at l ast 32-fold lower. 
A
B
titers to sera 6 and 16 wer  at least 8-fold l wer than that of A/Netherlands/602/09 
for all mu ants. 
To test if escape mutants had an antigenic advantage over non-escape mutants 
in evasion of the infant sera that discriminated between the mutants, the results 
from sera 7 (that had similarly high titers to all viruses), and 6 and 16 (that had 
low titers to all mutants) were omitted and the analysis was repeated. Non-escape 
mutants and 156ND had mean HI titers that ranged from similar to 2-fold lower than 
A/Netherlands/602/09, individual HI titers to the different sera were up to 3-fold 
lower (Fig. 4B, 4C). The remaining mutants, which were all escape mutants, had 
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mean HI titers 2 to 10-fold lower than A/Netherlands/602/09 HI titers, and had 
one or more individual HI titers that was at least 4-fold lower than HI titers to 
A/Netherlands/602/09. Therefore, substitutions responsible for antigenic change as 
measured by ferret antisera can also mediate escape from recognition by human 
antibodies elicited in response to a primary infection with an A(H1N1)pdm09-
like virus. However, in contrast to the ferret sera, the infant sera were sometimes 
non-discriminative (serum 7) or reacted low across the board with all mutants 
(sera 6 and 16). Thus, mutants 127DT, 153KE, 155GE, 156ND, 156NG, 156NS, 156NY, 
152VT156NS, and 155GE224EA escaped from recognition by antibodies in ferret sera 
and human infant sera (Figs. 3 and 4).
Analysis of virus replication 
Next, plaque assays were performed to test the effect of the introduced substitutions 
on replicative fitness. Plaque sizes were determined at a fixed time-point after 
inoculation and were used as a proxy for replication efficiency, i.e. larger plaques 
indicate more efficient replication. 
The majority of the mutants displayed plaque sizes similar to A/Netherlands/602/09 
(Fig. 5). Single mutants 187DE, 156NY, 224EA, 84SN, and 222DG displayed 
reduced plaque sizes. Mutants 127DT, 153KH, 153KE, 155GE, 153KQ, and 156ND 
had predominantly larger plaques. Of the ten mutants that had an antigenic effect 
in HI assays with ferret or infant sera, only 156NY and 224EA had substantially 
smaller plaques. The 155GE224EA double mutant displayed plaque sizes similar 
to A/Netherlands/602/09, indicating that 155GE compensated for the adverse 
effect of 224EA. Thus, eight mutants (127DT, 155GE, 156ND, 156NG, 153KE, 
156NS, 152VT156NS, and 155GE224EA) were antigenically different from 
A/Netherlands/602/09 with no apparent loss of replication efficiency 
(Figs. 3, 4, and 5).
Effect of substitutions on receptor binding specificity
To test if substitutions that caused antigenic change in the HI assays had altered 
receptor binding specificity, the escape mutants were tested in hemagglutination 
assays using normal TRBCs or TRBCs resialylated to contain either α2,3- or α2,6-
linked SAs. Removal of SAs from the TRBC surface and correct resialylation was 
confirmed in hemagglutination assays using the avian A/Vietnam/1194/2004 
(H5N1) and A/Netherlands/213/03 (H3N2) viruses. A/Netherlands/602/09 and all 
mutants yielded hemagglutination titers to TRBCs reconstituted with α2,6-linked SA 
(Table 2). Only mutants 153KE, 155GE and 156ND showed a very weak binding to 
TRBCs with α2,3-linked SAs. Mutants 156NG and 156NS showed markedly reduced 
binding to α2,6-reconstituted TRBCs as compared to unmodified TRBCs. Although 
some mutations that affect antigenic properties appeared to influence receptor 
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FIG 4 HI titer differences between viruses with wildtype or mutant HAs against 
human infant sera. (A) Symbols, order and nomenclature as in figure 3. (B) HI 
titers are color coded for the difference from A/Netherlands/602/09: orange; 
equal to or higher than A/Netherlands/602/09, yellow; up to 2-fold lower, 
green; 2 to 4-fold lower, cyan; 4 to 8-fold lower, blue; 8 to 16-fold lower, 
purple; 16 to 32-fold lower, magenta; at least 32-fold lower. NT: The virus 
serum combination was not tested. (C) The analysis was repeated with 
inclusion of only the sera that differentiated between the mutants (sera 6, 7, 
and 16 were omitted). Non-escape mutants were not tested to serum 25 
because of insufficient material available for this serum. Grey horizontal lines 
indicate the mean log2 HI titer difference from A/Netherlands/602/09 when this 
serum is also omitted for the other mutants.!
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ig. 4. HI titer differenc s between viruses with wild-type or mutant HAs against human infant sera. 
(A) Symbols, order, and nomenclature are as in Fig. 3. (B) HI titers re color-coded for the difference 
from A/Netherlands/602/09: orange, equal to or higher than that of A/Netherlands/602/09; yellow, 
up to 2-fold lower; green, 2- to 4-fold lower; cyan, 4- to 8-fold lower; blue, 8- to 16-fold lower; purple, 
16- to 32-fold lower; and magenta, at least 32-fold lower. NT, the virus-serum combination was not 
tested. (C) The analysis was repeated with inclusion of only the sera that differentiated between the 
mutants (sera 6, 7, and 16 were omitted). Non-escape mutants were not tested with serum 25 because 
of insufficient material available for this serum. Gray horizontal lines indicate the mean log2 HI titer 
difference from A/Netherlands/602/09 when this serum was also omitted for the other mutants.
specificity to some extent, a clear tendency towards reduced affinity for α2,6-linked 
SAs was not demonstrated.
Frequency of substitutions in natural isolates
We analyzed the frequencies of the tested substitutions in 10,422 A(H1N1)pdm09 
sequences from GenBank submitted between April 2009 and February 2014 
B
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Fig. 5. Effects of substitutions on virus replication. MDCK cells were inoculated with viruses containing 
wild-type or mutant A/Netherlands/602/09 HAs. After 36 h, the plaque sizes were determined as a 
measure of replication efficiency. Each point indicates the size of a single plaque. The mutants are 
ordered by increasing median plaque size, which is indicated by red horizontal lines. Escape mutants 
are in bold.
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FIG 5 Effect of substitution  on virus replication. MDCK cells were inoculated 
with viruses containing wildtype or mutant A/Netherl nds/602/09 HAs. After 
36 hours the plaque sizes were determined as a measure of replicatio  
fficie y. Each poi t indicates the size of  single plaque. The mutants are 
ordered by increasing median plaque size, which is indicated as red horizontal 
lines. Escape mutants are indicated in bold.!
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(data not shown). Four substitutions were detected in more than 1% of the sequences: 
three non-escape mutants; 222DE, 222DG, and 223QR (4.80, 1.94, and 1.60%, 
respectively), and escape mutant 155GE (1.46%). Of the mutants with substantially 
increased plaque sizes, substitutions 155GE, 156ND, 153KE were found in 1.46, 0.36 
and 0.17%, of the sequences, respectively. Substitutions 127DT and 153KH were not 
detected. Substitution 156NS, which had a large antigenic effect but did not affect 
plaque size was detected in 0.18% of the sequences. Other substitutions in escape 
mutants that did not affect plaque size or resulted in substantially smaller plaques 
were not detected.
Analysis of antigenic properties using human sera
The majority of the human population has a more broadly reactive antibody repertoire 
than influenza-virus inoculated ferrets or infants after primary infection due to previous 
infections or vaccination with seasonal A(H1N1) viruses (106, 107). Therefore we also 
5H1N1 PDM09 VIRUS: POSSIBILITIES FOR ANTIGENIC CHANGE
150
Table 2. Agglutination of TRBCs by viruses with wildtype or mutant HAsa
Antigen
HA titer 
TRBC VCNA α2,3-TRBC α2,6-TRBC
A/Netherlands/602/09 512 0 0 32
127DT 128 0 0 32
153KE 128 0 1 64
155GE 512 0 1 16
156ND 512 0 2 128
156NG 256 0 0 4
156NS 256 0 0 2
156NY 64 0 0 32
224EA 128 0 0 64
152VT156NS 128 0 0 8
155GE224EA 1024 0 0 1024
A/Vietnam/1194/2004 128 0 256 0
A/Netherlands/213/2003 256 0 0 256
a Hemagglutination titers are expressed as the HAU with unmodified TRBCs, TRBCs stripped from SAs using VCNA, 
or TRBCs resialylated to contain either α2,3- or α2,6- SA. A/Vietnam/1194/2004 and A/Netherlands/213/2003 
served as typical avian and human viruses with α2,3- and α2,6-SA preferences, respectively.
tested the mutants in HI assays to human sera obtained from individuals anticipated 
to have experienced both seasonal A(H1N1) virus and A(H1N1)pdm09 virus 
infections. We first tested the reactivity of a panel of pre-2009 swine (-origin) viruses 
(A/swine/Shope/56 and A/New Jersey/8/76) and human vaccine strains (A/USSR/92/77, 
A/Chile/1/83, A/Taiwan/1/86, A/New Caledonia/20/99, and A/Brisbane/59/07) 
to a ferret antiserum prepared to A/Netherlands/602/09. HI titers were below 
the detection limit of the HI assay at a starting dilution of 1/20 (data not shown), 
indicating that these viruses were antigenically distinct from A(H1N1)pdm09 
viruses. 21 sera obtained from individuals aged 7 to 85 at the time of serum 
collection (October 2009 – May 2011) were selected based on their ability to inhibit 
A/Netherlands/602/09 in HI assays. The sera were tested in HI assays to ten 
seasonal A(H1N1) viruses covering the period from 1977 to 2009 (Fig. 6A). All sera 
had detectable HI titers to five or more seasonal A(H1N1) viruses, demonstrating 
a broadly reactive antibody repertoire. Subsequently, the escape and non-escape 
mutants and A/Netherlands/602/09 were tested in HI assays using the selected sera 
(Figs. 6B and C). The mean HI titers of escape as well as non-escape mutants were less 
than 1.5-fold (0.54 log2) lower than A/Netherlands/602/09 HI titers, suggesting that none 
of the mutants escaped recognition by this panel of sera. The majority of individual HI 
titers to the different sera were also less than 2-fold lower than A/Netherlands/602/09 
HI titers. Six mutants had a single titer that was more than 2-fold lower than 
the A/Netherlands/602/09 HI titer: 155GE, 155GE224EA, 223QL, 222DG displayed 
a 4-fold lower HI titer; 224EA and 127DT had 8 and 12-fold lower HI titers, respectively. 
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The antigenic effect of the substitutions in neither non-escape nor escape mutants 
was therefore sufficient to escape recognition by this panel of human sera. 
DISCUSSION
In this study we attempted to identify amino acid substitutions that contribute to 
antibody escape of A(H1N1)pdm09 viruses. Substitutions introduced into the HA of 
A/Netherlands/602/09 were selected based on genetic and antigenic changes of 
influenza A viruses that circulated in the past and on substitutions associated with 
changes in receptor binding specificity. We show that at least nine mutants were 
antigenically distinct from A/Netherlands/602/09 in HI assays using ferret antisera and 
found that the substitutions that caused escape from ferret antibodies also evaded 
antibodies in some human sera collected after primary infection. 
Substitution 127DT introduces a glycosylation pattern (N-X-S/T-X) that potentially 
adds a carbohydrate side chain at position 125. Carbohydrate side chains can mask 
antibody epitopes and have been shown to change the antigenic properties of 
influenza viruses (61, 62). Seasonal A(H1N1) viruses that circulated since the 1930s 
until 1986 had a glycosylation site starting at position 127, viruses that circulated from 
1986 onwards had a glycosylation site starting at position 125. Both glycosylation 
sites were absent from the 1918 A(H1N1) and A(H1N1)pdm09 viruses. Absence of 
glycosylation at these positions has been suggested to contribute to the antigenic 
difference between seasonal A(H1N1) viruses and A(H1N1)pdm09 viruses (108). Our 
results indicate that re-introduction of a potential glycosylation site in this region was 
sufficient to escape from antibodies generated in response to A(H1N1)pdm09 virus. 
Substitutions 153KE and 155GE in A(H1N1)pdm09 virus are analogous to 
substitutions 156KE and 158GE  that were responsible for major antigenic 
changes during evolution of A(H3N2) viruses (77). The observation that these 
substitutions changed the antigenic properties of an A(H1N1)pdm09 virus is also 
in agreement with previous studies that reported escape of A(H1N1)pdm09 virus 
from monoclonal antibodies (109, 110), and from polyclonal antibody responses in 
ferrets (108, 111, 112). 
The four different substitutions introduced at position 156 (ND, NG, NY and NS) 
all had a large antigenic effect. Two additional substitutions on this position, 156NK 
and 156NE, were previously reported to escape antibody neutralization of A(H1N1)
pdm09 virus (110, 111). Interestingly, the large changes in biophysical properties of 
the substituted amino acids introduced by 156ND or 156NY (charge and volume 
differences, respectively) had a similar antigenic effect to the small difference in 
biophysical properties introduced by 156NS. This finding emphasizes the potential 
importance of this position for antigenic change of A(H1N1)pdm09 viruses. 
The antigenic effect of 155GE224EA in HI assays with ferret antisera was larger 
than the sum of the effects of the single substitutions. A possible explanation for how 
substitutions bordering opposite sides of the RBS can amplify each other’s effect on 
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Fig. 6. HI titer differences between viruses with wild-type or mutant HAs against human sera. (A) 
HI titers of human sera against antigenic variants of seasonal A(H1N1) viruses isolated between 
1977 and 2009 (USSR77, A/USSR/90/77; NL78, A/Netherlands/3075/78; TA89, A/Taiwan/1/89; 
NL87, A/Netherlands/414/87; NC99, A/New Caledonia/20/99; NL99, A/Netherlands/271/99; NL03, 
A/Netherlands/02/03; NL06, A/Netherlands/364/06; SS06, A/Solomon Islands/03/06; and NL09, 
A/Netherlands/1005/09). (B) HI titer differences between viruses with wild-type or mutant NL602 
HAs against human sera. Symbols, order, and nomenclature are as in Fig. 3. (C) HI titers are 
color-coded for the difference from A/Netherlands/602/09: orange, equal to or higher than 
A/Netherlands/602/09; yellow, up to 2-fold lower; green, 2- to 4-fold lower; cyan, 4- to 8-fold lower; and 
blue, 8- to 16-fold lower. The first two digits of the serum number indicate the age of the individual at 
the time of sampling.
antibody escape is given by the greater surface area of an antibody footprint in relation 
to the size of the RBS (113), which allows more efficient escape from antibodies that 
cover the RBS in addition to the proportion of antibodies evaded by the individual 
substitutions. Interestingly, substitution 224EA had a small antigenic effect in HI 
assays with ferret antisera but was substantially different from A/Netherlands/602/09 
when tested with infant sera. In tests with infant sera 155GE224EA and 224EA 
were equally different from A/Netherlands/602/09, indicating that 155GE did not 
add to the antigenic effect of 224EA. These results suggest that position 224 plays 
a more prominent role in escape from human antibodies than in escape from ferret 
antibodies. Antigenic variants with a substitution on this position may therefore not 
be readily detected in conventional HI assays using ferret antisera.
The high mutation rate of influenza A viruses and the observation that single 
substitutions caused substantial antigenic change during evolution of A(H3N2), 
A(H1N1), and influenza B viruses contradicts the relatively slow rate at which 
influenza viruses have changed antigenically (77). One possible explanation for 
this paradox is that substitutions responsible for escape from antibodies targeting 
the RBS have an adverse effect on HA function, necessitating the co-occurrence 
of compensatory substitutions, which slows down the emergence of new antigenic 
variants. Substitutions in and surrounding the A(H1N1)pdm09 RBS may affect 
receptor binding and consequently change replication efficiency (114). Surprisingly, 
we found that most of the substitutions that caused antigenic change in HI assays with 
ferret and human sera did not result in less efficient virus replication. Substitutions at 
positions 153 and 156 often had large effects on replication efficiency. Interestingly, 
change of the lysine at position 153 for three biophysically diverse amino acids all 
resulted in increased replication efficiency. Replacing the asparagine at position 156 
with either an aspartic acid or tyrosine had opposite effects on replication. These 
results suggest that positions 153 and 156 are key determinants of replication 
efficiency. It should be noted that replication assays are a surrogate measure of viral 
replication in vivo, and that results may vary with the model system used. In addition, 
differences in replication efficiency may in part be caused by the use of an A/Puerto 
Rico/8/34 backbone. However, other studies have also demonstrated that A(H1N1)
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pdm09 viruses with 153KE, 155GE, and 156ND had increased replication efficiency 
in eggs or MDCK cells (99, 108), and they were often associated with cell culture 
adaptation (99, 108, 111). 
The substitutions that caused antigenic change in HI assays with ferret and human 
infant sera were, with the exception of 224EA, located in or near the 151 - 159 
loop. Substitutions in this region have previously been shown to affect the antigenic 
properties of A(H3N2) and A(H5N1) viruses (77, 94). In addition, these positions often 
affected replication efficiency of the mutants constructed in this study. Amino acid 
substitutions at other positions tested in this study that caused similarly large changes 
in biophysical properties did not substantially change the antigenic properties or 
replication efficiency. However, it should be noted that it is possible that other amino 
acid changes outside the 151- 159 loop, that were not included in this study, can 
result in phenotypic change (115) . Our results are in agreement with previous studies 
that reported mice or human monoclonal antibodies (109, 110) or antibodies in ferret 
antisera (111) that target the 151 - 159 loop. We here show that several substitutions 
in or affecting the 151 - 159 loop caused antigenic escape while retaining replicative 
fitness. These results substantiate the importance of this region for antigenic evolution 
of A(H1N1) viruses. 
We found large differences in the reactivity of infant antisera. Surprisingly, three sera 
(from the youngest infants) had almost uniform HI titers to all mutants that were either 
the same as that of A/Netherlands/602/09, or much lower. Infection in the presence 
of maternally derived antibodies or mechanisms associated with the transformation 
of the neonatal immune system to a more mature immunological phenotype 
may explain the difference from the other infant sera (116, 117). Nevertheless, 
the different reactivities of these three sera warrant further investigation. However, 
the remaining three sera had reactivities similar to that observed with ferret antisera. 
This indicates that substitutions that caused escape from ferret antibodies also 
promote escape from human antibodies elicited in response to infection with an 
A(H1N1)pdm09-like virus. In contrast, the substitutions responsible for escape from 
ferret and infant sera were not sufficient to escape recognition by antisera from 
individuals that experienced infection with seasonal and pandemic A(H1N1) viruses. 
Thus, the antibody repertoire of the individuals that had a more experienced immune 
system included antibodies that were absent in the sera of infants. These results 
suggest that antibodies directed to epitopes on seasonal A(H1N1) viruses are cross-
reactive with epitopes on the mutants tested in this study, and thereby complement 
the antibody repertoire elicited in response to A(H1N1)pdm09 infection alone. 
The presence of such antibodies in much of the population may also explain why 
mutations that gave an in vitro replication advantage have not been detected at 
higher frequencies. Carter et al. showed that sera from ferrets sequentially infected 
with antigenically diverse seasonal A(H1N1) viruses can efficiently neutralize A(H1N1)
pdm09 virus, whereas sera from ferrets infected with a single seasonal A(H1N1) virus 
were not cross-reactive (118). Additionally, a recent study by Miller et al. indicated 
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that antibodies against previously encountered influenza A viruses are periodically 
boosted upon natural exposure to drift variants of the same subtype (106), possibly 
resulting in the more broadly reactive antibody repertoire observed here. This study 
and other studies (112, 115) suggest that the complexity of the antibody repertoire to 
A(H1N1) viruses in much of the human population cannot be represented by antigenic 
analyses based on single-infection ferret antisera. This limits the use of ferret antisera 
to test the ability of an antigenic variant to escape from population immunity.
In conclusion, substitutions in or near the RBS can influence the antigenic 
properties of A(H1N1)pdm09 viruses. Based on the current and previous studies into 
antigenic change of influenza A viruses (77, 94), it is probable that emerging antigenic 
variants of A(H1N1)pdm09 viruses will escape from population immunity because of 
substitutions  in or near the RBS. However, our results also suggest that the presence 
of antibodies directed to epitopes on seasonal A(H1N1) and A(H1N1)pdm09 viruses 
in much of the population limits the number of antigenic variants that can emerge to 
cause new epidemics. 
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SUMMARIZING DISCUSSION
Substitutions near the receptor binding site shape antigenic evolution
It is thought that the necessity to re-infect their hosts in the face of population 
immunity drives antigenic change of seasonal human influenza viruses. Influenza 
viruses escape population-level antibody-mediated neutralization by accumulating 
amino acid substitutions in the globular head domain of the hemagglutinin (HA) 
surface protein (32-34). Early studies on influenza virus antigenic change identified 
four (H1) or five (H3) regions of potentially important amino acid positions that could 
cause antibody escape upon mutation (32-34). It was postulated that at least four 
amino acid substitutions in two or more antigenic sites are necessary for an antigenic 
variant to become epidemically relevant (32). The studies described in this thesis 
demonstrate that antigenic change sufficiently large to escape recognition from 
antibodies to previously circulating antigenic variants never required more than three 
amino acid substitutions and that it was single amino acid substitutions that caused 
the majority of large antigenic changes during influenza virus evolution. For both 
influenza A and B virus and for the human and avian viruses, 15 of 19 major antigenic 
changes for which the molecular basis is known were primarily caused by a single 
amino acid change (chapters 2 and 3, and (31, 49)). Single amino acid substitutions 
introduced into a virus representing A(H1N1)pdm09 viruses were also sufficient to 
escape recognition by antibodies specific to A(H1N1)pdm09 viruses that circulated 
between 2009 and 2011 (chapter 5), and are thought to cause increased susceptibility 
of people in certain age groups to contemporary A(H1N1) viruses (112, 115). 
The antigenic sites of A(H3N2) virus contain 131 amino acid positions that cover 
much of the HA globular head (32, 33). Each of these positions potentially contributes 
to antigenic change. The 20 amino acids that could theoretically occupy each of 
the 131 positions imply a plethora of amino acid substitutions that may lead to 
escape from neutralizing antibodies. In chapter 2 we showed that major antigenic 
change during evolution of A(H3N2) virus was due to substitutions on key positions 
located immediately adjacent to the receptor binding site (RBS). Major change 
during A(H5N1) clade 2.1 virus evolution, and large antigenic differences between 
recent pre-2009 A(H1N1) viruses and between influenza B viruses, was also caused 
exclusively by amino acid changes adjacent to the RBS (chapters 2 and 3, and (49)). 
The most striking example indicating the importance of positions adjacent to the RBS 
for antigenic change was an experiment in which the amino acids on the seven key 
positions from an A(H3N2) virus that circulated in 2003 were introduced in the HA 
of a virus isolated in 1968. Although there were 54 amino acid differences between 
the HAs of these viruses, introduction of only the five amino acid differences on 
the key antigenic positions in the 1968 virus resulted in a mutant that had antigenic 
properties characteristic of viruses isolated in 2002 and 2003. Thus, the area 
immediately surrounding the RBS determines the antigenic phenotype of seasonal 
human influenza viruses and HPAI A(H5N1) clade 2.1 viruses.
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In chapter 2 we showed that substitutions at only seven key positions dictated 
35 years of A(H3N2) virus antigenic evolution, the work for chapter 3 showed that 
substitutions at six key positions explained the antigenic changes of A(H5N1) clade 
2.1 virus in chickens. Five of seven key positions of A(H3N2) virus and three of six 
key positions of A(H5N1) clade 2.1 virus were involved in major antigenic at least 
twice, suggesting that key positions were selected over other bordering positions to 
cause major antigenic change. Interestingly, the key positions identified for A(H3N2), 
A(H1N1), A(H5N1) and influenza B viruses were often analogous between influenza 
viruses. Six key positions shared between two or more influenza A subtypes and B 
viruses map to equivalent positions on the hemagglutinin (Table 1, Fig. 1A). 
Different influenza viruses, similar constraints
The results from chapter 4 suggest that the ability of key substitutions to cause 
large antigenic change of A(H3N2) viruses is largely independent of the amino acid 
context, emphasizing the potential of key positions to cause antigenic change. Based 
on chapters 2 and 3, we hypothesized that substitutions on key positions identified 
for other subtypes may cause antigenic change of A(H1N1)pdm09 viruses, which have 
to date remained antigenically similar to the viruses that caused the 2009 influenza 
Table 1. Amino acid positions responsible for major antigenic change of influenza viruses studied for 
this thesis.
Influenza A virus subtypes Influenza B virus lineage
H1 H1pdm09 H3 H5 B/Vic B/Yam
130a 133b 129
135b
137 133
140 144
145
155 151
153 156
155 158
156 159 165 166
187 183
189 185
193c 189
Numbering of the amino acid positions is according to Burke and Smith (144). The positions listed for all influenza 
viruses but A(H1N1)pdm09 viruses were responsible for major antigenic change during influenza virus evolution. 
The positions indicated for A(H1N1)pdm09 were identified to support antibody escape, but as A(H1N1)pdm09 
viruses have remained antigenically stable since 2009 they were not involved in observed antigenic change (chapter 
5). aMcDonald et al.(49) bFor three antigenic cluster transitions during evolution of A(H3N2) virus an accessory 
amino acid substitution was required to change the antigenic phenotype to that characteristic of the subsequent 
antigenic cluster (chapter 2). cA substitution on position 193 was responsible for the antigenic cluster transition 
between the VI75 and TX77 antigenic clusters, and was involved in an antigenic cluster transition a second time 
as accessory substitution for the SI87 to BE89 cluster transition (chapter 2). H3 positions indicated in grey are 
indicated for numbering conversion, but were not involved in antigenic change.
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Fig. 1. Amino acid positions bordering the RBS of an A/Aichi/2/68 A(H3N2) virus HA. (A) Structural 
representation of the RBS area. The monomers are indicated in white, grey, and black. Key positions 
identified in a single subtype are indicated in red, key positions shared between multiple subtypes 
and influenza B virus are indicated in green (defined in Table 1). Non-key positions bordering the RBS 
are numbered in grey fonts. The RBS is indicated in yellow. (B) Cartoon representation of the RBS area. 
The structural elements surrounding the RBS are arbitrarily defined and color-coded for reference: 
100-loop, yellow; 130-loop, blue; 140-loop, magenta; 150-loop, orange; 160-loop, green, 190-helix, 
red; 220-loop, cyan. Key positions are located in the 130-, 140-, and 160-loops and the 190 α-helix.
pandemic. Introducing single substitutions at key positions of A(H3N2), A(H5N1), and 
influenza B viruses into an A/(H1N1)pdm09 representative virus resulted in mutants 
that escaped recognition from A(H1N1)pdm09-specific antibodies (chapter 5). 
Collectively these results suggest that vastly different influenza viruses have similar 
constraints to escape from antibody-mediated neutralization. 
The work for this thesis suggests another constraint to antibody escape. Twenty-
four of 26 substitutions responsible for major antigenic change involved substantial 
alterations of the biophysical properties of the amino acids. Twenty-one amino acid 
substitutions resulted in a charge change, and five substitutions resulted in a large 
change in amino acid volume. These findings indicate that only a limited number of 
the possible amino acid substitutions were selected to cause major antigenic change 
(chapters 2 and 3).
However, many substitutions that would cause a similarly large change in 
the biophysical properties of the amino acids and that may result in antibody escape 
were not observed in wildtype viruses. We found that key substitutions for antigenic 
change of A(H3N2) viruses never required three nucleotide changes and were always 
caused by the smallest number of nucleotide changes possible. Some amino acid 
changes may be absent because they require multiple nucleotide substitutions 
and are therefore more difficult to access than the substitutions that have caused 
antigenic change. Others may revert the antigenic properties to a phenotype against 
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which there is already a high level of population immunity, or may simply not result 
in antigenic change. Finally, some substitutions that have a low genetic barrier and 
a large antigenic effect away from immunity to previous strains may have a deleterious 
effect on viral intrinsic fitness. 
The majority of amino acid substitutions responsible for antigenic change of 
A(H5N1) clade 2.1 viruses were not seen in seasonal human influenza viruses and vice 
versa. Although antigenic change of both subtypes was often caused by substitutions 
that affected amino acid charge, almost all antigenically important substitutions in 
A(H5N1) clade 2.1 virus also involved changes in amino acid hydrophilicity. Except 
for a single threonine to tyrosine substitution, hydrophilicity changes were absent 
from substitutions that caused antigenic change of seasonal human influenza viruses. 
Perhaps this difference is due to the different receptor specificities of A(H5N1) viruses 
and seasonal human influenza viruses. Additional work looking into the effects of 
HA amino acid substitutions on intrinsic fitness is necessary to test this hypothesis. 
Nonetheless, the use of limited sets of amino acids for antigenic change suggests 
that seasonal human influenza viruses and A(H5N1) clade 2.1 viruses are similarly 
constrained to escape antibody recognition, but both may utilize distinct amino acid 
subsets to couple the necessity for antibody escape with optimal HA functionality.
The small number of key positions and strong biophysical limitations 
to the substitutions at key positions (chapters 2 and 3), the limited influence of 
the amino acid context on the effect of key substitutions (chapter 4), and the finding 
that the antigenic effect of substitutions may be translated to other influenza viruses 
(chapters 2 and 5) suggest that antigenic change of influenza viruses may be much 
more predictable than previously anticipated.
Contribution of substitutions away from the RBS to antigenic change
We found that substitutions away from the RBS never caused substantial antigenic 
change (chapter 2). Almost 90% of the naturally occurring amino acid substitutions 
that delineated between the antigenically different groups of viruses, including 
some on positions adjacent to the RBS, had a small or undetectable antigenic effect. 
This result does not imply that substitutions away from the RBS are irrelevant for 
antibody escape because they may collectively add to a decreased recognition by 
antibodies raised to strains from earlier antigenic clusters. We showed in chapter 2 
that hemagglutination inhibition (HI) assay data and virus neutralization (VN) assay 
data correlated well, and that substitutions away from the RBS had no effect on the 
antigenic properties when tested in VN assays. Nevertheless, the antigenic analyses 
for this thesis were almost entirely based on HI assay data that rely on receptor 
binding interference. Other modes of antibody-mediated neutralization cannot be 
detected using HI assays. Antibodies that prevent fusion of the viral and endosomal 
membranes, that interfere with the release of progeny virus, or that activate other 
arms of the immune system by opsonization or antibody dependent cell cytotoxicity 
are not considered in the HI assay but may significantly contribute to viral clearance 
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(119-124). However, most such antibodies target conserved regions of HA and may 
therefore be less relevant for past antigenic change of influenza viruses.
Antisera prepared to pointmutants with a substitution responsible for antigenic 
change had substantially increased reactivity with antigenically advanced wildtype 
viruses, suggesting that a single amino acid change close to the RBS is biologically 
relevant (chapters 2 and 3). However, it has not yet been tested if a cumulative effect 
of key substitutions and substitutions on other positions are required in vivo to 
achieve a magnitude of antibody escape approximating that of wildtype viruses. To 
specifically study the contribution of substitutions that lead to antibody evasion in an 
immune host, the interference of innate and T cell immunity to viral clearance should 
be minimized. Passive transfer of antisera to naive animals followed by challenge 
with wildtype or mutant viruses is a possible method to determine if mutants with 
substitutions on key positions escape antibody neutralization as efficiently as wildtype 
viruses. Similar challenge studies are also necessary to test if recombinant viruses 
designed to contain the key amino acids to match an antigenic variant provide levels 
of protection comparable to vaccination or infection with wildtype viruses.
Intrinsic viral fitness
The rates of antigenic change for the A(H3N2) and A(H1N1) subtypes and influenza 
B/Victoria and B/Yamagata lineages are estimated at 1.01, 0.62, 0.42 and 0.32 units 
per year, respectively (125). For A(H3N2) virus the rate of antigenic change translates 
to antigenic cluster transitions occurring approximately once every 3.3 years (31). 
Major antigenic change occurred even less frequently for A(H1N1) and influenza 
B viruses (unpublished observations). Koelle et al. hypothesized that every position 
in an epitope is potentially important and that the amino acid context in which 
a substitution occurs determines if it results in antigenic change (56). In this model, 
influenza viruses evolve along antigenically neutral networks, thereby accumulating 
mutations that create the right context for a substitution to cause antibody escape. 
The neutral networks model accurately describes the hallmarks of A(H3N2) virus 
evolution, but suggests that the existence of a small set of key influential positions for 
antigenic change is unlikely. The results from chapters 2 and 4 are not in agreement 
with this suggestion. 
Because single substitutions were often sufficient to cause major antigenic change 
and every possible point mutation and many double mutations are generated with 
each viral replication cycle [chapter 2, (49, 126)], factors other than the occurrence of 
substitutions that caused large biophysical changes must have limited the frequency 
at which new antigenic clusters emerged. To explain this, we hypothesize that major 
antigenic change may come at an intrinsic fitness cost (chapter 2). A substitution 
that causes antibody escape but adversely affects HA functionality may only have 
a selective advantage if the adverse effect is compensated by co-mutations. In 
this scenario, the rate at which influenza viruses change antigenically is impeded 
by the necessity for co-mutations that offset intrinsic fitness loss. Thus, rather than 
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the necessity to shape an epitope for antibody escape the neutral networks model may 
have captured the selection of antigenic variants that have the right combination of 
substitutions that cause antigenic change and that offset intrinsic fitness loss. Further 
studies are required to obtain a better insight into the balance between antibody 
escape and intrinsic virus fitness. First, an assay that is sufficiently sensitive to detect 
the potentially minute differences in replication efficiency caused by single amino 
acid substitutions should be developed. A plaque assay-based method that may 
allow such sensitivity is currently near completion (R. Mögling et al., in preparation). 
Second, it should be determined if the hypothesized intrinsic fitness loss is present 
in mutants carrying key substitutions and if the paradox between high mutation rate 
and slow antigenic evolution can be explained by the necessity to compensate for 
intrinsic fitness loss. Third, the amino acid substitutions that offset intrinsic fitness 
should be mapped to provide important new insights in the dynamics of influenza 
virus antigenic evolution. Multiple studies have identified codons under positive 
selection during influenza virus evolution, and many positively selected substitutions 
occurred almost simultaneously and sped up fixation in the viral population (44-47, 
127-129). The positively selected substitutions that occur alongside key substitutions 
may provide clues to which amino acid changes may offset intrinsic fitness loss.
Mechanisms of antigenic change
The work by Smith et al. indicated that antigenic change of A(H3N2) viruses is 
punctuated, thus providing an alternative for gradual antigenic change as the 
absolute basis for escape from population immunity (31). Antigenic evolution of 
A(H1N1), A(H2N2), and influenza B viruses also appears to be punctuated (chapter 
2, (125), and unpublished observations). The identification of key positions in HA 
and single amino acid substitutions responsible for major antigenic change provides 
a molecular explanation for the punctuated nature of influenza virus antigenic evolution. 
The current understanding of influenza virus antigenic evolution thus no longer 
supports the minor and gradual antigenic change principle presumed by the antigenic 
drift model.
Another alternative for gradual antigenic change was provided by a study that 
looked into the contribution of reassortment to genetic variation. Multiple influenza 
virus lineages can persistently co-circulate and reassortment of the HA segment 
between viruses of different lineages may influence major antigenic change (130). 
Indeed, the SY97 to FU02 antigenic cluster transition during A(H3N2) virus evolution 
was associated with a reassortment event that involved the HA segment that carried 
the 156QH substitution (130-132). However, an elaborate study analyzing 286 
influenza virus full genome sequences that covered the entire period of A(H3N2) 
virus circulation showed that no other persistent reassortment events coincided with 
antigenic cluster transitions (132). Although reassortment could still play an important 
role in providing the right gene constellation to support the emergence of new 
epidemic strains, its direct contribution to antigenic change seems limited.
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 An interesting hypothesis based on the observation that passaging of A/Puerto 
Rico/8/34 (H1N1) escape variants through immune and non-immune mice leads 
to differences in receptor binding proposed that antigenic change is a by-product 
of changes in receptor binding avidity (57). A higher receptor binding avidity, 
the combined affinity that results from multivalent interactions, may be advantageous 
for the virus when infecting (partially) immune hosts because sialic acids and antibodies 
compete for binding to HA. When mutants with increased receptor binding avidities 
where passaged in non-immune mice avidity returned to the original state, a trade-off 
between intrinsic fitness and immune escape, and some substitutions responsible for 
this decrease in binding occurred in antigenic sites. The avidity hypothesis postulates 
that increased positive charge enhances avidity by increasing charge attraction with 
negatively charged cell surfaces and that substitutions that alter avidity frequently 
modify antigenicity of seasonal human influenza A viruses (57, 133). During the 35 
years of antigenic evolution of A(H3N2) viruses studied in chapter 2, the number 
of amino acid substitutions leading to an increase in positive charge were more 
prevalent than decreases in negative charge. However, for both the substitutions 
identified as responsible for cluster transitions and the cluster-difference substitutions 
[the amino acids that differ between all viruses of two antigenic clusters (31)] we 
found that some cluster transitions coincided with a (net) increase in positive charge 
while others were neutral or resulted in an increase of negative charge. In at least five 
major antigenic changes studied in chapter 2 the charge did not change as predicted 
by the avidity hypothesis. Importantly, the magnitude of antigenic change observed 
during most cluster transitions far exceeds the antigenic change observed during 
the passaging experiments in mice (57). The studies that support the avidity hypothesis 
used erythrocytes with decreasing amounts of sialic acids to titrate influenza 
viruses (57, 112, 133). Avidity was then determined by quantifying agglutination 
of erythrocytes with the lowest amount of sialic acids that showed agglutination 
similar to untreated erythrocytes. A major flaw in this method is that the amount of 
input virus was measured by HA assay. The HA assay also measures agglutination 
of erythrocytes and is therefore dependent on the amount of HA present on 
the surface of the virus, which has not been taken into consideration. More importantly, 
hemagglutination is dependent on the avidity of HA for sialic acids on erythrocytes. 
Given that A(H3N2) viruses continue to cause annual epidemics, the inability of 
most contemporary A(H3N2) viruses to agglutinate erythrocytes through HA binding 
suggests that avidity measurements using hemagglutination assays are of limited 
biological relevance. Although the avidity hypothesis provides a possible mechanism 
for the minor antigenic changes that occur within antigenic clusters it is insufficiently 
supported by empirical evidence to be considered an important mechanism driving 
antigenic evolution of influenza viruses. Thus, natural selection of antigenic variants 
that most efficiently escape neutralizing antibodies present in the human population 
remains the most plausible mechanism for major antigenic changes during influenza 
virus evolution to date. 
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Predicting influenza virus evolution
Vaccination is the primary method to prevent complications from influenza disease in 
humans and is an important intervention strategy to reduce the burden of influenza 
in poultry. The Achilles’ heel of vaccination is the highly variable nature of influenza 
viruses because it allows re-infection of previously immune hosts and is the cause of 
annually recurring influenza epidemics in humans. Optimal vaccine efficacy requires 
that the influenza strains included in the vaccine antigenically match the strains 
that circulate when the vaccine is administered. The time gap between selection 
of the vaccine strains and administration of the influenza vaccine demands forecasting 
the antigenic properties of strains that will circulate at least ten months later. Several 
studies therefore focused on predicting influenza virus evolution using genetic 
change as basis for prediction (44, 46, 47, 134). These studies often lacked insight in 
the phenotypic effects of the studied molecular changes. The work described in this 
thesis contributes to a genotype-to-phenotype translation for antigenic change and 
provides a rationale for sequence-based detection of escape variants. A currently 
ongoing follow-up study uses saturated mutagenesis on the A(H3N2) virus key 
positions to evaluate the effects of different amino acid substitutions on antigenic 
change and intrinsic fitness and will further support sequence-based identification of 
escape variants. 
An important open question is why key positions are reused within and between 
subtypes while other bordering positions were not involved in major antigenic 
change. The key positions among the different influenza viruses are clustered on two 
main areas bordering the RBS; an antigenic ridge that is formed by the 190 α-helix 
and part of the 160-loop on the membrane distal part of the RBS, and the protruding 
140-loop on the membrane proximal part of the RBS (Fig. 1, Table 1). A single key 
position, 133, is located in the 130-loop outside of the main areas (H3 numbering, 
a numbering conversion is provided in Table 1). Some bordering positions may not 
have contributed to major antigenic change because they are less accessible 
to antibody interaction than key positions. For example, positions 147 – 149 in 
the 150-loop and position 96 in the 100-loop are located below the concave structure 
of the RBS, and are conserved in nearly all A(H3N2) viruses. Positions in the 130-loop 
(131, 132), position 186 (preceding the 190 α-helix), and positions in the 220-loop 
(219 – 222) are not hidden. In particular positions 138, 140, and 143 (140-loop), and 
position 222 are surface exposed, located on protruding structures, and appear equally 
accessible for antibody interaction to key positions. In chapter 4 we hypothesized 
that local HA structure may reduce the magnitude of antigenic change caused by 
a substitution and non-key positions bordering the RBS may have restricted ability 
to cause structural changes. Finally, the 220-loop holds critical positions for receptor 
binding and the amino acids in this loop are almost entirely conserved between 1968 
and 2003 (24, 31, 95). Substitutions in the 220-loop and other non-key bordering 
positions that change the antigenic properties may come at too large an intrinsic 
fitness cost to be compensated. Structural constraints and the necessity to maintain 
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optimal receptor binding may limit the rate of antigenic evolution as well as 
the number of amino acid positions that contributed to antigenic change. To address 
the question if amino acid positions will be added to the set of key positions identified 
here, future studies should test if substitutions on bordering positions not involved in 
past antigenic change can cause antibody escape and evaluate their effect on intrinsic 
fitness compared to substitutions at key positions. 
The ferret sera used in HI assays are usually obtained after inoculation of previously 
naive animals with a single strain of influenza virus. Most humans experienced multiple 
influenza virus infections and have a more complex antibody repertoire. The current 
vaccine strain selection procedure uses HI assay data to identify viruses that best 
represent circulating viruses, but does not take prior immunity into consideration 
when selecting the vaccine strains. Fonville et al. recently introduced a method for 
the quantitative analysis of antibody-mediated immunity to antigenically variable 
pathogens (107). The results are presented as antibody landscapes, a visualization of 
serum antibody titers plotted as a function of antigenic relations between influenza 
viruses. Antibody landscapes thus provide a means to survey antibody immunity 
in the human population, allowing a more rational selection of vaccine strains and 
vaccine composition. Taking population immunity into account may be particularly 
beneficial for selecting the A(H1N1)pdm09 virus component of the influenza vaccine. 
We found that mutants that escaped recognition by A(H1N1)pdm09-specific antisera 
from ferrets and infants did not escape from recognition by antisera collected from 
individuals that experienced both seasonal and pandemic A(H1N1) virus infections 
(chapter 5). This observation suggests that antibodies to pre-2009 A(H1N1) and 
A(H1N1)pdm09 viruses act synergistically and may limit the possibilities of antigenic 
variants to evade population-level immunity. The absence of cross-reactivity between 
ferret antisera prepared to seasonal A(H1N1) viruses and A(H1N1)pdm09 viruses 
poses a challenge to identify antigenic variants that can escape from population-level 
immunity, because the more broadly reactive antibody response of adult individuals 
can currently not be represented easily by ferret antisera prepared to A(H1N1)pdm09 
viruses (96, 112, 115).
The longitudinal analysis of human sera using antibody landscapes by Fonville 
et al. showed that preemptively updating the vaccine may have the dual advantage 
of inducing antibodies against both advanced and previously circulating antigenic 
variants of A(H3N2) virus, which is anticipated to improve vaccine efficacy in much of 
the population (107). However, their results emphasize that the accuracy of predicting 
upcoming epidemic strains can be improved by taking the human antibody repertoire 
into consideration. 
The evolutionary dynamics that govern emergence of new antigenic clusters are 
incompletely understood. We hypothesized that antibody escape comes at an intrinsic 
fitness cost and that antigenic change is only part of the equation that determines 
the development of novel epidemic strains (chapter 2). The balance between antibody 
escape and intrinsic fitness should be further explored to determine if the hypothesized 
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intrinsic fitness cost explains the paradox between fast genetic evolution and slow 
antigenic change. If true, mapping the HA amino acid changes that offset intrinsic 
fitness loss caused by antigenic change will help answer the question when a vaccine 
update should be issued. The opposite functions of HA and NA during replication 
require that the binding properties of HA are balanced with NA activity (135, 136). 
Amino acid substitutions in NA or reassortment of HA or NA gene segments from 
other lineages may compensate for decreased receptor binding caused by antigenic 
change. Although HA is the most important antigen for neutralizing antibody 
responses, NA is similarly subject to antigenic change. Although the timing of NA 
antigenic change is often different from HA, single point mutations can also cause 
major antigenic change of NA and human sera react differently with strains that have 
antigenically different NAs (137). Influenza vaccine efficacy could therefore benefit 
from selecting vaccine strains that have both HAs and NAs that antigenically match 
epidemic strains.
The genetic composition of seasonal human influenza viruses is usually 
represented by consensus sequences obtained using Sanger sequencing of clinical 
isolates propagated on cell cultures or embryonated hen’s eggs. Such traditional 
genetic analyses lack the sensitivity to identify minority variants in the genetically 
highly diverse viral population in clinical samples and the resulting sequences may be 
biased towards genetic variants selected for optimal replication in the model system. 
Next generation sequencing (NGS) methods permit detection of minority variants 
with population frequencies below 1% and provide a powerful tool to address 
fundamental questions regarding the development of genetic traits associated with 
phenotypic change (15, 138-140). NGS methods have already been used to study 
genetic bottlenecks, immune escape, and intra-host evolutionary dynamics of other 
RNA viruses (141-143). The high throughput nature of NGS technologies allows full 
genome sequencing on large clinical sample sets and can be used to study the intra- and 
inter host genetic variation during and between influenza epidemics. Integrating the 
knowledge of global circulation patterns (81), population-level immunity, genotype-
to-phenotype translations, and large-scale genetic surveillance may eventually allow 
detection and potentially prediction of variants with epidemic potential before these 
can be detected using conventional antigenic analyses or Sanger sequencing, with 
obvious advantages to public health.
SUMMARY
The results presented in this thesis provide new insights in the antigenic evolution of 
influenza viruses and will help to improve selection of vaccine strains. Rather than the 
seemingly endless number of amino acid substitutions that influenza viruses can access 
to escape from antibody-mediated neutralization, we showed that the possibilities 
for influenza viruses to change antigenically are limited and that genetically vastly 
different influenza viruses have analogous ways to change antigenically. The small 
number of critical sites and restricted amino acid usage decimates the number of 
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possible escape variants from thousands to dozens and thus substantially increases 
the possibility to predict the antigenic component of influenza virus evolution. 
Follow-up studies should further define the limitations of influenza virus antigenic 
change, and should focus on the in vivo relevance of the findings presented here. 
The work for this thesis could form the basis for efforts towards identification of 
escape variants based on sequence information alone and provides a platform for 
studies into antigenic evolution of other antigenically variable pathogens.
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In mensen is influenza (griep) een luchtweginfectie die gepaard gaat met onder andere 
spierpijn, hoofdpijn, hoge koorts, en hoesten. Complicaties als gevolg van influenza 
komen het meest voor bij jonge kinderen, ouderen, en mensen met onderliggende 
medische problemen. Elk jaar ondervinden wereldwijd ongeveer 350 miljoen tot een 
miljard mensen problemen als gevolg van influenza. Influenzavirussen (griepvirussen) 
behoren tot de Orthomyxoviridae familie van virussen die een gesegmenteerd genoom 
bezitten dat bestaat uit negatief enkelstrengs RNA en een gesegmenteerd genoom. 
Influenzavirussen zijn onderverdeeld in types A, B en C. Influenza A virussen zijn verder 
onderverdeeld in subtypes op basis van de genetische en antigene eigenschappen 
van de oppervlakte eiwitten hemagglutinine (HA) en neuraminidase (NA). Momenteel 
zijn er 18 verschillende HAs en 11 verschillende NAs bekend. De combinatie van 
HA en NA bepaalt het influenza A virus subtype, bijvoorbeeld A(H3N2) virus of 
A(H5N1) virus. Het overgrote deel van de influenza A virus subtypes circuleert in wilde 
vogels, maar komt ook voor in onder andere mensen, varkens, paarden, honden, 
katten, vleermuizen en zeezoogdieren. Alleen van subtypes A(H1N1), A(H2N2), 
en A(H3N2) is bekend dat ze jaarlijkse griepepidemieën in mensen kunnen veroorzaken. 
Andere influenza A virus subtypes worden ook in mensen aangetroffen, maar deze 
zijn tot op heden niet of zeer beperkt tussen mensen overdraagbaar. Meestal zijn 
dat aviaire influenzavirussen (vogelgriepvirussen) die in pluimvee circuleren zoals 
A(H5N1) en A(H7N9) virussen. Influenza B virussen zijn in principe specifiek voor de 
humane gastheer hoewel zij ook in zeehonden zijn aangetroffen. Influenza C virussen 
infecteren alleen mensen. Deze infectie verloopt meestal mild. 
Wanneer een aviair influenza A virus, direct of via een tussengastheer zoals varkens, 
in de humane populatie terechtkomt en goed tussen mensen overdraagbaar is, kan 
deze een wereldwijde uitbraak veroorzaken. Een dergelijke wereldwijde uitbraak 
wordt een pandemie genoemd. In de afgelopen 100 jaar zijn er vier influenza virus 
pandemieën geweest: A(H1N1) virus in 1918, A(H2N2) virus in 1957, A(H3N2) virus 
in 1968, en A(H1N1) virus in 2009. Deze laatste wordt aangeduid als A(H1N1)pdm09 
virus om onderscheid te maken met de A(H1N1) virussen die voor 2009 circuleerden. 
Na de pandemieën bleven deze virussen aanwezig in de humane populatie als 
epidemische influenzavirussen (“seizoens-griepvirussen) en zijn samen met influenza B 
virussen verantwoordelijk voor de jaarlijks terugkerende griepepidemieën. Momenteel 
veroorzaken alleen A(H3N2) virussen, A(H1N1)pdm09 virussen, en influenza B virussen 
griepepidemieën. Sinds 1918 zijn ongeveer evenveel mensen aan de gevolgen 
van infectie met pandemische en epidemische influenzavirussen overleden. 
Het HA oppervlakte eiwit van influenzavirussen is verantwoordelijk voor 
het binnendringen in de gastheercel. De opname van het virus door receptor-
gemedieerde endocytose wordt geïnitieerd door interactie van aminozuren in 
de receptor bindingsplaats (RBS) van HA met siaalzuren op het oppervlak van de 
cel. Als onderdeel van de afweerreactie van de gastheer tegen influenzavirussen 
worden antistoffen gemaakt die gericht zijn tegen de aminozuren op het HA van 
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het virus waarmee iemand besmet of gevaccineerd is. Antistoffen gericht tegen HA 
kunnen een influenzavirus neutraliseren, onder andere door de binding van het virus 
aan de cel te blokkeren en daardoor vermenigvuldiging van het virus voorkomen. 
Bij een volgende infectie met hetzelfde of een antigeen vergelijkbaar influenzavirus 
kunnen deze antistoffen zeer efficiënt de vermenigvuldiging van het virus remmen. 
HA is daarom de belangrijkste component van het influenzavaccin (de “griepprik”). 
Doordat influenzavirussen regelmatig muteren ontstaan antigene varianten van het 
virus die kunnen ontsnappen aan immuniteit die is opgebouwd tegen influenzavirussen 
die eerder circuleerden. Daarom is het noodzakelijk het influenzavaccin periodiek 
aan te passen zodat de virussen in het vaccin overeenkomen met de virussen die op 
dat moment circuleren. Het proces van opeenstapeling van mutaties dat leidt tot 
verandering van de antigene eigenschappen van influenzavirussen wordt antigene 
drift genoemd.
Om inzicht te krijgen in de veranderingen die bijdragen aan antigene drift zijn al 
ruim 30 jaar geleden de aminozuurposities in HA in kaart gebracht die geassocieerd 
worden met ontsnapping aan antistoffen. Deze zeer invloedrijke onderzoeken waren 
gebaseerd op experimenten waarin influenzavirussen werden vermenigvuldigd 
in aanwezigheid van monoclonale antistoffen. Alleen virussen met mutaties die 
leiden tot ontsnapping aan neutralisatie door de monoclonale antistoffen kunnen 
zich in zulke omstandigheden efficiënt vermenigvuldigen. Een tweede manier om 
de antigeen belangrijke aminozuurposities van HA te identificeren was het vergelijken 
van de aminozuren van influenzavirussen die in opeenvolgende jaren epidemieën 
hadden veroorzaakt. Deze onderzoeken suggereerden dat voor influenza A(H3N2) 
virussen de aminozuren in vijf antigene regio’s verspreid over het HA bijdragen 
aan antigene variatie. De antigene regio’s op het HA van influenza A(H3N2) virussen 
bestaan uit totaal 131 aminozuurposities. Op basis van deze bevindingen werd 
aangenomen dat minimaal vier aminozuren verdeeld over twee of meer antigene 
regio’s moeten veranderen om een antigene variant te krijgen die een nieuwe 
epidemie zou kunnen veroorzaken. 
Een in 2004 gepubliceerde studie toonde aan dat influenza A(H3N2) virussen 
die circuleerden tussen 1968 en 2003 niet geleidelijk antigeen veranderden maar 
sprongsgewijs. Deze zogenaamde antigene “clusterovergangen” gebeurden 
gemiddeld elke 3,3 jaar. Gedurende deze periode hebben 11 antigene clusters 
gecirculeerd en waren er dus tien clusterovergangen. Het onderzoek beschreven 
in hoofdstuk 2 richtte zich op het identificeren van de aminozuurveranderingen die 
verantwoordelijk waren voor de clusterovergangen tijdens de evolutie van influenza 
A(H3N2) virussen. Omdat de aminozuurvolgorde van het HA van virussen die behoorden 
tot de elf antigene clusters bekend was, konden gericht aminozuurveranderingen in het 
HA van referentievirussen voor de verschillende antigene clusters worden aangebracht, 
waardoor de bijdrage van deze veranderingen aan de clusterovergangen kon worden 
bepaald. Voor de meeste clusterovergangen was een enkele aminozuurverandering 
voldoende om de antigene verschillen tussen influenzavirussen van opeenvolgende 
antigene clusters te verklaren. Voor de clusterovergangen waar twee of drie 
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aminozuurveranderingen voor nodig waren, werd het grootste deel van het antigene 
verschil ook veroorzaakt door slechts één aminozuurverandering. Alle veranderingen 
vonden plaats op slechts zeven aminozuurposities vlak naast de RBS. Vijf van 
de zeven aminozuurposities waren meerdere keren (mede)verantwoordelijk voor het 
verschil tussen antigene clusters. Antigene varianten met aminozuurveranderingen op 
de zeven “sleutelposities” werden dus steeds opnieuw door de natuur geselecteerd 
in plaats van varianten met veranderingen op de overige posities. Deze studie toont 
aan dat antistoffen gericht tegen de RBS een cruciale rol spelen voor de neutralisatie 
van influenzavirussen en dat een aminozuurverandering op één van deze posities al 
voldoende kan zijn om aan antistoffen gericht tegen eerdere virussen te ontsnappen. 
Vrijwel alle aminozuurveranderingen verantwoordelijk voor een clusterovergang 
resulteerden in grote verschillen in de eigenschappen van de aminozuren 
betrokken bij de verandering. Meestal resulteerde de verandering in een andere 
lading of een ander volume van de aminozuren. Een specifieke groep aminozuren, 
de hydrofobe aminozuren, was op één uitzondering na zelfs helemaal niet betrokken 
bij clusterovergangen. Tussen 1968 en 2003 heeft dus maar een klein deel 
van de mogelijke aminozuurveranderingen in HA geleid tot grote antigene verschillen, 
terwijl de overige aminozuurveranderingen (die mogelijk ook kunnen zorgen 
voor antigene variatie) beperkt effect hadden. De fouten in nieuwe kopieën van 
de genetische informatie die tijdens influenzavirus-vermenigvuldiging worden 
gemaakt, leiden ertoe dat gedurende een infectie vrijwel elke mogelijke 
aminozuurverandering voorkomt. De bevinding dat een enkele aminozuurverandering 
kan leiden tot een groot antigeen verschil suggereert dus dat antigene varianten van 
influenza A(H3N2) virussen weliswaar heel vaak ontstaan maar dat de mogelijkheden 
om uit te groeien tot een epidemische variant beperkt wordt door andere factoren 
dan alleen de eigenschap om te kunnen ontsnappen aan antistofherkenning. 
Ook voor influenza A(H1N1) virussen en influenza B virussen werden de meest 
recente clusterovergangen veroorzaakt door één aminozuurverandering direct naast 
de RBS en ook hier resulteerden de aminozuurveranderingen in grote verschillen in 
de eigenschappen van de aminozuren betrokken bij de antigene verandering. Deze 
resultaten suggereren dat de bevindingen voor het A(H3N2) virus subtype ook van 
toepassing zijn op de andere seizoens-griepvirussen. 
Indien grote antigene verschillen tussen influenzavirussen veroorzaakt 
kunnen worden door aminozuurveranderingen op de 131 aminozuurposities in 
de antigene regio’s en elk van de 20 mogelijke aminozuren zou kunnen bijdragen 
aan de verandering, zouden er vele duizenden mogelijkheden zijn om te ontsnappen 
aan het immuunsysteem. Het zeer kleine aantal aminozuurposities verantwoordelijk 
voor grote antigene veranderingen en beperkte gebruik van de potentiële 
aminozuurvariatie toont aan dat de mogelijkheden voor antigene veranderingen van 
het HA die leiden tot een antigene clusterovergang beperkt zijn. De antigene evolutie 
van humane influenzavirussen lijkt dus veel minder gecompliceerd dan algemeen 
werd aangenomen.
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Sinds 2003 zorgen hoogpathogene vogelgriepvirussen van het A(H5N1) subtype 
in Indonesië voor grote uitbraken in pluimvee. Net als seizoens-griepvirussen muteren 
A(H5N1) virussen in hoog tempo en is er veel genetische variatie. De A(H5N1) 
virussen die behoren tot de genetische lijn die wordt aangeduid als clade 2.1 komen 
uitsluitend voor in Indonesië. Op basis van genetische verschillen zijn clade 2.1 
virussen onderverdeeld in clades 2.1.1 – 2.1.3, en is clade 2.1.3 verder onderverdeeld 
in clades 2.1.3.1 – 2.1.3.3. De snelheid van verandering van A(H5N1) virussen is zo 
hoog dat deze indeling zeer regelmatig moet worden aangepast. Ondanks de enorme 
genetische variatie was er weinig bekend over de antigene verschillen tussen clade 2.1 
virussen. Om de antigene variatie in kaart te brengen hebben we, zoals beschreven in 
hoofdstuk 3, eerst de genetische variatie bepaald en referentievirussen geselecteerd 
die representatief waren voor de genetische variatie. Vervolgens zijn de antigene 
eigenschappen van de referentievirussen bepaald. Hieruit kon worden geconcludeerd 
dat er vanaf 2003 minimaal zes antigeen verschillende varianten verantwoordelijk zijn 
geweest voor uitbraken in pluimvee. Wanneer een nieuwe antigene variant van een 
seizoens-griepvirus ontstaat in mensen en epidemieën veroorzaakt, vervangt deze 
normaal gesproken de voorgaande antigene variant van dat subtype. Bij A(H5N1) 
clade 2.1 virussen in pluimvee bleek dit niet het geval te zijn. Tussen 2003 en 2011 
werden pluimvee uitbraken door virussen uit de verschillende genetische lijnen 
binnen clade 2.1 veroorzaakt en vaak bleven oude en nieuwe antigene varianten 
naast elkaar circuleren. 
De antigene afstand tussen de referentievirussen (een maat voor de antigene 
verschillen tussen virussen) correleerde slecht met de genetische afstand. Kennis 
van genetische variatie van clade 2.1 virussen geeft dus zeer beperkt informatie 
over antigene verschillen. Om inzicht te krijgen in antigene verschillen op basis 
van genetische informatie is het noodzakelijk de genetische veranderingen te 
kunnen vertalen naar het effect op de antigene eigenschappen van een virus 
zoals in hoofdstuk 2 voor seizoens-griepvirussen gedaan is. Om dit te bereiken 
werden gericht aminozuurveranderingen aangebracht in referentievirussen die 
de genetische variatie binnen clade 2.1 reflecteerden. Eén tot maximaal vier 
aminozuurveranderingen vlak naast de RBS waren verantwoordelijk voor de antigene 
verschillen tussen de referentievirussen. De sleutelposities voor antigene verschillen 
tussen clade 2.1 virussen vertoonde grote gelijkenis met de sleutelposities van 
A(H3N2) virussen, A(H1N1) virussen en influenza B virussen. Deze studie impliceert dat 
de aminozuurveranderingen in het HA van influenzavirussen van verschillende 
gastheren die kunnen leiden tot ontsnapping aan neutraliserende antistoffen op 
vergelijkbare manier beperkt wordt. 
Eén of enkele aminozuurveranderingen naast de RBS kunnen dus al voldoende 
zijn om een  influenzavirus zodanig te veranderen dat deze kan ontsnappen aan 
antistoffen opgewekt tegen eerder circulerende virussen. In hoofdstuk 4 hebben we 
getest of het antigene effect van een aminozuurverandering afhankelijk is van de 
aminozuurcompositie van het HA waarin de verandering plaatsvindt. Om dit te testen 
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zijn twee verschillende aminozuurveranderingen op verschillende aminozuurposities 
die verantwoordelijk waren voor clusterovergangen tijdens de evolutie van A(H3N2) 
virussen onafhankelijk van elkaar aangebracht in de referentievirussen voor de elf 
antigene clusters. Eén van de twee aminozuurveranderingen, verantwoordelijk voor een 
clusterovergang na meer dan twee decennia van A(H3N2) virus evolutie, veroorzaakte 
grote antigene veranderingen in zowel referentievirussen uit de eerste twee decennia 
van A(H3N2) virus evolutie als in referentievirussen uit de periode daarna. De grootte 
van de antigene veranderingen was vergelijkbaar met de veranderingen waargenomen 
voor natuurlijk voorkomende aminozuurveranderingen. Dat deze veranderingen 
tijdens de eerste twee decennia niet hebben geleid tot een nieuwe epidemische 
variant, ondersteunt de hypothese uit hoofdstuk 2 dat de mogelijkheden om uit te 
groeien tot een epidemische variant beperkt wordt door andere factoren dan alleen 
de eigenschap om te kunnen ontsnappen aan antistofherkenning. Hoewel de antigene 
veranderingen als gevolg van deze aminozuurverandering duidelijker waren dan 
de effecten van de verandering op de andere positie, waren de gemuteerde virussen 
in veruit de meeste gevallen antigeen verschillend van de referentievirussen. Het 
antigene effect van de veranderingen die hebben geleid tot clusterovergangen lijkt 
dus grotendeels onafhankelijk te zijn van de aminozuurcompositie van het HA waarin 
deze plaatsvinden. Deze resultaten benadrukken het belang van de sleutelposities 
voor antigene variatie van influenzavirussen. 
De A(H1N1)pdm09 virussen die sinds 2009 circuleren, zijn antigeen sterk 
vergelijkbaar met het varkens-griepvirus dat de pandemie veroorzaakte. Omdat na 
eerdere pandemieën de virussen na verloop van tijd muteerden en konden ontsnappen 
aan immuniteit tegen de pandemische virussen wordt ook voor A(H1N1)pdm09 
virussen verwacht dat er mutaties in het HA zullen plaatsvinden die een aanpassing 
van het vaccin noodzakelijk maken. Voor het onderzoek beschreven in hoofdstuk 5 
zijn aminozuurveranderingen aangebracht in het HA van een A(H1N1)pdm09 virus 
om aminozuurveranderingen die mogelijk bijdragen aan het ontstaan van antigene 
varianten in kaart te brengen. De aangebrachte aminozuurveranderingen werden 
geselecteerd op basis van de kennis uit hoofdstukken 2 en 3, aminozuurveranderingen 
die van invloed zijn op de binding aan de gastheercel en genetische verschillen 
tussen A(H1N1)pdm09 virussen, varkens A(H1N1) virussen, en A(H1N1) seizoens-
griepvirussen van voor 2009. Ten minste negen enkele aminozuurveranderingen in 
een klein gebied direct naast de RBS zorgden ervoor dat de gemuteerde virussen 
konden ontsnappen aan herkenning door antistoffen van fretten en kinderen 
gericht tegen A(H1N1)pdm09 virussen. Vrijwel al deze “escape” virussen hadden 
vergelijkbare bindingseigenschappen en vermenigvuldigden minimaal net zo 
efficiënt als het niet-gemuteerde virus. Op basis van deze resultaten zou het ontstaan 
van een epidemische variant met een of meer van deze mutaties verwacht kunnen 
worden. Geen van de mutanten gemaakt voor deze studie kon echter ontsnappen 
aan herkenning door antistoffen van volwassenen die infecties met zowel A(H1N1) 
seizoens-griepvirussen als A(H1N1)pdm09 virus hadden doorgemaakt. Deze 
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resultaten suggereren dat antistoffen gericht tegen de A(H1N1) virussen die voor 
2009 epidemieën veroorzaakten, bijdragen aan neutralisatie van antigene varianten 
van de huidige A(H1N1)pdm09 virussen waardoor het aantal aminozuurveranderingen 
dat zou kunnen zorgen voor het ontstaan van een antigene variant die kan ontsnappen 
aan antistoffen in de humane populatie drastisch wordt beperkt. 
De resultaten van de studies uitgevoerd voor deze promotie leveren nieuwe 
inzichten in de antigene evolutie van influenzavirussen. De identificatie van een klein 
aantal sleutelposities waartegen de meest effectieve antistoffen zijn gericht, kan 
helpen om de selectie van stammen voor gebruik in het influenza vaccin te verbeteren. 
In tegenstelling tot wat eerder werd aangenomen zijn de mogelijkheden om te 
ontsnappen aan antistofherkenning zeer beperkt. Het kleine aantal sleutelposities 
en beperkt gebruik van de mogelijke aminozuren vermindert het aantal antigene 
varianten waarvan werd aangenomen dat deze mogelijk kunnen uitgroeien tot een 
epidemisch influenza virus van vele duizenden tot slechts enkele tientallen. Bovendien 
hebben genetisch sterk verschillende influenzavirussen vergelijkbare manieren op te 
ontsnappen aan antistof herkenning. Deze kennis kan bijdragen aan de identificatie 
van antigene varianten op basis van alleen de genetische informatie van een influenza 
virus en vergroot de kans dat antigene evolutie van influenzavirussen ooit voorspeld 
kan worden.
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